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Abstract 
Xianzhen Yin 
Structure Pharmaceutics Based on Synchrotron Radiation X-Ray Micro-
Computed Tomography 
From Characterization to Evaluation and Innovation of Pharmaceutical 
Structures 
Keywords: Structure, Synchrotron Radiation Micro-Computed Tomography, 
Three Dimension, Fractal Dimension, Quantitative Characterization, Solid 
Dosage Form, Pharmaceutics 
Drug delivery systems (DDS) are essentially pharmaceutical products for human 
therapy, typically involving a mixture of active ingredients and excipients. Based 
upon quantitative characterization of structure, the thesis introduces the concept 
of classifying the architecture of DDS into four levels by their spatial scale and 
the life time period. The primary level is recognised as the static structure of the 
whole dosage form with a size from μm to cm with the final structure generated 
by formulation design. The secondary level categorises the structures of particles 
or sub-units to form a DDS with sizes from nm to mm as key units in processing 
such as mixing, grinding, granulation and packing; The tertiary level represents 
the dynamic structures of DDS during the drug release phase in vitro or in vivo 
incorporating the structure size range from nm to mm, which undergo changes 
during dissolution, swelling, erosion or diffusion. The spatial scale for the 
quaternary level is defined as the meso or micro scale architecture of active and 
non-active molecules within a DDS with sizes from Å to μm for the molecular 
structure of drug and excipients. 
Methods combining X-ray tomography, image processing, and 3D 
reconstructions have been devised and evaluated to study systematically 
pharmaceutical structures and correlate them with drug release kinetics of DDS. 
Based on the quantitative structural information of pharmaceutical intermediates 
and dosage forms, it is possible now to correlate structures with production 
processing, behaviour and function, and the static and dynamic structures of DDS 
with the release kinetics. Thus, a structure-guided methodology has been 
established for the research of DDS. 
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Chapter 1 
Introduction 
  
 2 
 
1.1 Drug Delivery Systems and Structure 
For the purpose of the treatment, cure, prevention, diagnosis of disease or 
enhanced physical or mental well-being, active pharmaceutical ingredients (APIs) 
should be transported in the body safely to achieve their therapeutic effect [1]. To 
achieve this, it is required that APIs are formulated and assembled into suitable 
deliverable dosage forms for convenient administration to patients. Drug delivery 
technologies have been introduced to modify drug release profiles, absorption, 
distribution and elimination of drugs for the benefit of improving product efficacy 
and safety, as well as patient convenience and compliance. Pharmaceutics is the 
subject which provides the underpinning scientific knowledge concerned with the 
transformation of drug substance, via formulation, into dosage forms and the 
various manufacturing processes used to provide high- quality, efficacious and 
safe medicines. 
Drug Delivery Systems (DDSs): Drug delivery is approached via various DDSs 
and is heavily integrated with dosage form and route of administration. The 
common routes of administration include the preferred non-invasive peroral 
(through the mouth), topical (skin), transmucosal (nasal, buccal/sublingual, 
vaginal, ocular and rectal) and inhalation routes [2]. DDSs should be considered 
as the completed forms of the pharmaceutical preparation in which prescribed 
doses of medication are included and be designed to achieve the delivery of 
drugs to target sites of pharmacological action. Procedures involved during the 
development of DDS include those concerning drug preparation, route of 
administration, site targeting, metabolism, and toxicity testing. For oral 
administration, DDSs are designed to resist action by gastric fluids, prevent 
vomiting and nausea, reduce or alleviate any undesirable taste and smells, 
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achieve a high concentration of drug at the target site, and/or produce a delayed 
or long-acting drug effect. 
Structure: The different types of dosage forms are usually classified by the 
specific structure, the route of administration, the physical form and size of the 
dosage unit. The various dosage forms can be considered across different scales 
of scrutiny and size (see Figure 1) - from the molecular to the macro level [3].  
 
Figure 1 Particle size range for different dosage forms [3]. 
For clinical applications, the final pharmaceutical structures can be divided 
into numerous conventional types - solutions, emulsions, suspensions, semi-
solids, and solids. During the processing of materials into final dosage forms, 
other intermediate structures can be found - crystals, powders, granules etc. Of 
the range of marketed drug delivery systems, solid dosage forms are the most 
common forms and provide the vast majority of marketed medicines. Solid 
dosage forms are usually classified by the static and dynamic structure before 
and during release, the typical forms including powders, pellets, granules, tablets 
and capsules, with the structural features of these forms and the corresponding 
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dynamic changes due to phenomena such as hydration, swelling, and diffusion 
during drug release and dissolution playing dominant roles in determining the 
quality and performance of the medicines. 
1.2 Primary Factors Defining the Structure of DDS 
1.2.1 The Properties of APIs and Excipients 
Most drugs are marketed as tablets, capsules or pellets. During 
manufacturing, APIs are transformed into dosage units with particular 
characteristics. Besides the APIs, non-medicinal functional substances, called 
excipients are added to enhance the drug form, quality, and efficacy. For the 
proper design and formulation of these major dosage forms, it is essential that 
fundamental physical, chemical, biologic and other characteristics of APIs and 
excipients to be used in fabricating the product are determined. This information 
should be considered as important both in product design and formulation 
development. Properties of APIs define the design space and the properties of 
excipients mainly determine the architecture of the dosage form. 
Properties of APIs that should be taken into account in the design of 
formulations include: a) the solubility of the drug which affects the bioavailability, 
the rate of drug release into dissolution media and the therapeutic efficiency of 
the pharmaceutical product; b) the dissociation content which is important since 
solubility and consequently absorption, can be altered by orders of magnitude 
with changing pH; c) partition coefficient (oil/water) which is a measure of the 
lipophilic/ hydrophilic balance and has been shown to be a contributing factor for 
the rate and extent of drug absorption; d) the dissolution rate of the drug, 
especially when it is the rate limiting step in the absorption process; e) crystal 
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properties and polymorphism - polymorphs generally have different melting 
points, x-ray diffraction patterns and solubility even though they are chemically 
identical. Differences in the dissolution rates and solubility of different 
polymorphic forms of a given drug are commonly observed; f) size and surface 
morphology of the drug particles influence the flow and the mixing efficiency of 
powders and granules. Size can also be a factor in stability with fine materials 
relatively more open to attack from atmospheric oxygen, the humidity, and 
interacting excipients than are coarse materials. 
Excipients are commonly used: a) to bulk up formulations as "bulking 
agents," "fillers," or "diluents", enabling convenient and accurate dispensing of a 
drug substance in formulation; b) to serve various therapeutic-enhancing 
purposes, such as facilitating drug absorption or solubility, or other 
pharmacokinetic considerations; c) to aid in the handling of the active substance 
concerned such as by facilitating powder flow or non-stick properties, in addition 
to aiding drug stability such as prevention of denaturation over the expected shelf 
life.  
1.2.2 Pharmaceutical Processing 
Pharmaceutical manufacturing processing usually consists of a series of unit 
operations executed in batch mode or in a continuous manufacturing operation 
to produce the desired quality product. Unit operations involve physical or 
chemical changes, such as mixing, milling, granulation, drying, compression, and 
coating. Process parameters are key factors in determining the structure of DDS, 
and when parameters have been adjusted both the external morphology and the 
inner fine structure of DDS are changed. 
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For solid dosage forms, typical processes employed which affect the 
architecture of the DDS include: a) mixing - to reduce composition variability in 
multi component powder blends; b) wet granulation - to create agglomerates, or 
granules, of powder blends; c) dry granulation - through roller compaction; d) 
mass transfer - for holding materials and conveying them; e) size reduction and 
milling - to reduce the particle size of raw materials, particularly APIs, or to reduce 
the size of granules generated by either wet or dry granulation; f) drying - a 
ubiquitous process in the handling and preparation of pharmaceuticals, which 
may be defined as the vaporization and removal of water or other liquid from a 
solution, suspension, or other solid-liquid mixture to form a dry solid; g) 
evaporation - may be defined as the removal of a solvent from a solution by 
vaporization but is usually restricted to the concentration of solutions by boiling; 
h) tableting - the compaction of powder blends to form a hard compact; i) 
encapsulation, enclose granules or powders of APIs and excipients into capsules; 
j) coating – frequently carried out for tablets that have an unpleasant taste, or to 
make easier to swallow, modify release behaviours, and extend the shelf-life of 
components that are sensitive to moisture or oxidation.[4] 
1.3 Structure Characterization Methods 
The conventional ways to evaluate pharmaceutical solid structures can be 
divided into two categories: a) indirect determination, e.g., using melting which 
provide some detail of structural differences of crystalline materials, powder X-
ray diffraction to characterize the molecular arrangement in crystals, nitrogen 
adsorption measurement to obtain the pore structure parameters of solid dosage 
forms [5]; and b) imaging methods which include two dimensional observation, 
e.g., microscopy, scanning electron microscope and transmission electron 
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microscope. As shown in Figure 2, the ability of a light source to penetrate a 
certain maximum depth determines the size and dimension of a sample that can 
be examined, with analytical methods based on different disciplines achieving 
different spatial resolutions.  
   
Figure 2 Light source used in Imaging methods 
1.3.1 2D Methods 
Optical Microscopy: The optical microscope, the oldest design of microscope, 
is easy to use for observation of the structure of dosage forms over a wide range 
of resolution. The structural detail can be directly observed by eye or captured by 
normal light-sensitive cameras to generate a micrograph. Based on the captured 
images of dosage forms, quantitative analysis can be performed. 
SEM: The scanning electron microscopy (SEM) is a type of electron microscope 
that produces images of a sample by scanning it with a focused beam of electrons. 
The electrons interact with atoms in the sample, producing various signals that 
can be detected and that contain information about the sample's surface 
topography and composition. The electron beam is generally scanned in a raster 
scan pattern, and the beam's position is combined with the detected signal to 
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produce an image. SEM can achieve resolution down to nanometer scale. 
Specimens can be observed in high vacuum, in low vacuum, and (in 
environmental SEM) in wet conditions. SEM is the most widely used method to 
observe the external surface structures of pharmaceutical dosage forms and 
powders, such as morphology, particle size distribution [6]. 
TEM: Transmission electron microscopy (TEM) is a microscopic technique in 
which a beam of electrons is transmitted through an ultra-thin (usually the 
thickness is about 100~200 nm) specimen. An image formed by the interaction 
of the electrons transmitted through the specimen is magnified and focused onto 
an imaging device, such as a fluorescent screen, on a layer of photographic film, 
or to be detected by a sensor such as a CCD camera. TEMs are capable of 
imaging at a much greater resolution than light microscopes, owing to the small 
de Broglie wavelength of electrons. This enables fine detail - even as small as a 
single column of atoms, which is thousands of times smaller than the smallest 
resolvable object in a light microscope to be examined. TEM forms a major 
analytical method in a range of scientific fields, in both the physical and biological 
sciences. TEMs find application in cancer research, virology, materials science 
as well as pollution, nanotechnology, and semiconductor research. 
AFM: Atomic force microscopy (AFM) or scanning force microscopy (SFM) is a 
high-resolution type of scanning probe microscopy, with demonstrated resolution 
in the order of a fraction of a nanometer. AFM is one of the foremost tools for 
imaging, measuring, and manipulating matter at the nanoscale. The information 
is gathered by "feeling" the surface with a mechanical probe. Piezoelectric 
elements that facilitate tiny but accurate and precise movements on (electronic) 
command enable precise scanning. In some variations, electric potentials can 
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also be scanned using conducting cantilevers. In more advanced versions, 
currents can be passed through the tip to probe the electrical conductivity or 
transport of the underlying surface. AFM has been used to study surface 
adhesion and morphology as a function of relative humidity (RH) for monoclinic 
acetaminophen [7]. 
However, most of the above mentioned methods are not true 3D approaches. 
Techniques such as SEM, Raman, ATM, ultrasound, vibrational spectroscopy 
and near infrared spectroscopy are generally applied for 2D observation. These 
methods reveal only structural information about the surface or inner region just 
below the surface, and in order to observe internal structures, samples must be 
sectioned or cut which destroys their original 3D structure. 
1.3.2 3D and 2.5D imaging 
Magnetic resonance imaging (3D): Magnetic resonance imaging (MRI) is an 
imaging technique used primarily in medical settings to produce high quality 
images of the inside of the human body. MRI is based on the principles of nuclear 
magnetic resonance (NMR), a spectroscopic technique used by scientists to 
obtain microscopic chemical and physical information about molecules. MRI 
started out as a tomographic imaging technique, that is it produced an image of 
the NMR signal in a thin slice. However MRI has advanced beyond a tomographic 
imaging technique to a volume imaging technique. Magnetic resonance imaging 
uses a back projection technique similar to that used in CT. The magnetic 
resonance imaging primarily images the NMR signal from the hydrogen nuclei. 
The proton possesses a property called spin which can be thought of as a small 
magnetic field, causing the nucleus to produce an NMR signal. A quantitative 
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ultra-fast MRI technique, together with 19F NMR spectra and 1D 19F profiles has 
been applied to study the dissolution process of commercial HPMC matrix tablets 
[8]. 
Raman Imaging (2.5D): Raman imaging combines the beneficial properties of 
Raman spectrometry, such as negligible sample preparation and sharp 
vibrational bands, with the power of high-resolution chemical imaging in detecting 
patterns and heterogeneity in analysed samples. The micro-spectrometric 
techniques apply two approaches, global imaging and point mapping techniques, 
for characterizing an area. Both techniques provide a hypercube of data with two 
spatial and one spectral dimension. Raman imaging method has been used to 
characterize the effect of different manufacturing technologies on properties of 
tablets, such as API and excipient distribution, polymorphism, tablet strength, and 
estimated API content [9]. 
Terahertz imaging (2.5D and 3D): Terahertz radiation consists of 
electromagnetic waves within the ITU-designated band of frequencies from 0.3 
to 3 terahertz and wavelengths range from 1 mm to 0.1 mm. Terahertz radiation 
is unique in that it can penetrate into and through a number of materials, such as 
polymers, ceramics, and amorphous pharmaceutical materials. Images or 
chemical data can be extracted from the reflected or transmitted radiation. Also, 
many crystalline materials have characteristic spectral features in the terahertz 
range. Recently, terahertz radiation has been used in pharmaceutical 
applications such as polymorph identification and quantification, phase transition 
monitoring, and characterization of hydrate forms [10-12]. 
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Ultrasound (3D): Ultrasound imaging refers to the application of sound waves of 
frequencies greater than 20 kHz and up to the values in excess of 25 MHz. They 
are used in many applications including plastic welding, medicine, jewelry 
cleaning, and nondestructive testing. For a nondestructive test, ultrasonic waves 
give the ability to “see through” solid/opaque material and detect surface or 
internal flaws without affecting the material adversely. Ultrasonic wavelengths 
can be focused, reflected, and refracted and are transmitted through air, water, 
and solids such as steel by high-frequency particle vibrations. When waves are 
transmitted in solid objects, the directed energy is reflected by boundaries 
between materials and also any cracks or voids in solid materials. These reflected 
waves, caused by internal defects, can be compared to the reflected waves from 
the external surfaces, enabling the size and severity of internal defects to be 
identified. 
Micro Computed Tomography (3D): X-ray micro-computed tomography (μCT), 
a powerful non-invasive investigative technique, has been applied to observe the 
three dimensional structure of various objects and has great potential for 
providing information of the microstructure of particulate based solid dosage 
forms. In contrast to conventional techniques, the μCT technique allows non-
invasive, visualization of internal and microstructural details at micron scale 
resolution [13, 14]. The physical principle is the interaction of ionizing radiation, 
such as X-rays with matter, where, in the energy range typically used for CT 
imaging, the so-called photon-effect including absorption, diffraction and 
scattering builds the main interaction mechanism.  
With the ongoing development of CT systems, this technique can operate at 
many different levels of resolution in combination with novel image processing 
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algorithms and analytical techniques. These new techniques have enabled this 
methodology to be applied in a range of new applications. 
1.4 Objective of the Dissertation 
1.4.1 Grey box in pharmaceutics 
A key challenge, attracting increasing attention from pharmaceutical 
scientists, is to provide mechanistic understanding of the behaviour of drug 
substances and functional formulation components at all stages of the transition 
of a drug substance from a powdered state into final dosage forms and deliver 
optimal bio-performance of the medicine in patients. As shown in Figure 3, APIs 
and excipients are processed by different unit operations within a set of 
parameters into the specific form of DDS with a deliverable structure. Then the 
pharmaceutical properties including physical, chemical and biological 
characteristics are analysed and the disintegration, dissolution and drug release 
profile of the DDS evaluated. For current scientific researches and industrial 
applications, a quality strategy is implemented by the control of key attributes of 
material input characteristics and processing parameters. In many cases, 
optimizing the processing parameters is based on empirical experimentation and 
experience without systematic discipline. For the prediction of the target DDS 
quality from the input attributes and processing parameters theoretical or multi-
variable analytical models are required. The construction of these models is 
dependent upon a huge database from well-designed experiments and thorough 
analysis. However, the mechanism of how the raw material attributes and the 
processing parameters affect the quality and pharmaceutical behaviours of 
dosage forms remain a ‘black box’ with only a corner as yet uncovered. 
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Figure 3 Processing, Structures and Pharmaceutical Behaviours of DDS
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1.4.2 SR-μCT and 3D reconstruction technique 
In pharmaceutical research, non-invasive high resolution data are essential 
for extracting and rendering the finest structural information and to minimize the 
partial volume effect typical of medical CT scanners. Nonetheless, the major 
limitation of laboratory µCT equipment is that pharmaceutical samples of only up 
to a few centimetres in diameter can be examined. The current ‘ideal’ system for 
imaging highly (re)mineralized objects of pharmaceutical interest is synchrotron 
radiation-based micro-computed tomography (SR-µCT).  
Synchrotron Radiation and Synchrotron Radiation Light Source ：
Synchrotron radiation is an electromagnetic radiation from radially accelerated 
charged particles. It is produced in synchrotrons with bending magnets, 
undulators, or wigglers. It resembles cyclotron radiation except for being 
generated by accelerating ultrarelativistic particles including electrons forced to 
travel in a curved path by a magnetic field. In theory, the relativistic speed will 
change the observed frequency due to the Doppler effect by the Lorentz factor, 
γ. Relativistic length contraction then bumps the frequency observed in the lab 
by another factor of γ, thus multiplying the GHz frequency of the resonant cavity 
that accelerates the electrons into the X-ray range. The radiated power is given 
by the relativistic Larmor formula while the force on the emitting electron is given 
by the Abraham–Lorentz–Dirac force. The radiation pattern can be distorted from 
an isotropic dipole pattern into an extremely forward-pointing cone of radiation. 
Synchrotron radiation is the brightest artificial source of X-rays. The planar 
acceleration geometry appears to make the radiation linearly polarized when 
observed in the orbital plane, and circularly polarized when observed at a small 
angle to that plane. Amplitude and frequency are focused to the polar ecliptic[15, 
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16]. Synchrotron radiation may be artificially achieved in synchrotrons or storage 
rings or naturally by fast electrons passing magnetic fields. When the circulating 
electron beam is deflected by the bending magnets in the storage ring, an intense 
flux of electromagnetic radiation has been generated. Synchrotron radiation is 
characteristically polarized, emitted in a narrow cone and has frequencies 
ranging over the entire electromagnetic spectrum.[15] 
 
Figure 4 Shanghai Synchrotron Radiation Facility 
Synchrotron radiation may occur in accelerators either as a nuisance, 
causing undesired energy loss in particle physics contexts, or as a deliberately 
produced radiation source for numerous laboratory applications. In the 1960s and 
1970s, the advantages of using synchrotron radiation for spectroscopy and 
diffraction have been realized by an ever-growing scientific community. 
Accelerators were initially built for particle physics research, and synchrotron 
radiation was used in "parasitic mode" when bending magnet radiation had to be 
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extracted by drilling extra holes in the beam pipes. The first storage ring 
commissioned as a synchrotron light source was Tantalus, at the Synchrotron 
Radiation Center, first operational in 1968. [17] As accelerator synchrotron 
radiation became more intense and its applications more promising, devices that 
enhanced the intensity of synchrotron radiation were built into existing rings. 
Third-generation synchrotron radiation sources were conceived and optimized 
from the outset to produce brilliant X-rays. Fourth-generation sources that will 
include different concepts for producing ultrabrilliant, pulsed time-structured X-
rays for extremely demanding, and also yet-to-be-conceived, experiments are 
under consideration. 
Bending electromagnets in accelerators were first used to generate this 
radiation, but to generate stronger radiation, other specialized devices – insertion 
devices – are sometimes employed. The third-generation synchrotron radiation 
sources are typically reliant upon these insertion devices, where straight sections 
of the storage ring incorporate periodic magnetic structures (comprising many 
magnets in a pattern of alternating N and S poles) which force the electrons into 
a sinusoidal or helical path. Thus, instead of a single bend, many tens or 
hundreds of "wiggles" at precisely calculated positions add up or multiply the total 
intensity of the beam. These devices are called wigglers or undulators. The main 
difference between an undulator and a wiggler is the intensity of their magnetic 
field and the amplitude of the deviation from the straight line path of the electrons. 
There are openings in the storage ring to let the radiation exit and follow a beam 
line into the experimenters' vacuum chamber. A great number of such beamlines 
can emerge from modern third-generation synchrotron radiation sources. 
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Shanghai Synchrotron Radiation Facility, SSRF (Figure 4), is a third-
generation of synchrotron radiation light source, and is an invaluable tool for the 
Chinese scientific research and industry communities. Up to now, SSRF is the 
biggest scientific platform for science research and technology development in 
China. 
In contrast with micro CT, the SR-μCT (Figure 5) uses the synchrotron 
radiation X-ray as a light source to achieve high-speed imaging, intensive 
strength, high spatial resolution (to sub-micron or nano-scale), noninvasive 
fluoroscopy, to be able to scan, quantitatively evaluate and visualize the 3D 
structure of DDS. The advanced performance of SR-μCT is due to a number of 
factors. Include - the wide X-ray energy region 1~>200keV photon energy which 
can be generated; high intensity of beam: the total power is 600 KW, which is 
tens of thousands times higher than that of X-tubes; reduced time of obtaining 
the experimental data; high brilliance: brilliance which is hundreds of times higher 
than that of X-tubes; the synchrotron light is fully polarized. As a result, SR-µCT  
is an increasingly important tool to research the structure of biological molecules, 
medical molecules and dichromatic magnetic materials [18]. 
 
Figure 5 SR-μCT scanning 
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3D Reconstruction：3D reconstruction from multiple images is the creation of 
three-dimensional models from a set of images. It is the reverse process of 
obtaining 2D images from 3D scenes. The essence of an image is a projection of 
a 3D scene onto a 2D plane, during which process the depth is lost. The 3D point 
corresponding to a specific image point is constrained to be on the line of sight. 
From a single image, it is impossible to determine which point on this line 
corresponds to the image point. If two images are available, then the position of 
a 3D point can be found as the intersection of the two projection rays. 3D 
reconstruction is the process of capturing the shape and appearance of real 
objects.  
Tomographic reconstruction is a type of multidimensional inverse problem 
where the challenge is to yield an estimate of a specific system from a finite 
number of projections. The mathematical basis for tomographic imaging was laid 
down by Johann Radon. A notable example of applications is in computed 
tomography (CT) where cross-sectional images of patients are obtained in a non-
invasive manner. In practice for tomographic image reconstruction, often a 
stabilized and discretized version of the inverse Radon transform is used, known 
as the filtered back projection algorithm (Figure 6).  
 
Figure 6 Back-projection reconstruction 
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Methods combining X-ray tomography, image processing and 3D 
reconstructions to study the architecture and drug release kinetics of DDS have 
been developed and are detailed in this thesis 
1.4.3 Architecture and properties, behaviour and functions 
The concept that architecture determines the function is often described in 
terms of cells and their constituents, which has contributed to the rapid 
development of biology and life science over the last several decades. Shapes 
and physicochemical characteristics of proteins, cells, tissue and organs relate to 
their specific function. The links between structure and function can also be 
observed in pharmaceutics. The drug release behaviours of DDS are mainly 
determined by the static architecture and dynamic change such as disintegration, 
erosion, diffusion, degradation, swelling and etc. [19]. The intermediate structure 
of the solid dosage unit also plays an important role in the function and 
effectiveness of final drug products. Characterization of particles is an important 
requirement for pre-formulation and formulation studies since particle 
morphology, size, shape, mechanical properties can influence the selection of 
other formulation ingredients and selection of specific production processes. 
Drug particle size can influence a range of important performance criteria, such 
as powder flow and mixing, dosage unit content uniformity, dissolution rate, 
bioavailability, stability, and thus has an important role in the formulation, 
processing and ultimately therapeutic efficiency in patients. Thus, manufacturers 
producing a particulate based medicine need to understand and quantify any 
differences between batches of particulate materials for product development 
and quality control purposes. 
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Figure 7 Framework of thesis and the four levels of drug delivery system architectures 
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The  research of this thesis has focused on creating and developing a 
strategy for applying the μCT technique for investigating the morphology and 
internal structure of solid dosage forms and powders at different levels or 
architecture (see Figure 7). As a result, the whole spatial information on a 
particular powder or solid dose unit can be obtained by this method. In addition, 
distributions of geometric characteristics describing size, shape, and spatial 
arrangement of the particles can be estimated after imaging and analytic 
separation of data of the individual particles [20] [21]. This powerful method has 
been employed to provide detailed morphological information such as pore shape, 
spatial distribution, and connectivity of porous particles which can be correlated 
with the dissolution properties of the drug delivery system [22, 23]. It is also 
shown that the μCT combined with discrete element method (DEM) can be used 
to investigate particle packing in a process of pharmaceutical tablet manufactured 
by powder compaction [24]. In this dissertation, the powerful three dimensional 
(3D) research tool, the SR-μCT technique has been applied to demonstrate its 
potential for DDS research to explore the world of fine internal structures and the 
dynamic behaviours in architecture oriented drug release kinetics. The structure 
of thesis is visualized in Figure 7.  
Methodology design for quantitative characterization of structure: 
Methods based on 3D reconstruction for the quantitative evaluation of the 
irregular micro-structures of DDS as well as particles from intermediate 
processing are researched and developed. In addition, new methods for SR-μCT 
imaging of the pharmaceutical samples devised to present the full details of the 
surface morphology and the internal 3D structure, including the image processing 
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method, 3D reconstruction method, and construction and optimization of 3D 
models. 
Characterization of DDS and DDS component structures: 
After consolidating the theoretical and methodological parts of imaging and 
structural analysis, systematic methods and applied research are carried out for 
typical drug delivery systems at different dimensional scales. The unique sample 
preparation methodologies developed are compared to other preparations 
measured by synchrotron radiation. Since most of the sample ingredients are 
organic substances, optimization procedures have focussed on such samples for 
synchrotron radiation imaging to optimize the resolution, imaging parameters on 
the contrast and calculation methods. After CT measurement, the true three-
dimensional structure of prepared samples have been obtained by reconstruction. 
In addition, new software to determine the fractal dimension is considered to be 
useful to link material fractal dimension with pharmaceutical properties as the 
drug release rate to achieve quantitative analysis of the irregularity for complex 
structures. 
Interpretation of the dosage form structure: 
The quantitative structural studies are performed for the fine structure of 
large-size dosage forms, such as drug crystals, powders of the formulated 
particles and tablets on a wide spatial scale from submicron to 5000 μm and 
combined with the release features of drug delivery systems to create a structure-
based drug delivery theory and methodology. The structural studies cover the 
entire ‘life span’ of the drug delivery systems, from material selection, formulation 
design, process optimization to patient administration and drug release in vitro 
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and in vivo. Based on a SR-μCT three-dimensional reconstruction, image 
analysis, quantitative characterization, data mining, modelling and simulation 
technologies are combined to conduct cross-scale, multi-level networking and 
dynamic structure research for drug delivery systems and establish the structural 
pharmaceutical research system. Following the concept of Quality by Design 
(QbD), the quality of the final products is established from the structural 
pharmaceutical formulation research to develop more controllable novel drug 
delivery systems. 
Pharmaceutical structures to be investigated:  
The methodologies used to examine the range of samples are described and 
validated in chapter 2. Correlation between the micro-structures of interest, the 
ISO-Surface model construction and 3D steric quantitative parameters and the 
pharmaceutical relevant characteristics and the properties of DDS are explored. 
Where alternative experimental and analytical procedures are required for 
specific sample types, these are introduced in the later Chapters and further 
details provided in the Appendices. 
Chapter 3 reports on examination of DDS samples at Level 1 architecture 
includes spherical granules, irregular granules, pellets of multi-unit DDS, crystals 
and agglomerated crystal particles of polymorphs, osmotic pump controlled 
release tablets and hydrogel matrix sustained release tablets. 
In Chapter 4, investigation of DDS samples at level 2 architecture was 
reported. The intermediate structures include blend granules during mixing, blend 
granules during shaking, deformation behaviour of crystal particles during 
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compaction, orifices for osmotic pump tablets after laser drilling were studied for 
the evaluation of pharmaceutical processing.  
Chapter 5 focus on the level 3 architecture and the relationship between 
dynamic structures and drug release behaviours. Samples include single pellet 
of multi-unit DDS, osmotic pump tablets and hydrogel matrix tablets during 
release. Based on the quantitative characterization of the changing structures to 
the reveal the dominant release mechanism. More importantly, the developed 
dynamic computed tomography methods was used for the in-situ testing of novel 
osmotic pump tablet. 
Although the methods and principles include the procedure and workflow of 
preparation of samples, image acquisition, parameters optimization, image 
processing and 3D reconstruction were described generally in the section of 
methodology development. The detailed information related with the particular 
samples tested in the foregoing chapters was provided respectively and included 
in the Appendix section to avoid much repetitive descriptions in the main part of 
thesis. 
a) Particles, granules and pellets. The blend homogeneity and segregation of 
binary mixtures are investigated using frequency distribution of a particle 
structure based statistical model. The internal fine structures of granules and 
microspheres are quantitatively characterized and correlated with the single 
pellet release characteristics or release profiles of the microspheres. 
b) Polymorphs of drug crystals. Polymorphism denotes the existence of more 
than one crystal structure of a substance, and is of great practical and theoretical 
interest for the chemical and pharmaceutical industries. In many cases, it is 
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challenging to produce a powder with all particles chemically pure and of the 
same crystal form and to establish a sensitive detection method for the 
identification of crystal form in a mixture of polymorphs. 
c) Osmotic pump tablets. Investigation of the internal 3D steric microstructure 
uncovered the drug release mechanism of the monolith pump controlled release 
systems. The fractal dimensions of tablet core structures calculated based on the 
box counting method are used to link the irregular internal structure of an osmotic 
pump tablet with its drug release kinetics. 
d) Gel matrix tablets. Investigation of the quantification of swelling and erosion 
in the controlled release tablets of a poorly water-soluble drug has enabled a 
model of 3D release kinetics to be established. 
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Chapter 2 
Methodology Development for 3D 
Structural Characterization 
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2.1 Materials and equipment 
2.1.1 APIs and Excipients 
a) CLP I and CLP II, Clopidogrel bisulphate (purity of 99.9%) were provided by 
Shenyang Pharmaceutical University (Shenyang, China).  
b) Acetaminophen with purity of 99.45% was provided by Anhui Fengyuanlikang 
Pharmaceutical Co., Ltd., (China). 
c) PVP/VA (Plasdone® S630) was purchased from Shanghai Chineway 
Pharmaceutical Tech Co., Ltd. (Shanghai, China) 
d) Gelatin capsule shells of different size were provided by Xinchang Hechang 
Co., Ltd. (Zhejiang, China). 
e) Starcap 1500® Co-Processed Starch Excipient, was provided by Shanghai 
Colourcon Coating Technology Limited (China). 
f) Microcrystalline cellulose granules (Celphere®), were supplied by Anhui 
Shanhe Pharmaceutical Excipients Co., Ltd.(China).  
g) Octadecanol, was supplied by Hunan Erkang Pharmaceutical Co., Ltd. 
h) Eudragit E100 (PMA) was supplied by Hanghai Chineway Pharmaceutical 
Tech. Co., Ltd.,(China) 
i) Sodium phosphate monobasic dihydrate, sodium hydrogen phosphate and 
phosphoric acid were provided by Sinopharm Chemical Reagent Co., Ltd., 
(China). 
j) Captopril was gifted by Changzhou Pharmaceutical Factory Co., Ltd., (China). 
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k) Lactose (Ludipress® LCE) was provided by BASF (Germany). 
l) Sodium chloride was provided by Ciji Medicine Pharmacy (China).  
m) Magnesium stearate was provided by Anhui Sunhere Pharmaceutical 
Excipients Co., Ltd., China. 
n) Cellulose acetate (398-10NF) was provided by Easter Chemical Company 
(USA). 
o) Polyethylene glycol (4000 g/mol) was purchased from Sichuan Hanhua 
Pharmaceutical Excipients Co., Ltd. (China). 
p) The other chemical reagents used were all of the analytical grade and 
purchased in China. 
2.1.2 Marketed drug delivery systems 
a) Felodipine sustained-release tablets (Linuo; each tablet containing 5 mg of 
felodipine) with orifices drilled on both the upper and lower, were supplied by 
Hefei Lifeon Medication Group (Hefei, China). 
b) Felodipine extended release tablets (Plendil®, each tablet containing 5 mg of 
felodipine, lot number: 1010014) were produced by AstraZeneca PLC, China. In 
addition to the active ingredient felodipine, the tablets contained the following 
inactive ingredients: cellulose, red and yellow oxide, lactose, polyethylene glycol, 
sodium stearyl fumarate, titanium dioxide, and other ingredients. 
c) Tamsulosin hydrochloride (TSL) sustained release capsules were purchased 
from Astellas Pharma China Inc. (Shenyang, China). In addition to the active 
ingredient of tamsulosin hydrochloride, the pellets contained the following 
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inactive excipients: methacrylic acid copolymer, microcrystalline cellulose, 
triacetin, polysorbate 80, sodium lauryl sulfate, calcium stearate 
(http://www.accessdata.fda.gov/drugsatfda_docs/label/ 
2005/020579s016lbl.pdf). The mixture of all substance was granulated after the 
addition of the aqueous liquid material to form pellets, which can be classified as 
typical matrix cores pellets, according to the patent (European Patent 
EP0533297).  
2.1.3 Analytical equipment and other devices 
a) Bruker D8 Advance powder diffractometer (Bruker, Germany) equipped with a 
2.2 kW sealed Cu X-ray source, a graphite monochromator to filter out the Cu K 
β radiation, and a NaI (Tl) scintillation detector. The XRD patterns were measured 
on using Cu-Ka radiation (l = 1.5418 Å). The voltage and current were 40 kV and 
40 mA,respectively. Reflection mode was used in the 2θ range of 3-40° with a 
scan speed of 15° min-1 (step size 0.025°, step time 0.1 s) with a LynxEye 
detector. All the data were acquired at ambient temperature (20℃). The data 
were imaged and integrated with RINT Rapid and diffraction peaks-analyzed with 
Jade 6.0 software from Rigaku. Calibration of the instrument was performed using 
a Corindon (Bruker AXS Korundprobe) standard. 
b) Chinese Pharmacopoeia Dissolution Apparatus II (Tianjin TDTF Technology 
Co., Ltd., China). 
c) Freeze dryer FD5-3, China-GOLD SIM(Beijing) InternationalCo. Ltd., (China). 
d) Agilent 1260 series HPLC system (Agilent Technologies Inc., China). 
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e) G6460 tandem mass spectrometer (Agilent Technologies Inc., China) 
equipped with an atmospheric pressure chemical ionisation (APCI) module. 
f) Luna C18 column (150 mm×4.6 mm, 5 μm, Phenomenex) 
g) SEM, Hitachi S520 device (Hitachi, Japan) 
h) Inverted phase contrast microscopy (TS-100F, Nikon, Japan). 
i) Particle sizing system (Camsizer XT, Retsch, Germany). 
j) X-ray digital camera 4008 pixel× 2672 pixel with direct coupled (micro) fiber-
optic (photonics Science Ltd, Robertsbridge, UK) in Figure 8. 
 
Figure 8 X-ray digital camera from Photomic Science 
k) Diffraction-limited microscope optics (1.25×, 2×, 4×, 10× and 20× magnification) 
l)  High-resolution 2048 pixel× 2048 pixel CCD camera (pco.2000, PCO AG, 
Kelheim, Germany) in Figure 9. 
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Figure 9 High resolution CCD camera from PCO AG 
m) Lu2SiO5: Ce scintillator (10 μm thickness) 
n) YAG:Ce scintillator (200 µm thickness) 
o) Laboratory Shaker (MS 3 digital, IKA, Germany). 
p) Spraying system (Spray gun, W-71, Iwata, Japan). 
q) Dissolution apparatus (ZRS-8G, Tianjin Haiyida Co., Ltd., China). 
r) High-resolution 2048 pixel × 2048 pixel sCMOS camera (ORCA Flash 
4.0Scientific CMOS, Hamamatsu K.K, Shizuoka Pref., Japan). The physical pixel 
size was 6.5 μm in Figure 10. 
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Figure 10 High resolution sCMOS camera from HAMAMATSU 
s) 6-Axis Positioning Stage for the holding of sample form PI (Physik Instrumente) 
LP, USA and Kohzu Precision co. Ltd, Japan in Figure 11. 
 
Figure 11 High precision positioning stages 
t) Synchrotron radiation facility and resource  
As a third generation synchrotron radiation facility, the SSRF provided large 
tuning range (10-100keV), monochrome and high flux X-ray and started its user 
operation in May 2009. The X-ray Imaging and Biomedical Application Beamline 
(BL13W1) is composed of a 1.9 Tesla wiggler, 6 set of filters for high heat load 
reducing, and double crystal monochromator cooled with liquid nitrogen. X-rays 
are derived from an electron storage ring with an accelerated energy of 3.5 GeV, 
and an average beam current of 180 mA. The light source is hybrid-type wiggler 
with periodic length 14 cm and the number of the period is 8. Maximum K-value 
is designed to be 24.8 at minimum wiggler magnet gap of 17 mm. The 
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fundamental radiation covers the energy range from 8.0 to 72.5 keV by tuning the 
gap from 17 to 35 mm. At the end station, sets of digital X-ray detectors are 
employed with the pixel size range from 0.165 to 13 micrometers. Imaging 
methods of microscopic computer tomography (micro-CT, Figure 12), in-line 
phase contrast imaging (IL-PCI) and X-ray fluorescence imaging are provided for 
scientific researches on high Z and low Z samples in the field of biomedical, 
material, archaeology, environmental science. Spatial resolution of 0.8 μm and 
time resolution of 1 ms can be achieved. 
 
Figure 12 The beam line for X-ray imaging and biomedical application at Shanghai Synchrotron 
Radiation Facility 
Where the Wiggler is an insertion device used for the generation of 
synchrotron radiation, slits and choppers are used to shut down the beam as 
necessary, filters for selective transmission of light, DCM to monochromatize the 
X-ray, a sample stage and CCD to capture the images.  The SR-μCT tomographic 
images of prepared samples were acquired at a relatively low energy. The size 
of the beam was approximately 45 mm (horizontal) × 5 mm (vertical) and a 
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double-crystal monochromator with Si (111) and Si (311) crystals was used to 
monochromatize the X-rays. The monochromatized has a flux density about 5.8 
× 1010 ph/s/mm2 at 16 KeV and the energy resolution was Δ E/E = 5 × 10−3. 
2.1.4 Software and Workstation 
a) X-TRACT SSRF CWS x64 (Version 6.5 Commonwealth Scientific and 
Industrial Research Organization, Australia, http://www.ts-
imaging.net/Default.aspx ) is an image analysis and processing application with 
functionality targeting researchers working in imaging science and technology 
fields, especially in optical, electron and X-ray microscopy and astronomy. It was 
developed by international cooperation with the CSIRO in Australia. With these 
software packages, phase contrast reconstruction, fast micro CT reconstruction 
and other image processing are achieved. Remote data processing and transfer 
have also been realized. 
b) VGStudio Max (Version 2.1, Volume Graphics GmbH, Germany) provides 
unique functionality for precise and fast analysis of voxel data, visualization and 
analysis of CT data in combination with the optional add-on modules. 
c) Image Pro Analyser 3D (Version 7.0, Media Cybernetics, Inc., USA) 
d) Image Pro Premier (Version 9.0, Media Cybernetics, Inc., USA) 
e) Amira (Version 6.0, Konrad-Zuse-Zentrum für Informationstechnik Berlin (ZIB, 
Germany, FEI, Inc. SAS, USA) 3D software platform for visualizing, manipulating, 
and understanding biomedical data coming from all types of sources and 
modalities. 
f) ImageJ (Version 1.49, National Institute of Health, USA) 
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g) Matlab (2013a, Mathwork. Inc., USA) 
h) PITRE: a CPU based software package that supports phase retrieval for 
propagation-based phase-contrast imaging/tomography (PPCI/PPCT), extracting 
apparent absorption, refractive and scattering information from DEI, and CT 
reconstruction. H-PITRE, CT reconstruction software accelerated by GPU 
i) DCM: software for the data-constrained modelling and characterization of 
material compositional microstructure and properties, developed by CSIRO 
(http://research.csiro.au/dcm) 
j) PASW Statistics version 18.0 (Polar Engineering and Consulting) 
k) Dell Precision M6800 Workstation (Windows 7 64bit SP1, DirectX 11, Core i7-
4900MQ @ 2.80GHz Quadcore, Dell Motherboard  0XD1M5 Intel Haswell, 32 GB 
Samsung DDR3L 1600MHz , SSD IT LCS-512M6S 2.5 7mm 512GB, GPU Nvidia 
Quadro K5100M 8 GB) 
l) Microsuper Workstation (Windows 7 64bit SP1, DirectX 12, Xeon 2650 @ 
2.20GHz Octacore × 2, Supermicro Motherboard  X9Di, 64 GB Kingston DDR3 
1600MHz , SSD Intel 480GB, GPU Nvidia Quadro M5000M 8 GB) 
2.2 Synchrotron radiation and micro-computed 
tomography 
2.2.1 Preparation of samples 
In order to evaluate temporal changes in pharmaceutical DDS 
microstructures, optimum samples should be prepared. Several critical factors 
such as X-ray absorption intensity, water content, stability of samples, containers, 
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statistical significance, size of samples and parallel control of experiment can 
have a marked effect on the SR-μCT test and data generated. 
X-ray absorption intensity 
The intensity values associated with the different features of an SR-μCT 
image are determined by the X-ray transmission measured by an X-ray detection 
system, which is dependent on the material’s atomic mass and the energy of X-
rays [14, 25]. Different elements in pharmaceutical samples have different X-ray 
absorption intensity. To identify the targeted element precisely, other elements in 
pharmaceutical samples used for the SR-μCT test need to be identified and 
distinguished. The physical nature of samples, however, does affect its X-ray 
absorption over and above its bulk density. For instance, porosity either above 
the system resolution limit or at sub-voxel levels will result in differences in X-ray 
absorption that will be seen as different grey levels, and this will be in turn depend 
on variables such as the distributive characteristic of the porosity, the point-
spread function of the X-ray source, and the pixel size of the camera.  
The complexity of sample interfaces 
Material interfaces also need to be considered, as the degree of complexity 
will determine how detectable the boundary will be. In some instances, where 
mixing of materials is extensive, a fairly diffuse boundary may be imaged; in other 
instances, the interface may be less complex giving rise to sharper delineations. 
In other cases, the porosity and, hence localized density, may be affected by 
sample interactions occurring at boundaries.  
Density and density distribution 
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Density sensitivity is an important issue to be taken into consideration when 
performing SR-μCT scans. The basic density of the materials being imaged is 
clearly a major factor. If two adjacent materials have a similar density then they 
may not be differentiated unless some other properties such as different hydration 
levels act to modify their base density.  
Water content 
Water will interfere with imaging. Samples should contain as little water as 
possible. Owing to this interference imaging acquisition using SR-μCT technique, 
samples containing water must be dried prior to image acquisition. Three 
methods have been considered for the pretreatment of the samples in SR-μCT 
experiments: (a) drying in an oven, (b) freeze-drying, and (c) absorbing as much 
liquid as possible with filter paper and storage at room temperature over silica gel. 
For methods (a) and (c) for certain samples such as the matrix gel tablets 
samples tend to shrink, and the gel formed on the surface of the tablet core would 
collapse causing changes to the internal gel structure during the imaging process. 
However for these samples, the freeze-drying method was found to maintain the 
microstructure of the hydration layer as much as possible due to its rapid cooling 
process.  For these samples, it is considered that the freeze-drying method 
caused minimal change to the structure of the tablet core and was selected for 
all further work. 
Stability of samples 
Consideration was also given to the stability of sample components. The 
energy of X-ray in SR-μCT is high and will heat samples, and some may undergo 
 38 
 
physical and chemical changes. Therefore, samples used for SR-μCT scan are 
required to have good thermal stability.  
Size of samples 
Image resolution should be chosen primarily according to the absorption of 
samples. Higher resolution indicates a smaller acquisition window. Thus, limited 
by the acquisition windows during the SR-μCT test, the size of samples should 
be carefully considered.  
Choose of containers 
In this study, samples used for SR-μCT scan need to be positioned in certain 
containers such as plastic tube and capsule shells. These containers require the 
features of rigidity, thinness, weak X-ray absorption and homogeneous structure.  
Fixation of samples 
To capture enough image information, the sample stage will rotate 180 ° 
during the SR-μCT scan. Rotation of the sample stage could lead to unexpected 
movement of samples, especially for the powder and granule samples. Thus, 
samples should be rigidly fixed.  
Number of samples 
A different number of samples are required to be examined depending on 
the specific investigation target. If the study objective is a focus on the 
macroscopical action, such as investigation of granular systems, samples of a 
large number granules should be chosen. In contrast, when for sample 
microscopical internal structures are being investigated tens of granules may be 
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sufficient on condition that the results have statistical significance. In order to 
recognize two or multi-component systems in each granule by SR-μCT, a diluent 
with weak absorption can be added to separate each granule. When quantifying 
swelling and erosion in felodipine extended release tablets for example, 18 
tablets were taken and divided into nine groups, each containing two tablets and 
a standard dissolution test was carried out. At 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 
and 8.0 h, two tablets were removed from the dissolution medium and prepared 
for further testing [25]. 
Samples of dynamic process studies 
It would be advantageous to visualize the internal structure of materials post-
manufacturing and focus for example on dynamic properties of pore structure and 
porosity changes during drug dissolution and diffusion from tablet samples. SR-
μCT can produce 3D images of materials with a voxel size of around several 
micrometres cubed, allowing the visualization of internal and microstructural 
details with different X-ray absorbencies. Whilst in vitro dissolution test is usually 
used to evaluate the drug release behaviour of DDS, such as tablets. SR-μCT 
can be used to evaluate the temporal changes in the pharmaceutical 
microstructure during drug release. For metal element containing active 
pharmaceutical ingredients with relatively high densities, such as ferrous 
sulphate, tablets containing these materials can be imaged directly using the SR-
μCT technique during dissolution testing. The dissolution medium will not 
influence either the imaging or the visualization of the microstructure of the tablet 
core. However, for non-metallic drugs with similar density to the dissolution 
medium, such as felodipine, that do not have metallic elements in their molecular 
structure, the dissolution medium will interfere with the imaging [26]. 
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Unfortunately, most drugs are not metallic compounds. Therefore, for studying 
drug dissolution effects dynamically, tablets taken out from the dissolution 
medium must be dried prior to the image acquisition. In published research, 
tablets are first frozen in liquid nitrogen or ultralow temperature refrigerator then 
dried using a freeze dryer [27].  In the studies reported in this thesis, in order to 
maintain the shape of the tablets from dissolution testing, swollen tablets were 
carefully removed using small spoons together with about 2 mL of the medium 
and placed individually in 24-well plates with 2 mL of the corresponding 
dissolution medium added to maintain the original shape of the tablets. The 24-
well plates containing the tablets in various states of hydration and erosion were 
then immediately placed into the ultra-low-temperature refrigerator at −80°C for 
12 h. After this process, the tablets were freeze-dried over a period of 24 h at 
−50 °C and 10 mTorr using a freeze dryer. These tablets were then kept in the 
dry cabinet under ambient temperature (relative humidity of 20%) for further SR-
μCT tests and were not reused in dissolution tests [28].  
This method has also been evaluated to dry the felodipine monolith osmotic 
pump tablet prior to image acquisition. However, due to the special structure of 
the monolith osmotic pump tablet and the fact that the volume expansion of water 
during the phase transition from liquid to ice during freezing  leading to the 
internally dissolved solution and suspension content of the drug in the tablet core 
being forced out through orifices, this procedure was not used. Furthermore, the 
remains of the tablet cores are mainly gels, and the formation of water crystals at 
low temperature may destroy the internal microstructure. 
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2.2.2 Image acquisition 
Accurate and precise experimental results based on the high quality images 
acquired during the CT scans are essential. In order to guarantee the precision, 
it is imperative to optimize the parameters according to the objective of 
experiment and the properties of prepared samples. The various parameters 
requiring consideration are as follows: 
a) The resolution of images is determined both by the magnification of the lens 
and the pixel size of CCD. As the CCD is fixed, the higher resolution means a 
smaller area of acquisition window. There is thus a trade-off between the size of 
the whole sample and the expected resolution required to examine the smallest 
component in the microstructure. 
b) The photon energy of synchrotron X-rays have a range of 1~>200 KeV which 
has potential for damaging the samples. For the selection of X-ray energy, factors 
such as the sample components, molecular weights, density of materials and the 
thickness of sample should be considered. 
c) The exposure time affects the X-ray photon number reaching the detector. 
When the exposure time increases, the flux of CCD to capture a projection will 
be raised. A CT scan with an unsuitable exposure time will not generate 
highquality images. A long exposure time may lead to an overexposure that would 
affect the contrast between materials and increase the scan time of every sample. 
In the case of underexposure, the signal-noise ratio will be reduced. In addition, 
the radiation dose should be taken into account as a long time exposure to X-ray 
can result in deformation of sample and radiation damage. 
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d) The distance between sample and detector (DSD) is a key factor in in-line 
phase contrast SR-μCT, and especially useful for the imaging of materials with 
low-Z elements and low-density. Within a certain distance, longer DSDs provide 
an improved phase contrast which benefits distinguishing materials with small 
difference in density that cannot be distinguished by the absorption contrast 
method. 
e) The number of projections is typically determined by the size of the sample 
and the precision required for the experiment. During the scanning, the sample 
rotates 180° and projections will be captured at certain angles. More projections 
will enhance the quality and restrain any artefacts (i.e. misleading or confusing 
alteration in data or observation, commonly found in experimental science, 
resulting from flaws in technique or equipment). however, more projections will 
lengthen the scanning time and will lead to potential radiation damage as 
mentioned above. 
Prepared samples need to be positioned in a suitable container and attached 
to the sample stage to prevent any unexpected movements during scans. Axis 
adjustment of the sample stage is also necessary to make sure that there is no 
deviation in the horizontal direction during sample rotation. After X-ray 
penetration through the sample, the projections are magnified by diffraction-
limited microscope optics and digitized by a CCD camera. For each acquisition, 
a certain number of projection images over 180° sample roration are taken. Light 
field images (i.e. X-ray illumination on the beam-path without the sample) and 
dark-field images (i.e. X-ray illumination off) are also collected during each 
acquisition, for corrections due to electronic noise and variations in the X-ray 
source brightness. 
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Table 1 Parameters of SR-μCT scans for different samples.	
Samples X-ray Energy /Kev 
DSD 
/cm 
Resolution /
μm 
Projections 
/pic 
Exposure 
time /ms 
Cellulose pellets and 
starch granules 13 25 13.00 630 1000
Tamsulosin sustained 
release pellets 16 12 3.70 720 3000
Clopidogrel polymorphs 
crystal particles 16 12 3.70 720 2000
Clopidogrel polymorphs 
crystal tablets 16 12 3.70 720 2000
Felodipine osmotic 
pump tablets 13 25 5.92 900 4000
felodipine HPMC gel 
matrix tablet 13 10 9.0 720 4000
Laser drilling orifices 18 10 3.25 720 1000
Droplet driven osmotic 
pump tablet 18 10 3.7 720 2000
Dynamic CT 18 10 6.5 230 2
 
2.2.3 Phase contrast and phase retrieval 
In order to investigate the distribution of low Z materials in samples, the 
propagation-based imaging (PBI) method can be used for phase contrast imaging 
for the simplest experimental implementation. The imaging parameters should be 
optimized according to preliminary experiments and references. From the 
theoretical complex refractive index detail, it is required that to enhance the phase 
contrast X-rays with a lower energy should be selected for imaging (Figure 13). 
For interrogating various sample properties including composition, density and 
proportions, samples were scanned at low energy for achieving the balance 
between the penetration ability and the higher flux to reduce the imaging times. 
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In order to enhance the contrast to show a small difference in density, the sample-
to-detector distance was also adjusted appropriately.  
 
Figure 13 The delta/beta ratio for a range of materials between 10-150 keV x-ray energy 
 
The projected images for the samples were reconstructed using the X-
TRACT SSRF CWSx64 (CSIRO, Commonwealth Scientific and Industrial 
Research Organization, Australia, http://www.ts-imaging.net) to perform a direct 
filtered back projection algorithm. To enhance the quality of reconstructed slices, 
propagation-based phase contrast extraction was carried out. In phase contrast 
imaging, the amplitude and phase of X-rays are affected by the interaction of the 
wave with matter and the forward diffraction is formally be described by the 
complex refractive index (n) of the medium as 
n = 1 - δ - iβ                                                                                                 
The refractive index δ results in a phase shift, and the absorption index β is linked 
to the linear absorption coefficient μ. The theoretical values of β and δ were 
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calculated with the X-ray attenuation properties model of DCM (software for the 
data-constrained modelling and characterization of material compositional 
microstructure and properties, which was developed by CSIRO, 
http://research.csiro.au/dcm). The larger sample-to-detector distances increased 
the contrast primarily due to the contribution from differences in the refractive 
properties across the sample in addition to differential absorption. In combination 
with Homogeneous Transport of Intensity Equation (TIE-Hom) phase retrieval 
achieves high quality reconstructed 3D images. The value of β can be accurately 
reconstructed with TIE-Hom and conventional CT reconstruction from a single 
projection image per view angle. In contrast, the accuracy of reconstruction of δ 
depends strongly on the choice of the “regularization” (δ/β) parameter in TIE-Hom. 
During phase extraction, the parameter of δ/β can be adjusted to theoretical 
values. After phase retrieval and reconstruction, the calculated β in the images 
must be truncated and rescaled to a grey value of 0 to 255 (8 bit grey level) [29].  
2.2.4 The 3D reconstruction and quantitative characterization 
3D reconstruction from reconstructed slices is used for the creation of three 
dimensional models. The projections were converted to reconstructed slices 
using a filtered back-projection algorithm. In order to enhance the quality of 
reconstructed slices, a phase retrieval algorithm is included for phase contrast 
extraction. The 3D rendered data were analysed with commercially available 
software such as VGStudio Max (Volume Graphics GmbH, Germany), Amira 
(Visualization Sciences Group, France) and Image Pro Analyser 3D (Media 
Cybernetics, Inc., USA) to obtain qualitative and quantitative information. After 
segmentation, slices were all converted into black and white images by removal 
of the background and noise. Then 3D ISO-Surface models were constructed 
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with segmented slices. The surface level, surface range and the simplification 
parameters were adjusted to optimize the models. Then all objects in the samples 
were extracted to calculate the steric parameters. 
As the model construction and analysis are compute-intensive tasks, the 
reconstructed slice stacks were converted into 8-bit greyscale format and 
cropped for accuracy and computational efficiency. Then, the resized slices of 
samples were processed to enhance quality, reduce noise and analysed to 
determine the threshold grey values to distinguish different materials and micro-
structures. In most case the quantitative criterion to distinguish the objects of 
interest is the grey value, but for some samples with ultra-complex structures or 
challenging material contents, the morphological information will be more suitable. 
All samples in the same group experiments were processed with consistent 
parameters to ensure that all result can be compared quantitatively. 
The optimized 3D models provide full detail of the surface morphology, as 
well as the internal 3D structure. Based on the difference in grey value between 
materials, objects or micro-structures of interest can be extracted from the 3D 
models by segmentation. With the ISO-Surface model many 3D steric 
quantitative parameters can be calculated. The names and descriptions of these 
parameters are listed below: 
Volume: Volume of object in calibrated units; 
Surface area: Surface area of object in calibrated units; 
Width: Size of bounding box in X direction; 
Height: Size of bounding box in Y direction; 
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Depth: Size of bounding box in Z direction; 
Centre X: X coordinate of the centre of object; 
Centre Y: Y coordinate of the centre of object; 
Centre Z: Z coordinate of the centre of object; 
Box Volume: Volume of object's bounding box (V = W * H * D); 
Box ratio: Ratio between maximum and minimum size of the bounding box. (R = Max / 
Min); 
Volume fraction: Ratio of object's volume to the box   volume (R = Vobj / Vbox); 
Diameter: Equivalent diameter of object; 
Sphericity: Sphericity of object, calculated as 6 volumes of object divided by equivalent 
diameter and surface area of object. For a spherical object this parameter equals 1, for 
all other shapes it is less than 1; 
Radius (max):  Maximum distance between an object's centroid and surface; 
Radius (min):  Minimum distance between an object's centroid and surface; 
Radius Ratio: Ratio between Radius (max) and Radius (min); 
Feret (max): Maximum distance between two parallel planes enclosing an object; 
Feret (min):  Minimum distance between two parallel planes enclosing an object; 
Feret Ratio: Ratio between Feret (max) and Feret (min); 
Surface deviation: is calculated as the deviation of end points of a triangle normal. The 
calculations are done as follow: all triangle normal vectors of the surface are normalized 
(length set to 1) and the average distance from the mean position of the end-points to all 
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other vectors is calculated. A uniform surface will have a deviation of 0, and the maximum 
deviation of 1.336 will occur for a sphere. 
These parameters enable additional parameters such as porosity, specific 
surface area and roughness to be calculated which help to further describe the 
morphology of the sample. Relationships can then be explored between all the 
structural parameters and correlated with the properties of the sample, which 
include the drug content, drug release kinetics and how is the pharmaceutical 
processing affectting the structure. In addition, multivariate analysis, data mining, 
and modelling methods can be introduced to construct statistical models. 
2.3 Dynamic computed tomography method 
Drug substances and DDS ingredients are usually low Z materials. In order 
to study drug release characteristics in situ, monochromatic-beam-based high-
contrast quantitative dynamic CT needed to be devised and developed. When 
conventionally white beam is used to realize dynamic CT, the quantitative 
properties of the sample are lost. In this study, monochromatic beam based 
phase-contrast quantitative dynamic CT has been established with a millisecond 
time resolution and a spatial resolution of 6.5 μm. The developed method is able 
to record continuously 200 seconds of a dynamic process by adapting a sCMOS 
sensor based detector and introducing compressed sensing (CS) theory into CT 
reconstruction. Additionally with the phase retrieval algorithm implemented, 
quantitative information of the sample is extracted for further analysis.  
Compressed sensing (also known as compressive sensing, compressive 
sampling, or sparse sampling) is a signal processing technique for efficiently 
acquiring and reconstructing a signal, by finding solutions to underdetermined 
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linear systems. Compressed sensing is based on the concept that, through 
optimization, the sparsity of a signal can be exploited to recover it from far fewer 
samples than are required by the Shannon-Nyquist sampling theorem. The 
possibility of recovery depends on two conditions. The first is sparsity, which 
requires the signal to be sparse in some domain. The second one is incoherence 
which is applied through the isometric property which is sufficient for sparse 
signals. Total variation can be seen as a non-negative real-value function defined 
in the space of real-value functions (for the case of functions of one variable) or 
in the space of integrable functions (for the case of functions of several variables). 
In image reconstruction, it is applied as total variation regularization where the 
underlying principle is that signals with excessive details have high total variation 
and that removing these details, while retaining important information such as 
edges, would reduce the total variation of the signal and make the signal subject 
closer to the original signal in the problem. 
For the purpose of image reconstruction, minimization models are used. The 
current CS Regularization models attempt to address this problem by 
incorporating sparsity priors of the original image, one of which is the total 
variation (TV). Conventional TV approaches are designed to give piece-wise 
constant solutions. This method, though fast, subsequently leads to over-
smoothing of edges resulting in blurred image edges. TV methods with iterative 
re-weighting have been implemented to reduce the influence of large gradient 
value magnitudes in the images. This has been used in computed tomography 
(CT) reconstruction as a method known as edge-preserving total variation [30]. 
This method would have 2 stages: the first stage estimates and refines the initial 
orientation field - which is defined as a noisy point-wise initial estimate, through 
 50 
 
edge-detection, of the given image. In the second stage, the CS reconstruction 
model is presented by utilizing a directional TV regularizer.  
The incorporation of compressive sensing reduced the number of projections 
required while maintaining image quality. Combined with a rapid sCMOS detector, 
the data acquisition process is speeded up, which makes X-ray dynamic-CT more 
practicable. Moreover, a phase retrieval algorithm based on one set of projections 
was developed to provide quantitative information of the sample. During data 
processing, GPU-CUDA based parallel computing architecture is employed to 
process the massive SR-μCT data. As a result, in-situ investigation on the drug 
delivery dynamics can be carried out at SSRF, while the microstructures of the 
pharmaceutical preparations with quantitative and high-contrast information, 
were revealed three dimensionally. 
The methodology developed for investigating the dynamic microtomography, 
focuses on improving the time resolution and the high spatial resolution. The 
generation and evolution of the microstructures during drug release process, 
especially at its initial state, is critical to the investigation on the driving 
mechanism of the drug release process. High spatial resolution and high contrast 
imaging form the basis of achieving quantitative analysis (Figure 14). 
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Figure 14 Experiment condition for dynamic CT 
Improving the time resolution: The rate of change of the microstructures during 
drug release is relatively fast, and tracking of microstructure changes in a short 
time is crucial to the research on the correlation between structure and release 
kinetics. Practical approaches include decreasing the exposure time and 
reducing the number of projections. 
Improve the contrast: Since the active ingredient and excipients of conventional 
pharmaceutical preparations are weak absorbing organic materials, improving 
the discrimination among different materials is critical for studying the internal 
drug distribution of the preparations. The investigation on the release mechanism 
of the drug formulation also needs in situ determination on the structure changes 
during the release process. Therefore, the discrimination between material 
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preparation and the dissolution medium needs to be further improved by reducing 
the distance of dissolution medium that the X-ray needs to penetrate. 
Phase retrieval: Single image based phase retrieval is used for component-
resolving imaging for samples of mixtures. Considering the duality effect of the 
binary mixed substances, derived phase-absorb duality Bronnikov algorithm and 
phase-absorb duality Born approximation algorithm are applied to improve 
quantitative accuracy of phase retrieval. The anti-noise ability of phase retrieval 
algorithm was optimized, taking into account the sample constituents, statistical 
noise and structural noise. 
General comments 
In this Chapter, SR-μCT imaging methodology is described for quantitative 
characterization of the structure. Principles of the synchrotron radiation imaging 
include the preparation of samples, optimization of imaging parameters and the 
evaluation of image quality are described. Protocols and workflow of data 
analysis especially image processing and 3D reconstruction have been 
established. In the next chapter, the developed methodology will be applied to 
define the quantitative evaluation of irregular micro-structures of DDS as well as 
particles from intermediate processing to demonstrate the potential of the new 
methods for quantitative analysis in describing the detail of the surface 
morphology and the internal 3D structure of solid pharmaceutical structures.
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Chapter 3 
Characterization of Typical 
Pharmaceutical Structures 
- Quantification of Irregular and 
Complex Structures 
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3.1 The structure of pharmaceutical particulates 
3.1.1 Spherical microcrystalline cellulose core pellet and 
irregular starch granules 
Granule Morphology Characterization by SR-μCT 
The individual granular systems of microcrystalline cellulose and starch are 
characterized using SR-μCT(detailed information please refer to: S 1 Granule 
sample preparation and reconstruction). Highly resolved tomographic images with 
high quality phase contrast were derived for each single particle after 3D 
reconstruction. During image segmentation, a region growth algorithm was 
implemented to separate particles in contact with each other. Then, four particles 
of each granular system were randomly selected to show the morphologies and 
spatial information (Figure 15). As can be seen, the morphologies of the 
microcrystalline cellulose and starch granules are markedly different. As 
expected, compared with the irregular shaped starch granules, the 
microcrystalline cellulose granules show a regular spherical profile.  
 
Figure 15 The morphologies of randomly selected four particles imaged by SR-μCT. 
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 (a) particle 1, (b) particle 2, (c) particle 3 and (d) particle 4 of the starch granules, (e) 
particle 1, (f) particle 2, (g) particle 3 and (h) particle 4 of the microcrystalline cellulose 
granules, the scale bar is 1000 μm. 
The characteristics of the two types of particles as determined by SR-μCT 
also differ in many parameters (Table 2, Table 3). The equivalent diameter is 
defined as the diameter of a ball of equivalent volume. Width, height and depth 
represent the side lengths of a minimum sized bounding box for a particle. 
Depending on the measuring method applied, the particle size is derived from 
different physical properties (i.e. volume, surface area and equivalent diameter). 
The results show that the microcrystalline cellulose granules have a smaller 
particle size compared with the starch granules. In attempting to describe the 
shape of particles, several parameters including box ratio, volume fraction and 
sphericity are introduced. Box ratio is the ratio between maximum and minimum 
side length of the bounding box (box ratio value≥1; values closer to 1 the more 
spherical the granule). The volume fraction is defined as the volume of a particle 
divided by the volume of its bounding box (the volume fraction value of a sphere 
is 0.52; the closer to a value of 0.52 the more spherical the granule). As can be 
seen, the microcrystalline cellulose and the starch granules differ in that the 
former is more spherical, whereas the latter is more irregular shaped, with results 
showing good agreement with the 3D image (Figure 15). These analyses confirm 
that the characteristics of both spherical and non-spherical granules, including 
particle size and shape information, can be measured efficiently by SR-μCT. 
Furthermore, since characterizing individual granule is an important requirement, 
this investigative process carried out supports this ambition. 
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Table 2 The characteristics of starch granules obtained by SR-μCT.	
starch granules  a b c d 
Volume /μm3 1.40E+08 1.52E+08 1.96E+08 1.46E+08 
Surface area /μm2 1.34E+06 1.40E+06 1.65E+06 1.37E+06 
Diameter /μm 646.39  634.87  739.00  686.67  
Width /μm 689.18  713.24  765.25  678.43  
Height /μm 644.33  660.08  712.19  683.38  
Box ratio 0.49  0.51  0.49  0.46  
Volume fraction 24.78  25.46  27.70  25.14  
Sphericity 0.97  0.98  0.99  0.98  
Table 3 The characteristics of microcrystalline cellulose granules obtained by SR-μCT. 
microcrystalline 
cellulose a b c d 
Volume /μm3 6.36E+08 7.09E+08 1.05E+09 1.13E+09 
Surface area /μm2 8.98E+06 7.38E+06 1.04E+07 1.27E+07 
Diameter /μm 1066.93  1106.28  1260.21  1292.61  
Width /μm 1712.91  1568.80  1867.80  2301.87  
Height /μm 2006.54  1321.27  1656.59  1933.99  
Box ratio 1.58  1.19  1.13  2.00  
Volume fraction 0.15  0.25  0.18  0.22  
Sphericity 0.40  0.52  0.48  0.41  
Granular system analysis using statistical methods 
Based on characteristic data of about 50 particles, the individual granular 
systems are described by means of frequency distributions. The individual 
granular system is highly homogeneous in that the frequency distributions of 
volume, surface area and sphericity are similar in both upper and lower levels 
(Figure 16, Figure 17). In comparison with the microcrystalline cellulose granules, 
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most starch granules are larger with broader volume and surface area 
distributions. For this reason, the frequency distributions of volume and surface 
area are not suitable to be applied to distinguish between the two different 
granular systems. However, the frequency distributions of sphericity are markedly 
different, lying within relatively narrow ranges (Figure 16c, g, Figure 17c, g). Thus, 
the microcrystalline cellulose and starch granules can be distinguished from 
mixed systems by calculating the frequency distribution of sphericity. Depending 
on the sphericity of each granule, the reconstructed images of granular systems 
are displayed with different colours. The colour scheme has been chosen such 
that yellow to red illustrates an increasing and high sphericity whereas green to 
dark blue corresponds to an increasing and low sphericity. Images show that the 
individual granular systems are highly homogeneous (Figure 16d, h, Figure 17d, h). 
The two species have markedly different sphericity, with the yellow to red regions 
demonstrating higher sphericity of the microcrystalline cellulose granules as 
compared to the green to blue regions of starch ones.  
It is not possible to determine accurately the physical characteristics of all 
particles since a number of particles cross the boundary of the image. As large 
particles run a higher risk to cross the boundary, removing all boundary particles 
from the analysis may induce a bias. In our study, the boundary particles were 
excluded from the system manually. A minus-sampling edge correction was also 
applied such that all particles having their centre of the bounding box inside the 
observation window are completely contained in the image. The statistical 
evaluation is then confined to these particles.  
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Figure 16 The frequency distribution and 3D images of individual starch granular system.  
(a-d): Frequency distribution profiles of volume (a), surface area (b) and sphericity (c) and 3D 
image (d) for starch granules in the upper level of the cylindrical vessel. (e-h): Frequency 
distribution profiles of volume (e), surface area (f) and sphericity (g) and 3D image (h) for starch 
granules in the lower level of the cylindrical vessel, the scale bar is 2000 μm and the standard jet 
colormap indicates the sphericity range from 0.0 to 1.0. 
 
Figure 17 The frequency distribution and 3D images of individual microcrystalline cellulose 
granular system. 
 (a-d): Frequency distribution profiles of volume (a), surface area (b) and sphericity (c) and 3D 
image (d) for microcrystalline cellulose granules in the upper level of the cylindrical vessel. (e-h): 
Frequency distribution profiles of volume (e), surface area (f) and sphericity (g) and 3D image (h) 
for microcrystalline cellulose granules in the lower level of the cylindrical vessel, the scale bar is 
2000 μm and the standard jet colormap indicates the sphericity range from 0.0 to 1.0. 
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3.1.2 Pellets of multi-particulate dosage form  
Multi-particulate solid dosage formulations contain numerous discrete 
particles (e.g., pellets and granules) that are filled into hard gelatine capsules or 
compressed into tablets, forming a single dose unit. Multi-unit dosing forms have 
gained considerable popularity over conventional single unit products for 
controlled release technology due to the following advantages: a) rapid 
dispersion in the gastrointestinal tract to maximise drug absorption, reducing 
peak plasma fluctuations and minimize potential side effects without lowering 
drug bioavailability; b) reducing susceptibility of dose dumping than reservoir- or 
matrix-type single-unit dosage forms; c) flexibility during product development 
because pellets containing different drug substances can be blended to formulate 
a single dose form. However, although several technologies for the production of 
multi particulate systems have been designed, thus far the mainstream 
technologies used industrially are still based on spray-drying, spheronization, and 
film-coating technology. Limitation of process variables caused by multiple 
formulation steps can act as technical hurdles in manufacturing reproducibility 
and reduced product safety and efficacy [31]. 
Visualisation of surface morphology and internal 3D structure 
Tomographic imaging techniques help improve our understanding of the 
quality, performance and release mechanisms of pharmaceutical dosage forms. 
In these studies, as mentioned previously the full 3D image is not recorded 
directly; instead, it is obtained by reconstructing 2D image cross-sections and 
stacking the reconstructed slices (for detailed information on S 2 Imaging and 
quantitative characterization of single pellets see S 2). The high-resolution 3D 
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images obtained from SR-μCT refer in this section to a model that reproduces 
the morphology and microstructure of a pellet (Figure 18a); the 3D rendering model 
displays comprehensive detailed structural information on all pellets in the 
sample. From 2D slice and reconstructed 3D model, voids in pellets are clearly 
identified. The voids are spherical in shape which is thought to be caused by the 
volatilization of binder solution in the drying process. A porous pellet and a solid 
pellet are randomly selected to show the morphological and microstructural 
information (Figure 18b). The differences in the shape, size, morphology and 
internal structure of each pellet are clearly visualised, although it was difficult to 
distinguish the solid pellets from those with voids using only the apparent 
morphology. Internal void could not be detected without the CT technology. 
 
Figure 18 Characterisation of the pellets. 
 a The reconstructed 3D model of pellets imaged using SR-μCT showed the sphericity with the 
blue to red regions demonstrating incrementally higher sphericity; b a typical solid pellet and one 
with a void, the scale bar is 1000 μm and the standard jet colormap indicates the sphericity range 
from 0.7 to 1.0. 
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3D Parameter Calculations 
The traditional measurement methods for the speciﬁc surface area of 
powdered materials are gas adsorption [32] and the ethylene glycol monoethyl 
ether method. SR-μCT in contrast provides three-dimensional topographic 
images on the sub-micrometer scale. Therefore, pellet properties, such as the 
diameter, the surface roughness and the internal void, can be extracted from 
these images, clearly visualised and used to calculate the volume and speciﬁc 
surface area for each pellet. 
The ability to visualise the microstructures of the individual pellet from the 
results of the CT scans and 3D reconstructions from samples containing many 
individual pellets is valuable when investigating the drug release mechanism. 
When attempting to describe the pellets, approximately 40 steric quantitative 
parameters can be obtained from the reconstructed model. The most important 
ten parameters that are closely related to the release profile have been selected 
by principle component analysis (PCA) and are listed in Table 4. Here the 
diameter is the diameter of a ball with an equivalent volume and the void fraction 
is the volume of the void divided by that of the pellet. 
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Table 4 The names, descriptions and the units of the 3D Parameters 
3D parameters Description  Units 
Volume Volume of the whole pellet μm3 
Surface area Surface area of whole pellet μm2 
Diameter Equivalent diameter of whole pellet μm 
Sphericity A measure of how spherical an object is Dimensionless 
Volume of void Volume of the void μm3 
Surface area of void Surface area of the void μm2 
Void fraction The volume of voids over the total volume % 
Specific surface area The surface area per unit volume μm-1 
Surface area without void  Surface area of the pellet without void μm2 
Drug content in unit volume The amount of drug in unit volume ng/μm3 
 
Based on the data above, the pellets were different in size and shape from 
one another within the approximately 1000 pellets in each Tamsulosin sustained 
release capsule. The total capsule fill of pellet particles is described using a 
frequency distribution (Figure 19) which shows that the size (volume, surface area 
and diameter) distributions have a wide range and do not exhibit Gaussian 
distributions. In addition, most pellets have a value close to 1 for sphericity, while 
some pellets are still irregular. The specific surface area of most pellets is 
between 0.007 and 0.035 μm-1. Approximately 50% of the pellets are solid, and 
the other half have voids with variable volumes and surface area distributions. 
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Figure 19 The frequency distribution for different parameters of the pellets 
In Figure 20, the blue domains represent the pellets with small surface areas, 
and red domains represent large surface areas. The smaller pellets (with respect 
to surface area and volume) were more spherical. A few pellets were ovoid in 
overall shape due to the deformation under pressure during the pellet formation 
and coating processes. The deviations in size decreased when the particles were 
more spherical. However, no strong correlation was detected between the void 
fraction and the other parameters. For example, the void fraction distribution and 
the diameter showed a random tendency without a significant co-relationship 
(Figure 20 b). 
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Figure 20 Correlation between (a) pellet volume and sphericity, (b) diameter and void fraction.  
The colour coding (bar on the right) referred to the surface area of the pellet. 
In summary, based on the SR-μCT technique, detailed information regarding 
the surface morphology, internal 3D structure and quantitative pore 
characteristics of the pellets were clearly visualised from the 2D monochrome X-
ray CT images and reconstructed 3D tomography images. 
3.2 Crystal form identification in polymorphic mixtures 
Polymorphism is the ability of the atoms and/or molecules of solid material 
to exist in more than one crystal structure, and can potentially be found in many 
crystalline materials including polymers, minerals, and metals. Polymorphism is 
of great theoretical and practical interest for the pharmaceutical industries, since 
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different polymorphs of the same compound exhibit diverse physicochemical 
properties of solubility, dissolution rate, stability, and mechanical properties, 
thereby influencing the bioavailability and therapeutic efficiency of the formulated 
drug products[33, 34]. Many polymorphic drug substances approved by the 
regulatory authorities are for one specific polymorph of the compound [35]. 
However, individual polymorphs may convert to another during manufacturing 
process and storage, particularly when a metastable form is used and a resulting 
more stable polymorph is likely to exhibit a lower dissolution rate. Since an 
amorphous form is thermodynamically less stable than the crystalline form, 
spontaneous crystallization from an amorphous drug substance may also occur 
[36, 37]. Therefore, the investigation of crystal polymorphism of active 
pharmaceutical ingredients (APIs) is of increasing importance to the 
pharmaceutical industry, either in the early stage of drug discovery research or in 
the development and manufacture of a drug delivery system. 
Several techniques can be applied to identify and characterize solid-state 
forms and polymorphic composition of APIs in raw materials and dosage forms, 
such as X-ray diffraction (XRD), thermal methods (including differential scanning 
calorimetry (DSC), thermal gravimetric analysis (TGA) and isothermal 
microcalorimetry (IMC)), vibrational spectroscopy (including mid-infrared (IR), 
near-infrared (NIR), Raman, and terahertz pulsed spectroscopy (TPS)), solid 
state NMR (SS-NMR), atomic force microscopy (AFM), optical and electron 
microscopy [38-41]. Whilst powder X-ray diffraction (PXRD) has increasingly 
been regarded as the definitive test for the crystallographic identification of 
polymorphs, it can only be used to quantify non-crystalline or second component 
crystalline material down to levels of 5% [33]. In addition, its use for quantitative 
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analysis is often marred for samples with complex scattering patterns, since the 
isolation of the diffraction peaks of the APIs and excipients peaks may be difficult 
and some low intensity peaks may exist in the background because of the effect 
of residual solvent in the sample, factors which may interfere with the 
interpretation of results[33]. 
For clopidogrel bisulphate (CLP), six polymorphs are known, but only two 
(form I and form II) are used as therapeutic agents. Form II as well as several 
solvate forms and amorphous form of the substance are patented, but Form I is 
now out of patent control and available for generic product development and 
marketing[42, 43]. As clopidogrel bisulphate polymorphs comprise an 
enantiotropic system, and Form II is the thermodynamically more stable form at 
room temperature[44], there is a potential for the occurrence of Form II in Form I 
both in the production steps and during the storage period. Thus, a suitable 
analytical technique for the detection and quantification of low levels of the stable 
form II in the metastable Form I material is needed. A recent publication has 
reported on the quantitative analysis of clopidogrel bisulphate polymorphs by X-
ray powder diffraction[42]. The authors used whole powder pattern 
decomposition as well as classical direct methods for quantification in the range 
of 10-80% Form I in Form II. The limit of detection using both methods is in the 
range of 1-2% of phase content in the mixture. A previous study utilized 
transmission FT-IR spectroscopy for the quantitative measurement of clopidogrel 
bisulphate polymorphs[43], by using unique peaks of the forms in the analytical 
range of 10-90% Form I in Form II. Low levels of Form II in Form I are 
undetectable because characteristic bands of Form II are not visible in the IR 
spectra of the mixture below 30%. Recently, vibrational spectroscopic methods 
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have been developed for quantitative analysis of Form II of clopidogrel bisulphate 
in Form I and Form II polymorphic mixtures. Results show that both IR and 
Raman spectroscopy combined with chemometrics are suitable to quantify low 
levels of Form II in Form I, down to 2 and 3%, respectively, a limit of detection 
less than 1%[44].  
However, it is still a great challenge to identify quantitatively the polymorphs 
in multi-component mixtures, or with binary mixtures in which the crystalline form 
of interest is present at a low level. Microscopic methods based on the image 
acquisition followed by a suitable image-analysis scheme to extract 
morphological details may be useful tools to quantify the trace amount of 
polymorphs by morphology. These approaches are likely to prove especially 
powerful for the characterization of minor phases in mixtures and, provided that 
a suitable crystallite can be located, the analysis can be performed on 
exceptionally small amounts of material. The particular value of these methods 
lies in the possibility it offers for combining imaging, diffraction and spectroscopic 
data from the same sample, with the potential for simultaneous acquisition of 
different data types. For example, in scanning mode, direct imaging of the crystal 
lattice can be coupled with spectroscopic analysis to yield chemical information 
at the unit cell level; in imaging mode, the technique is routinely used for the 
identification and characterization of defect structures; and in diffraction mode, 
detailed investigations of both symmetry and crystal structure are possible [45, 
46].  
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The present study employed synchrotron radiation X-ray computed 
microtomography (SR-μCT) to devise and develop an accurate and sensitive 
method for identification and quantification of polymorphs, using forms I and II of 
clopidogrel bisulphate (CLP) crystal particles as a model (detailed information 
please refer to: S 3 Crystallographic analysis and reconstruction of CLP polymorphs 
particles). The SR-μCT was first employed to visualize the morphology and to 
identify qualitatively CLP I and CLP II. The steric parameters of CLP polymorph 
particles, such as size, sphericity and surface properties were calculated. Then a 
new parameter, VBP (Volume bias percentage) was derived which eliminated 
interference from any other excipients present to achieve the quantitative 
identification of polymorphs with an in-situ 3D view. 
3.2.1 CLP polymorphs characterization 
The XRPD profiles of CLP I and II are shown in Figure 21, and these are 
in good agreement with those reported in literatures [43, 47]. The optical 
microscopy and SEM images in Figure 21 indicate that particles of the two 
polymorphs are all polycrystalline rather than individual larger single crystals, 
but the primary particles within the polycrystalline assemblies of CLP-I 
particles are smaller and more spherical, in contrast with the larger columnar 
single primary crystalline units of CLP-II which form an irregular and rough 
surface for the polycrystalline assembly. 
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Figure 21 PXRD and morphology of CLP I and CLP II crystal particles. 
 (a) PXRD, (b) optical microscopy and SEM morphology of CLP I, (c) optical microscopy and SEM 
morphology of CLP II. 
Quantitative characterization of the polymorphs.  
Based on the analysis of grey values, all of the crystal particles in the sample 
were extracted by the grey level segmentation. Then the highly resolved 
tomographic images of CLP I and CLP II with high quality phase contrast were 
derived for each single particle after 3D reconstruction as shown in Figure 22. Both 
samples had hundreds of individual microcrystalline particles, which were 
coloured with pseudo-colour according to the volumes of particles. Then, four 
particles of each crystal form were randomly selected to show the morphologies 
and spatial information (Figure 22). As can be seen, the morphologies of the CLP 
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I and CLP II differ from each other. The particle shapes of the two crystal forms 
were all irregular but the surface of CLP II exhibited a greater degree of 
topographical roughness than CLP I, a finding which is in good agreement with 
that shown in the optical microscopy and SEM images. 
 
Figure 22 3D images of individual CLP I and CLP II microcrystalline particles in the capsule after 
extraction and construction. 
 (a) Particles of CLP I and (b) particles of CLP II. Morphologies of randomly selected four particles 
(c) particles of CLP I and (d) particles of CLP II, the scale bar is 1000 μm and the standard jet 
colormap indicates the volume range from 6E5 to 2E7. 
Based on characteristic data of single particles, the individual primary 
particles clusters of CLP I and CLP II are described by means of the frequency 
distribution of volume, surface area, diameter, box ratio, volume fraction, 
sphericity, radius min and Ferret min, as shown in Figure 23. In comparison with 
the CLP I particles, the diameter distribution shows that the particle cluster of CLP 
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II has a larger average diameter, although both clusters were all fractionated with 
standard sieves prior to scanning (CLP I from 150 μm to 400 μm, CLP II from 200 
μm to 400 μm,). This finding is likely to be caused by the difference in 
morphological properties between the two crystal forms, as can be seen from 
Figure 23. The CLP I microcrystalline particles are all oblate objects with relatively 
smooth surfaces in contrast to those of CLP II which are all much more irregular, 
rough and complex. The particle cluster of CLP I exhibits a wider distribution 
range in volume, surface area and diameter. The distribution of box ratio indicates 
that the microcrystalline particles of CLP II are thinner and flatter, and the particle 
cluster of CLP I shows low values in volume fraction and sphericity as the shape 
of the particles is more regular. The CLP I particles are narrow and flat in shape 
with a relatively smooth surface. In comparison with the particle cluster of CLP I, 
the CLP II shows a smaller radius min and larger Feret min indicating that the 
shapes of particles are more irregular and have deep voids and pores present on 
the surface. 
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Figure 23 Number frequency distribution profiles of individual CLP I and CLP II microcrystalline 
particles. 
 (a) Volume, (b) Surface area, (c) Diameter, (d) Box ratio, (e) Volume fraction, (f) Sphericity, (g) 
Radius min, (h) Feret min (n = 4544). 
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3.2.2 Quantitative analysis of the surface morphology 
In order to establish a quantitative method to identify CLP I and II, 
relationships between the 3D steric parameters have been investigated. As 
shown in Figure 24a, the equivalent diameters and the surface area of particles 
and the trend lines of CLP I and CLP II show a standard cubic relationship, and 
a degree of differentiation. As the exponential index in the fitting equation for CLP 
I is 1.992 and close to 2, the integer for a perfect relationship between the 
diameter and surface area for a sphere. In contrast, the corresponding value for 
CLP II is 2.1454, higher than for CLP I and larger than 2, demonstrating that the 
surface of CLP II is more complex and irregular.  
 
Figure 24 Relations between different 3D steric parameters. 
 (a) Relation between diameter and surface area, (b) Radius ratio and Ferret ratio, (c) Radius min 
and Ferret min, (d) Surface deviation and ferret min (n = 4544). 
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The same tendency can also be seen from Figure 25 b, c and d, 
especially the correlation between the Feret min and the Radius min. The 
correlation for CLP I shows a good linear relationship which indicates that 
the CLP I microcrystalline particles are regular with a flat facet, whilst on the 
other hand, the Feret min of CLP II particles has a higher value than the 
radius min due to the coarser surface and pores distributed on the surface 
of particle. Furthermore, these findings obtained from the morphological 
parameters are consistent with the SEM result. However, data for CLP I and 
II in these correlations are all overlapping and require separation to achieve 
direct and quantitative polymorphic identification. Thus, new quantitative 
parameters and methods are needed to be created, developed and validated 
to characterize the roughness and pattern of surfaces. 
3.2.3 Crystal form classification based on surface morphology 
patterns 
A crystal or crystalline solid is a solid material whose constituent atoms, 
molecules, or ions are arranged in an ordered pattern extending in all three spatial 
dimensions form a periodic arrangement. In addition to their microscopic structure, 
large crystals are usually identifiable by their macroscopic geometrical shape, 
consisting of flat faces with specific characteristic orientations.  
An ideal crystal is a single crystal with a perfectly regular lattice in regular 
shapes, consisting of flat faces (also called facets) which are oriented in a specific 
way. In reality, a crystal particle's external shape is determined by the crystal 
structure (which restricts the possible facet orientations), the specific crystal 
chemistry and bonding (which may favour some facet types over others), and the 
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conditions under which the crystal is formed. In practice and common use, 
individual particles are composed of a number of smaller crystals – a 
microcrystalline assembly - and are not regular in morphology. Therefore, we 
propose a hypothesis: that the surface morphology of typical particles composed 
of microcrystals has a high specificity which is different from other polymorphs of 
the same chemical compound. Thereby the shape pattern of the surface is closely 
related and determined by the crystal form as polymorphs frequently exhibit some 
difference in single crystal shape and the aggregation mode whereby single 
crystals form microcrystalline assemblies. It is proposed that these patterns can 
be used for the classification of the polymorph. 
In order to classify quantitatively the crystal form based on the morphological 
property of particles, a new method has been developed for the characterization 
of the pattern of the particles’ surfaces. At first, after the 3D model construction, 
every particle in the sample was extracted individually and moved into a 
sufficiently empty computing space; secondly, the original 3D model was 
processed by the low pass filter algorithm at the degree of 999 (the 
quantitative analysis of surface pattern indicated that the sizes of pores 
distributed on the surface were close to 999) for smoothing the surface to 
generate a new smoothed 3D model; then the smoothed model was sliced into a 
stack of 2D slices, and the original slice was subtracted from the new stack; finally, 
the residual part after subtraction was used to construct the deviation model. The 
sum volume of all objects in the model divided by the volume of original model 
was defined as the Volume Bias for the characterization of surface roughness 
(Figure 25).  
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Figure 25 Quantitative characterization of the particles’ surface pattern. 
The original 3D model of the CLP I (a) and CLP II (d) particles, the 3D model of the CLP I (b) and 
CLP II (e) particles after smooth with 9*9*9 low pass filter algorithm, volume bias of the CLP I (c) 
and CLP II (f) particles. 
ܸܤܲ ൌ ∑ ൣܮ݋ݓ݌ܽݏݏ஺௩௘௥௔௚௜௡௚	ଽൈଽൈଽሺܵܣሻ െ ܵܣ൧௜,௝,௞௜,௝,௞∈ெ௔௦௞ ∑ ܵܣ௜,௝,௞௜,௝,௞∈ெ௔௦௞ൗ ൈ 100%      Eq. (1) 
Where 
VBP is the Volume Bias Percentage based on Surface Smoothing. 
SA is the original 3D matrix of crystal particle. 
∑ ܵܣ௜,௝,௞௜,௝,௞∈ெ௔௦௞  is the volume of crystal particle above the threshold value. 
ܮ݋ݓ݌ܽݏݏ஺௩௘௥௔௚௜௡௚	ଽൈଽൈଽሺܵܣሻ  is the lowpass filtering of 3D matrix of 
crystal particle with the averaging algorithm at the size of 999. 
In the experiment, totally 4544 (include 2710 particles of CLP I and 1834 
particles CLP II) particles have been scanned, and the respective VBP values 
were calculated. As shown in Figure 26, the VBP values clustered into two classes 
with values of CLP II generally higher than those of CLP I. The volume bias values 
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of CLP I have a narrow distribution range, and most are close to 0. In contrast, 
the distribution of volume bias values of CLP II is wide and several particles have 
high values. After analysis, the highest 1% of CLP I and the lowest 1% of CLP II 
(totally 45 particles include 27 CLP I and 18 CLP II) VBP values were used to 
calculate an average value. In this way the average value of 0.004915 has been 
obtained and was selected as the threshold value for the classification of two 
crystal polymorphs. The overall accuracy is 99.91% (4 particles misidentified out 
of the total of 4544) as there are 2 CLP I and 2 CLP II particles misidentified by 
the VBP value. As listed in the Table 5, the one by one matching analysis indicates 
the average accuracy was 99.82±0.21 % at 9 different polymorphic mix ratios. 
The lowest detectable limit has been found to be 1%. 
 
Figure 26 Volume bias analysis of 4544 CLP I (n = 2710) and CLP II (n = 1834) particles 
With SR-μCT, the high resolution structure of every single particle can be 
visualized from the 3D X-ray CT images. With the N-in-One analysis, from only 
one CT scan, the 3D morphological information of hundreds even thousands of 
crystal particles can be obtained and a wide range of 3D quantitative parameters 
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can also be calculated. Generally, the solid form morphology of a chemical 
compound is defined in terms of its molecular structure and arrangement. 
Besides the crystal form, crystal habit describes the shape and aggregates that 
a certain compound is likely to form. The crystal morphology is also an important 
character for the identification of crystal form, whereas the challenge is the 
quantitative characterization of the 3D morphology of crystalline particles. In this 
research, the concept of volume bias percentage (VBP) has been proposed for 
the quantitative characterization of the surface roughness and the surface 
morphology pattern. Thus a new method has been developed for the quantitative 
identification of the crystal form of clopidogrel crystal at a high accuracy level 
(above 99.91%); in a wide particle size range of microcrystalline particles (the 
diameter of samples in our study covering from 150 μm to 400 μm). Importantly, 
interference of excipients, which is commonly found, can be avoided a fact which 
demonstrates an advantage of this technique over, other polymorph identification 
methods. 
 
3.3 The internal micro-structure of tablets 
3.3.1 Micro-structure of Osmotic Pump Tablets 
The clinical performance of a drug molecule is not only dependent on its 
inherent therapeutic activity, but also largely dependent on the speed and extent 
with which it is delivered to the site of action by means of a drug delivery system 
(DDS) [48, 49] . Oral controlled release systems hold the major market share for 
modified release systems because of the ease of administration and patient 
compliance. The well-designed drug delivery systems provide desired drug 
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concentration at the absorption site, maintaining the plasma drug level within the 
therapeutic range for a period of time, and hence can reduce the dosing 
frequency and adverse side effects to a minimum [50-52]. 
Among the various oral controlled drug delivery systems, osmotic drug 
delivery systems (ODDS) delivering active agents by constant inner osmotic 
pressure, have received special attention [53]. ODDS’ have many advantages 
over other oral controlled drug delivery systems. The zero-order drug release 
kinetics of ODDS is neither dependent on the drug chemical properties, nor the 
patient’s physiological factors nor concomitant food intake [54]. The drug release 
kinetics of the ODDS shows dependency on formulation factors, including the 
solubility of drugs within the tablet core, the osmotic pressure of the core 
component(s), the semi-permeable membrane characteristics, and the delivery 
orifice size [55]. 
Recently, advances has been reported on the design of ODDS, from single 
chamber osmotic pumps to multiple chamber osmotic pumps [56]. More than 
thirty ODDS products have been developed and launched in the market [57] and 
more than two hundred patents and numerous publications have reported on 
formulation aspects, clinical results and safety aspects [58-62]. Whilst the tablet 
structure is obviously the primary physical characteristic of the ODDS, few 
research attempted to visualize the internal structure and the dynamic changes 
of the ODDS tablet core during the drug release process. Methods for detailed 
information please refer to S 6 Pre-treatment of felodipine osmotic pump tablet. 
Visualization of the surface morphology and the internal 3D structure 
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Figure 27 shows the 2D monochrome X-ray CT images of felodipine MOTS at 
different sampling time (0.5, 1.0, 3.0, 6.0 and 8.0 h) during dissolution testing. 
The semi-permeable membrane, the tablet core, and the drug delivery orifices 
have been visualized. The small voids generated during the tablet processing are 
also visible at the tablet core (image A). From Figure 27 (image D at 3.0 h), it is 
also observed that the solid content is detached from the tablet core with 
associated erosion and swelling. The surface properties of the tablet shell 
maintain the original morphology up to 8.0 h, there is evidence of collapses at the 
surface of the tablet shells.  
As shown in Figure 27, most of the tablet core remains as a solid or semi-solid 
form with cracks emerging at 0.5 and 1.0 h. At 3.0 and 6.0 h, the tablet core 
disaggregates and several voids are generated and become increasingly larger 
along the side adjacent to the drug delivery orifice. At 8.0 h, the majority of the 
content of the tablet core has dissolved and passed out of the orifice. It is 
interesting to observe that the shape of the remaining tablet core varies irregularly, 
a feature which is different from the concept a formulation scientist might imagine. 
It is also observed that some aggregates adhered to the internal wall of the tablet 
shell at 8.0 h and 10.0 h, a feature which partially correlated with the release 
percentages of felodipine at 8.0 h and 10.0 h as 73 % and 82.4 %. 
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Figure 27 2D monochrome X-ray CT images of felodipine MOTS viewing from different aspects 
(A: top; B: front; C: back; D: the reconstructed image; air appears dark, grey represents the solid 
moiety of the tablet core, grey edge represents the semi-permeable membrane, the scale bar is 
5mm). 
Figure 28 illustrates the reconstructed 3D tomographic images at different 
release time points, demonstrating the dynamic changing of the internal 3D 
structure characteristics of the felodipine MOTS. The shape of the tablet is elliptic 
at 0.5 and 1.0 h. With the continuing hydration of the tablet core, the initial regular 
shapes of the cores change into more irregular forms with several voids 
appearing after 3.0 h. Interestingly, the changes in shape at positions near the 
delivery orifices are more marked than that at other locations, suggesting the 
release of felodipine near the delivery orifices is faster than from other regions.  
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Figure 28 Reconstructed three dimensional images of felodipine MOTS at different sampling time. 
(the red circles indicate the orifices, the scale bar is 5mm, yellow represents the solid moiety of 
the tablet core, air appears grey (after reconstruction, some moiety in Figure 27 is not seen in 
Figure 28)). 
In summary, based on the SR-μCT technique, the surface morphology, the 
internal 3D structure of the MOTS and their changing characteristics are clearly 
visualized from the 2D monochrome X-ray CT images and the reconstructed 3D 
tomographic images. 
3.3.2 Micro-structure of Swellable Sustained Release Matrix 
Tablets 
Among a variety of oral controlled release drug delivery systems, water 
swellable matrix systems, particularly those containing hydroxypropyl 
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methylcellulose (HPMC), are widely used due to the relative simplicity of 
formulation compositions, ease of manufacturing, and low cost, as well as 
acceptance by regulatory authorities and applicability to drugs with a wide range 
of dose and solubility [63, 64]. 
Much attention has been given to the mechanism governing the transport of 
solutes. In recent articles, mathematical models have been reviewed which 
describe drug release from tablets with HPMC matrices [65]. Diffusion equations 
for a semi-infinite medium were also proposed [66, 67]. Subsequently, a model 
accounting for both the volume change of the swellable tablet upon contact with 
the aqueous medium and the countercurrent diffusion of the solute was 
developed [68]. Following the work on the swelling and dissolution behaviour of 
the polymeric matrix systems [69, 70], it was found that the thickness of the 
continuously forming hydration layer upon water penetration into the matrix was 
proportional to the square root of time when the swelling front was moved faster 
than the eroding front. Constant thickness of the hydration layer and zero order 
drug release could be achieved when swelling and erosion fronts synchronized 
their movements [71]. More recently, the importance of the diffusion front, the 
interface between the remaining undissolved drug and the dissolved drug in the 
hydration layer, has been highlighted [72]. The authors postulated that erosion of 
the matrix was the rate-limiting step for the release of poorly water-soluble drugs 
whilst for highly soluble drugs, the rate-limiting step was water penetration [73] or 
diffusion [74].   
SR-μCT has also been employed to investigate tablet swelling in real time 
by following the movements of embedded glass microsphere tracers [75]. Axial 
expansion of tablets has been observed, which may be due to mechanical 
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relaxation of residual compaction stresses. This expansion appears to be 
accompanied by extensive bubble formation, which may retard water penetration 
into the tablets. Whilst this methodology can characterize the swelling behaviour 
of gel-forming formulations in real time, water in the swelling medium may 
interfere with the image acquisition. 
A set of two dimensional monochrome projections are presented in Figure 29 
A to show the surface morphology and the hydration layer of swollen felodipine 
HPMC matrix tablets. The hydration layer, the glassy tablet core, the relative 
movement of the erosion and swelling fronts with time, are clearly visible. The 
images also show the microstructures and the changes in the core with time. The 
HPMC matrix swells following absorption of water resulting in the increase of the 
matrix dimensions. After 0.5 h, the hydration layer is visible and grows gradually 
with time. After 5.0 h, the thickness of hydration layer is reduced. The size of the 
glassy core reaches a maximum at 6.0 h, and then reduces as the polymer 
hydrates to a greater extent. These phenomenon are consistent with the finding 
of the gravimetric analysis (Figure 29). After 8.0 h the matrix is entirely hydrated 
with no core remaining. Over the period from 1.0 h to 6.0 h, the thickness of the 
hydration layer exhibits only minor changes indicating the constant release rate 
of the felodipine HPMC matrix tablets over this time period. 
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Figure 29 In vitro dissolution, hydration and erosion of felodipine sustained release tablets. 
 (A) Dissolution profile. Error bars indicate the SD (n=6). (B) Percentage of weight gain (■) and 
mass loss (▲). (C) 2D monochrome X-ray CT images during drug dissolution. Error bars indicate 
the SD (n=3), the scale bar is 5mm. 
Reconstructed three dimensional structures of felodipine tablets are created 
with segmented slices, as shown in Figure 30 A. The length, width, height, volume 
and the surface area values of the whole tablet are shown in Figure 30 B. The 
length, width and height of the tablet all increase within the first 1.0 h as the tablet 
swells following its contact with the dissolution medium. The length and width 
then start to decrease from 2.0 h onwards as the HPMC matrix erodes. The height 
of the tablet, however, remains the same. The volume and surface area of the 
tablet reduced with time. 
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Figure 30 Changes to internal structures of the whole tablet during drug dissolution. 
 (A) Reconstructed three dimensional images. (B) Volume (﹡) and surface area (□) values. (C) 
Length (◆), width (■) and height (▲), the scale bar is 5 mm. 
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The total projected images are reconstructed using the software developed 
by SSRF to perform a direct filtered back-projection algorithm [76]. In order to 
enhance the quality of reconstructed slices, the X-TRACT SSRF CWS x64 
(Commonwealth Scientific and Industrial Research Organization, Australia, 
http://www.ts-imaging.net/Default.aspx) is used for phase contrast extraction. 
The reconstructed slice stack is converted into 8 bit greyscale format and re-
sliced vertically. Then, the vertical slices of tablets at different time points (include 
the well hydrated tablets and the tablet with totally dried core) are analysed to 
determine the threshold grey values to distinguish the erosion diffusion, the 
diffusion front and the swelling front. The quantitative criterion to distinguish the 
erosion front, the diffusion front and the swelling front is exemplified by the 
sample at 0.5 h (Figure 31).  
 
Figure 31 The quantitative criterion to distinguish the erosion front, the diffusion front, and the 
swelling front 
(With the line profile of vertical slice of the sample at 0.5 h, the front with grey value of 18 is 
the erosion front, 100 is the diffusion front, and 150 is the swelling front; the intermediate 
portion between the erosion front and the swelling front is the hydration layer) 
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As shown in Figure 30, the completely hydrated erosion layer has a grey value 
from the background value from 18 to the value of 100; the grey value between 
100 and 150 is the partially hydrated hydration layer and the glassy layer has a 
grey value above 150. Thus, the front with grey value of 18 is the erosion front, 
that with a value of 100 is the diffusion front, and the swelling front is shown by 
the layer with a grey value of 150. The intermediate portion between the erosion 
front and the swelling front is the hydration layer. 
The quarter view of the hydration layer is shown in Figure 32 together with 
plots of the volume of the hydration layer and the surface area of the hydration 
layer with time. The reduction in the volume of the hydration layer is slower than 
that of the whole tablet, indicating that the drug release rate is influenced by 
matrix erosion.  
 
Figure 32 Visualization and quantitative analysis of the hydration dynamics during drug 
dissolution. 
 (A) Reconstructed three dimensional images of the hydration layer. (B) Volume (﹡) and surface 
area (□) values of the hydration layer, the scale bar is 5 mm. 
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In summary, based on the SR-μCT technique, changes in the surface 
morphology, the internal 3D structure of the tablets and the hydration layer can 
be clearly visualized from the 2D monochrome X-ray CT images and the 
reconstructed 3D tomographic images. 
 
General comments 
The findings presented in this chapter demonstrate the great potential of SR-
μCT for improving understanding of solid pharmaceutical structures in different 
kinds of tablets and granular materials during manufacturing. Granular samples 
of microcrystalline cellulose granules, starch granules, pellets and crystal 
particles were characterized with particle distribution by calculating many 
quantitative parameters and the frequency distribution. With a statistic method for 
testing sphericity, spherical cellulose and irregular starch granules were 
distinguished even though there’s bare difference in grey values. Most 
challenging is that, with the high-precision quantitative parameters generated 
from the high resolved 3D structures, Volume Bias Percentage based on Surface 
Smoothing (VBP) was successfully developed. Based on the VBP method, minor 
differences between the two kinds of irregular rough crystal particles have been 
quantified for the identification of the polymorphs of clopidogrel bisulphate with a 
total matching rate of 99.91% and a lowest detectable limit of 1%. The 
microstructures and the surface morphology of osmotic pump tablets and 
swellable matrix tablets were investigated. The steric structures with high spatial 
complexity were visualized and characterized quantitatively. In chapter 4, studies 
are focused on pharmaceutical processes including mixing, tableting and laser 
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drilling. With the quantitative characterization method, the interactions between 
the microstructure and the processing parameters investigated to provide a 
further understanding of typical pharmaceutical manufacturing. 
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Chapter 4 
Evaluation of Pharmaceutical Processes 
-The Intermediate Structure during 
Processing 
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4.1 Structure profiling of mixing and segregation of 
granules 
In this section, synchrotron radiation X-ray computed microtomography (SR-
μCT) was used to investigate mixing and segregation of a model two-component 
system, consisting of powdered microcrystalline cellulose and starch granules, 
blended in a cylindrical vessel. Compared with the conventional X-ray computed 
microtomography, the synchrotron radiation light source usually provides 2 higher 
orders of photon flux in relative parallel beam morphology. Moreover, SR-μCT 
permits the rapid acquisition of data with high intensity and strong collimation via 
a high specification detector [14, 77]. This investigation uses the results of SR-
μCT to obtain characteristics of particles such as average size, sphericity and 
surface area collectively, with an in-situ 3D view to achieve a greater 
understanding of granular behaviour. Furthermore, statistical analyses of the 
particle parameters are used to investigate particle distribution and dynamics of 
granular systems. Thus, this study aims to develop a characterization method 
with SR-μCT, which can measure morphological characteristics and monitor 
blend homogeneity of the particle systems, for use in optimizing mixing processes 
of pharmaceutical production. 
4.1.1 Homogeneity measurement of two-component systems 
Details of the preparation and physical properties of the two sets of granules 
have been given in S 1. Prior to measuring the blend homogeneity, the 
microcrystalline cellulose and the starch granules were filled into the cylindrical 
vessel (with a diameter about 10.0 mm) with initially segregated fractions. They 
were loaded along the longitudinal axis, each with a volume of 0.5 ml and total 
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volume was 1.0ml. Two granular systems were composed of microcrystalline 
cellulose granules loaded first and the starch granules followed. The total height 
of sample after loading in the cylindrical vessel was 13.0 mm. 
For further experiments, the longitudinal axis of the cylindrical container was 
inclined at an angle to a horizontal axis of rotation manually to simulate a pattern 
of mixing (Figure 33 a). Rotation speed (VR) was set at 30 rotations per minute 
(rpm). To study the influence of the number of rotations, the cylindrical container 
was rotated for 5 and 20 seconds (s). Then, samples at the upper, middle and 
lower levels of the container were imaged in an upright position within the X-ray 
light beam Figure 33 b). In consideration of the maximum height of X-ray beam, 
both the heights of the acquisition window for the samples were set as 3315 μm. 
 
Figure 33 The schematic diagram of sample pretreatment and image acquisition. 
 (a) mixing process, (b) imaging process. 
The sample which was rotated for 20 s in the previous step was then vibrated 
by shaking to simulate a pattern of material handling. To investigate the influence 
of the time of vibration, the mixed granular system was vertically vibrated for 5 
and 20 s by the shaker, with vibration speed (VV) of 2000 rpm. Then, as before, 
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samples at the upper, middle and lower levels of the container were scanned in 
an upright position within the X-ray beam and each height of the acquisition 
window for the samples was set as 3315 μm. 
Mixing index 
A mixing index is frequently used to describe the degree of mixing in powder 
blends quantitatively. Many definitions and mixing indexes, usually based on the 
standard deviation of component content in samples of the mixture, have been 
proposed to describe the difference in composition throughout the mixture [22]. 
Considering Np particles in the upper, middle and lower levels in total, the 
arithmetic mean of sphericity value is given as follows:  
̅ݏ ൌ ଵேು ∑ ݏ௜
ேು௜ୀଵ                                                                                                  Eq. (2) 
where si is the ith value of s, which represents a sphericity of the particle, Nl 
particles in one level. The sample variance of a single level is given as follows:  
ߪଶ ൌ ଵே೗ିଵ∑ ሺݏ௜ െ ̅ݏሻ
ଶே೗௜ୀଵ                                                                                    Eq. (3) 
In order to quantify the effect of mixing by image analysis, we calculated a 
numerical index S, defined as follows:  
ܵ ൌ ఙ௦̅ ൌ ට
ଵ
ே೗ିଵ∑ ሺݏ௜ െ ̅ݏሻଶ
ே೗
௜ୀଵ
ଵ
ேು ∑ ݏ௜
ேು௜ୀଵ൘                                                           Eq. (4) 
where ̅ݏ is the mean sphericity measured over the totality of the particles in 
all of the three levels of the container, ߪ is the standard deviation of the individual 
level. For a perfect mix value of S would be 0, and the higher value indicates a 
low degree of mix. 
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4.1.2 Result of mixing experiments 
In order to characterize the mixing processes, the influence of the time of 
rotations was investigated, as described above. Images were taken at different 
times for a rotation speed of 30 rpm, and displayed with different colours 
depending on the sphericity of the particles after 3D reconstruction (see Figure 34). 
As these two different kinds of granules can be distinguished with sphericity 
(please refer to section 3.1.1). Resulting images show via a time series of 3D 
images that the homogeneity of the two-component system increases with 
increasing the time of rotations TR. It can be seen that at time 0 that the mixture 
was initially segregated prior to rotation so that the colour boundaries are well 
defined in the middle level. As a consequence of rotation in the same direction, 
two types of particles separate along the cylinder axis for TR= 5 s. The system 
tends towards homogeneity without any colour boundaries for TR= 20 s. 
 
Figure 34 Influence of the time of rotations TR for the mixed granular system. 
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 VR = 30 rpm. Each line corresponds to the same level of the cylindrical vessel. Images of each 
column correspond to the same time of rotation. The scale bar is 2000 μm, the standard jet color 
map reflects the sphericity value from 0.0 to 1.0. 
Quantification of these images by normalized frequency distribution confirms 
these observations. The frequency distribution of particles according to the 
sphericity parameter in the two-component system is normalized such that 
different scales of each profile are unified. As can be seen from the profiles in 
Figure 35, in general, the degree of coincidence of three curves for upper, middle 
and lower levels tends to increase with time. However, the degree of a 
coincidence for 5 s appears higher than for 20 s. This might be confusing if this 
interpretation is accepted without further analysis. It has been shown that the 
homogeneity of the mixed system after 20 s rotation is better than after 5 s (Figure 
34). This means that the sphericity statistical profiles do not totally capture the 
true pattern evolution after rotating the sample. It can, however, be used to some 
extent to evaluate the homogeneity of the mixed system, whereas the in-situ 
images are of particular importance to confirm the statistical estimates. These 
results also suggest that methods based on image–image correlations would 
improve the data analysis. Furthermore, due to the different particle sizes of the 
two types of granules, the number and frequency of starch granules are lower 
than those of microcrystalline cellulose granules. It can be seen in Figure 35 that 
the frequency of starch granules decreases in the upper level and increases in 
the middle and lower levels of the sample container with an increasing time of 
rotations TR. Taking into account the relative amounts of the components, the 
frequency of microcrystalline cellulose granules with smaller particle size tends 
to increase in the upper level and decrease in the middle and lower level. 
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Considering the totality of the analyses, the results show that the homogeneity of 
the mixed system increases with increasing time of rotations TR, in accordance 
with visualization of the 3D image (Figure 34). 
 
Figure 35 The homogeneity of the two-component system increases with increasing the time of 
rotations TR. 
A mixing index on the basis of standard deviation for the sphericity is 
calculated to evaluate quantitatively the mixing homogeneity of the samples. The 
mixing index value is strongly dependent on the particle size and 3D shape, i.e., 
an increasing number of microcrystalline cellulose granules lead to a decrease of 
mixture standard deviation, and the mixing index value rises with increasing 
number of starch granules.  
All the particles are microcrystalline cellulose in the lower level for 0 s and 
the S is at its lowest value as described in connection with Figure 34 and Figure 36. 
If the value of mixing index is higher than that of the lower level for 0 s, some 
starch granules must be present in the level. Similarly, microcrystalline cellulose 
must be present in the level, if the value of mixing index is lower than that of the 
upper level for 0 s. As expected, the mixing index value of the upper level 
decreases with an increasing time of rotations TR (Figure 36). The results illustrate 
that the number of microcrystalline cellulose granules rises in the upper level with 
an increasing TR. Namely, the mixture homogeneity of the upper level increases. 
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Meanwhile, the mixing index value and homogeneity of the lower level rises with 
an increasing TR. Compared with the middle level of 0 s, there are more starch 
granules in the middle level after 5 s and more microcrystalline cellulose after 20 
s.  
The upper, middle and lower levels can be regarded as three sampling zones 
in the container. The closer the mixing index values of three levels, the better the 
mixing will be. As can be seen from Figure 36, the mixing index values of the three 
levels become closer with increasing TR. This finding also illustrates that the 
degree of homogeneity for the whole granular system rises with an increasing TR, 
in accordance with the results shown in the 3D image (Figure 34). 
 
Figure 36 The changes of mixing index in each level with an increasing TR. 
4.1.3 Segregation experiments 
For the two granules sets being studied with differences in size and shape, 
it was observed that segregation increased for the longer time of vibration at 2000 
rpm (Figure 37). Compared with the initial mixed sample which was rotated for 20 
s, segregation occurs at TV = 5 s and increases at TV= 20 s. For the granular 
mixture, the starch granules have a tendency to rises to the top of the sample. At 
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the same time, the microcrystalline cellulose granules move down to the bottom 
of the container. 
 
Figure 37 Influence of the time of vibration TV for the mixed granular system after TR= 20 s at 30 
rpm. VV = 2000 rpm. 
 Each line corresponds to the same level of the cylindrical vessel. Images of each column 
correspond to the same time of vibration. The scale bar is 2000 μm, the standard jet color map 
reflects the sphericity value from 0.0 to 1.0. 
A time series of statistical sphericity profiles describing segregation of the 
mixed system shows that the degree of coincidence of the three curves for upper, 
middle and lower levels tends to decrease (Figure 38). These findings indicate that, 
as expected, the segregation increases with longer TV. In addition, the frequency 
of starch granules rising in the upper level with longer TV, corresponds to a 
decrease in the distribution of microcrystalline cellulose granules at the same 
level. In contrast, the relative amounts of starch granules reduce and the number 
of microcrystalline cellulose granules increases in the lower level. The results 
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illustrate that the starch granules preferentially rise to the top and the 
microcrystalline cellulose granules percolate down to the bottom of the container, 
confirming the previous visualization of the 3D images (Figure 37).  
 
Figure 38 The segregation of the two-component system increases with increasing the time of 
vibration TV. 
As can be seen from the Figure 39, the mixing index of the upper level rises 
rapidly with increasing time of vibration TV, which illustrates that the number of 
starch granules in the upper level increases with increasing TV. In contrast, the 
increases in mixing index values of middle and lower levels are considerably 
lower with an increasing TV. These results show that the number of starch 
granules increases to a small degree in the upper level over a long periods of TV. 
Overall, the differences among the mixing index values of upper, middle and 
lower level tend to become larger with an increasing TV. The quantitative results 
of mixing index are consistent with visualization of the 3D image (Figure 37).  
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Figure 39 The changes of mixing index in each level with an increasing TV.  
The distributions of granular systems calculated by frequency analysis are in 
good agreement with the images obtained from SR-μCT for the mixtures 
examined. The shape information, such as sphericity and box ratio can be 
measured and utilized to explore systems of greater relative particle complexity. 
A mixing index on the basis of standard deviation for the sphericity is calculated 
to evaluate quantitatively the mixing homogeneity of the samples, which provide 
descriptions and visualizations of the imaging data. This model-based approach 
could, therefore, be used in other material processing challenges such as 
granular compaction or shear. This phenomenon may be associated with the 
larger size and non-spherical shape of the starch granules.  
As a rapid and non-invasive technique, SR-μCT methods have great 
potential for clarifying the relationships between physical characteristics of 
granules and operation processes in the area of granular materials and provide 
the possibility for further investigation of pharmaceutical processes. 
4.2 Deformation of clopidogrel bisulfate polymorphs 
during tableting 
Powder compression represents an essential unit operation in the 
pharmaceutical industry since the compressed tablet represents the most 
common solid dosage unit used throughout the world for the delivery of medicines 
to patients. Mechanical properties, such as compactability, compressibility, 
elasticity, plasticity, and brittleness of the excipients and drugs as powders, 
dictate how formulations will behave during tablet processing and perform as drug 
delivery systems. The physicochemical and solid state properties of powders, 
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such as their polymorphism, moisture content, particle shape, particle size, and 
surface roughness, affect the mechanical properties of tablets formed from these 
constituent powders. Therefore, understanding the potential influence of these 
parameters on the properties of the products during and after compaction is 
important [78]. 
Many solid pharmaceuticals exhibit polymorphism resulting from the 
possibility of forming at least two crystalline arrangements of molecules in the 
crystal lattice [79, 80]. Generally, the polymorphs often exhibit different solid-state 
properties, density, habits, refractive index, melting properties, solubility, 
dissolution rate, and mechanical properties [81]. Moreover, under specific 
environmental conditions, such as pressure and temperature, as well as chemical 
purity the structure of polymorphs represents the packing of the molecules in the 
crystal lattice, which directs the solid-state properties of the crystals and also 
influences the compaction behaviour of powders [82]. 
During compaction, particles  rearrange at the initial stage of compression 
and then deformation takes place during consolidation. Deformation behaviour of 
powder under stress depends primary on the mechanical properties - elastic, 
plastic, brittle fracture or a combination of these mechanisms. Elastic deformation 
is time independent, reversible and does not continuously influence tablet 
strength. However, plastic deformation is an irreversible process that contributes 
to the formation of particulate bonds that generate the tablet strength [83]. During 
the direct compaction process, the density distribution inside the tablets is often 
heterogeneous due to the inter particle friction and die wall friction. Since the 
shape of tablets used in pharmaceutical industry varies between flat-faced 
cylindrical tablets to more complex geometries with embossing, density variations 
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in pharmaceutical tablets may be important and affect the compact mechanical 
properties [84] as well as leading to non-uniformity of three dimension (3D) 
internal structure between individual tablets and consequently potential non-
uniform drug release patterns. Density distribution has been investigated using 
NMR tomography [85] and autoradiography [86]. Recently, X-ray 
microtomography has been used successfully in pharmaceutical development 
studies [87]. 
The relationships between the mechanical properties, deformation behaviour 
and the molecule structure of the polymorphs have been studied for example 
ranitidine hydrochloride polymorphs. Powder X-ray diffraction (PXRD), differential 
scanning calorimetry (DSC), and optical and polarized microscopy were 
combined with compressibility plots and a Heckel analysis to confirm the greater 
plastic deformation of ranitidine form II over form I. The Heckel equation provides 
a method for transforming a parametric view of the force and the displacement 
data to a linear relationship for the materials undergoing compaction [88]. While 
studying the compression behaviour of orthorhombic paracetamol crystals, the 
resulting tablets were broken into small pieces, and 2D images of compressed 
crystals were obtained using SEM [89]. However, this approach has several 
disadvantages. The analytical method destroys the integrity of the tablet and 
might damage the structure of the individual crystal particles to some extent 
during tablet breakage. Moreover, SEM is not an in situ measurement and is 
unable to reflect the deformation behaviour of the crystals during and after the 
compaction process. Other current methods use various mechanical parameters 
include Young’s modulus, Poisson’s ratio, yield stress, and fracture toughness to 
reflect the deformation characteristics of powder [90]. Such approaches do not 
 104 
 
provide high-resolution visualization of the in situ behaviour of individual crystals 
within the tablets. In addition, methods such as SEM that are used to probe the 
shape of a limited number of crystal particles do not provide a statistical 
confidence since all of the crystal particles in the intact tablets are not evaluated. 
Within pharmaceutical material science and drug delivery research, SR-μCT 
has been used to visualize and quantify the microstructure of particles and the 
distribution of chemical composition for individual particles and their assemblies 
[23, 28, 91]. SR-μCT has also been used to distinguish clopidogrel bisulfate (I 
and II) in combination with multilayer perceptron. The polymorphs of the drugs 
could be identified and predicted through the numerical description of the 3D 
morphology [92]. However, to our knowledge, the visualization of the deformation 
behaviour of crystals in situ has never been reported as measured by SR-μCT. 
In this study, the deformation behaviour of two polymorphs of clopidogrel 
bisulfate (CLP I and CLP II) was investigated by SR-μCT. As reported, these two 
polymorphs of CLP were investigated for in-die and out-of-die compaction 
behaviour using compressibility, tabletability and compactibility (CTC) profile, 
Heckel, and Walker equations, and the difference in compaction behaviour was 
explained in terms of the different molecular packing of two forms [90]. This study 
aims to develop a characterization method for SR-μCT that can determine the in 
situ deformation behaviour of the CLP polymorphs after compaction and to 
analyse the relationship between the polymorphic structures and mechanical 
behaviour during tableting. 
(Detailed experimental information is provided in S 4 Reconstruction of compaction 
behaviours of CLP polymorphs) 
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4.2.1 Characterization of CLP crystal particles 
The results of the PXRD measurements were consistent with those reported 
previously (Figure 40) showing PXRD patterns of both CLP I and CLP II [90]. There 
were clear differences in the X-ray diffraction peaks for CLP I and II polymorphs. 
The region 12-13º 2 was characteristic for polymorph II while the peak at 21º 
signified form I, without any overlap of peaks from the other polymorph in these 
regions.  
 
Figure 40 PXRD and SEM of CLP I and II crystal particles. Powder X-ray diffraction overlay of 
CLP I and II. 
 (a). SEM (300×) of CLP I (b) and II (c). 
Scanning electron microscopy.  As discussed in section 3.2, SEM was 
employed to characterize the surface morphology of the CLP polymorphs. And 
morphological differences were visible between CLP I and CLP II. The surface 
morphology of CLP II was  rougher than CLP I. The images (b) and (c) in Figure 
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40 showed that a large number of individual crystals combined into a larger 
polycrystal. The subunits of CLP I particles were all smaller than those of CLP II, 
indicating that CLP I crystals were more densely packed compared to those of 
CLP II, and the larger subunit size of CLP II introduced a loose structure of the 
accumulated particles due to larger pore space between the particles.  
Structure of CLP polymorphs particles measured by SR-μCT.  CLP particles 
were distinguished from the excipients due to the noise reduction and phase 
retrieval. The grey value of the background was close to 0 for the excipients and 
the wall of the capsule as a container for the powders was between 80 and 120, 
and the CLP particles gave a grey value above 150. Two dimensional (2D) slices 
of the crystal particles are shown in Figure 41; the bright areas represent CLP 
particles and the PVP/VA are illustrated in grey. 
Based on the analysis of grey values, all of the crystal particles in the 
samples were extracted. Afterward, highly resolved tomographic images of CLP 
I and CLP II with high quality phase contrast were derived for each single particle 
after 3D reconstructions (Figure 41, b and e). For the two samples, all of the crystal 
particles were included in the analysis, and individual particles were assigned a 
colour according to the volume of the individual particles. The morphological 
structure of the CLP I and CLP II particles were clearly different. Both crystal 
forms were irregular but the surface topography of CLP II showed greater 
roughness than CLP I (Figure 41, c and f). 
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Figure 41 Monochrome 2D slices and 3D morphology of CLP I and II crystal particles.  
2D slices of the samples contain CLP particles diluted with PVP/VA (a, d), 3D images of crystal 
particles in the capsule after extraction and construction (b, e), and the randomly selected 
individual CLP I (c) and CLP II (f). The colour gradients reflect particle volume, ranging from about 
8.0E+4 μm³ (dark blue) to 4.0E+7 μm³ (red), the scale bars of a, b, d and e are 1000 μm and 
scale bars of c and f are 300 μm. 
4.2.2 Visualization of the crystal deformation behaviour in tablets 
by SR-μCT 
    Tablets containing hundreds of pure particles of CLP I or CLP II diluted with 
PVP/VA were put into individual capsules with an internal diameter identical to 
that of the tablets. From the SR-μCT scan and the analysis of phase contrast 
extraction by X-TRACT, 2D slices were obtained (Figure 42), showing the 
individual crystal particles within the tablet distinguished from the PVP/VA by the 
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difference in the grey level, as discussed above. Compared to the powder 
samples in Figure 41, the CLP crystal particles showed a change in shape as a 
result of the compaction process. Specifically, the particles of CLP I exhibited a 
flatter morphology, while many CLP II particles were fractured into smaller sized 
particles. 
 
Figure 42 Monochrome 2D slices of CLP tablets.  
CLP I (a, b) and CLP II (c, d). (a,c) and (b, d) are planes from the different angles (the outside 
border is the shell of the gelatin capsule, the container to fix the tablet on the objective table). 
    Both the tablets contained the same weight of CLP particles and excipients, 
compacted under the same conditions, and the same compression ratio. The true 
density of CLP I is 1.504 cm3 and 1.471 cm3 for CLP II. With the same mass 
weight of CLP in the compressed tablets, it might be expected that CLP II would 
have a larger volume than CLP I. However the final size, especially the thickness 
of the tablet was markedly different, namely, 3.5 mm for CLP I and 3.0 mm for 
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the CLP II. The tablet of CLP I exhibited 17% of elastic recovery following 
compaction when the pressure was released, but CLP II did not show such a high 
degree of elastic recovery. 
All the 2D slices were processed by VGStudio Max and Image Pro Analyser 
3D software, and the reconstructed 3D images of tablets obtained. Figure 43 
shows the 3D morphological images of all particles within the tablet samples. In 
the surface regions of the tablets, the CLP I and CLP II particles exhibited large 
changes in morphology. The CLP I particles were flattened, while most of the 
CLP II particles were fragmented and lost their original shape. In the lower 
pressure regions, the CLP I particles remained well separated from each other 
and changed slightly in shape, while the CLP II particles fragmented, although 
less so when adjacent to the die wall. 
By deleting particles that retained their original shape and could be 
distinguished from the other drug particles from the 3D-structure analysis, the 
reconstructed images of the deformed and fragmented particles in the tablets 
were obtained (Figure 43). The images reveal that the particles underwent 
extensive deformation at the surfaces of the tablets. The shapes of the particles 
were flattened and combined into agglomerates under pressure, particularly the 
particles of CLP II. Therefore, images prepared by SR-μCT clearly visualized the 
consequences of the different deformation behaviour of CLP I and CLP II. 
Although some particles of CLP I combined to form large agglomerates, it was 
still possible to identify their characteristic shape. In contrast, particles of CLP II 
were fragmented and compressed into a connected framework. 
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Figure 43 3D models of CLP particles in tablets. Left insets represent CLP I particles, right insets 
represent CLP II particles, 
 (a) and (d) are the 3D models of all particles in tablets, (b) and (e) are the 3D models of 
unattached particle clusters in the tablets, (c) and (f) are the 3D models of agglomerated particles 
in tablets. The scale bar is 1,000 μm. 
The drug particles of CLP I that retained their original shape and remained 
separated from each other after compaction were distributed around the centre 
of the tablets (Figure 43). The degree of deformation for the particles separated 
from each other was markedly reduced compare with that for particles at the 
surface of the tablets. It is likely that these particles deformed under different 
applied pressures. In general, for the curved faced tablets, the highest density 
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regions were found to be close to the die wall, while the lower density regions 
were located in the centre of the tablets [93].  
The different deformation behaviour in the various regions of the tablets 
reflects the heterogeneous density distribution within the tablet. The degree of 
particle deformation reveals how the particles reacted to the applied pressures 
during tableting. The greater degree of deformation, the greater forces the 
particles experienced. By considering the different deformation behaviours of the 
CLP I or CLP II particles, the tablets can be segmented into three sections. The 
area subjected to the high pressure tended to be close to the surface, while 
intermediate pressure regions remained in the central core of the tablets; the low 
force region is the middle layer between the surface and the central core of the 
tablets. Figure 44 (e) illustrates these sections of the pressure distribution spaces: 
section A as the intermediate pressure zone, section B as the lowest pressure 
area, and section C as the highest pressure section. 
4.2.3 Quantification of crystal deformation behaviour in tablets   
SR-μCT has been performed on the CLP I and CLP II tablets to extract single 
particle data for the visualization and quantitative characterization of the 
deformation behaviour of the two polymorphic forms. The shapes of particles and 
other 3D parameters changed during compaction providing data for further 
statistical analysis. The SR-uCT thus generates 3D quantitative data not 
generated by conventional detection methods available for powder compaction 
studies. 
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Figure 44 3D quantitative parameters of CLP I and CLP II before and after compression. 
 Particle volume and sphericity distribution changes during tableting of CLP I (a, b) and CLP II (f, 
g). (■show the normalized volume/sphericity frequency of particles before tableting, ■show the 
normalized volume/sphericity frequency of particles in tablets after tableting.) The ellipsoid 
parameters distribution of crystal particles before and after compaction (c, h. for oblate, d, i. for 
prolate and e, j. for oblate/prolate-1). (■before compaction, ◆after compaction). The left set of 
graphs represents CLP I, the right represents CLP II. 
    The volume distribution of the particles changed during tablet formation (Figure 
44, Table 5). Before tableting, most of the particle volumes of CLP I and CLP II 
were distributed in the same range from 4.0E+06 μm3 to 1.2E+07 μm3. After 
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compaction, some particles were crushed and compressed into large clusters. 
When the clusters were rejected and eliminated from the analysis, the particle 
volume distribution of CLP I was filtered into from 3.2E+06 μm3 to 4.0E+06 μm3, 
while the particles volume distribution of CLP II was filtered into from 4.0E+06 
μm3 to 1.2E+07 μm3. Generally, the particle volumes of both CLP I and CLP II 
were reduced. The different changes in the particles volume distribution reflected 
the difference in their deformation behaviours during tableting. 
The sphericity distribution also changed after tableting (Figure 44, Table 4). 
Before tableting, most particles were distributed from 0.85 to 0.95. The sphericity 
of a small percentage of particles that originally exhibited low sphericity increased 
after compaction. This effect may be linked to the crushing of some particles. 
However, the sphericity of most particles in the tablet decreased. The degree of 
change in the sphericity was higher in CLP II compared to CLP I and the width of 
the distribution became wider. Sphericity of CLP II particles also showed large 
changes than for CLP I. In addition, the sphericity of CLP II particles was smaller 
than CLP I after tableting. These findings support the view that particles of CLP 
II are more readily deformed, exhibiting greater compressibility i.e. the ability to 
be reduced in volume at a given pressure.  
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Table 5 Sphericity of CLP I and CLP II before and after tableting. 
Parameters CLP I CLP II 
Sphericity-Before tableting 0.873 ± 0.056 0.840 ± 0.045 
Sphericity-After tableting 0.826 ± 0.089 0.747 ± 0.011 
Oblate-Before tableting 0.435 ± 0.005 0.375 ± 0.005 
Oblate-After tableting 0.467 ± 0.005 0.400 ± 0.007 
Prolate-Before tableting 0.392 ± 0.005 0.449 ± 0.008 
Prolate-After tableting 0.341 ± 0.004 0.406 ± 0.007 
Eclipse-Before tableting 0.354 ± 0.040 -0.030 ± 0.032 
Eclipse-After tableting 1.616 ± 0.050 0.695 ± 0.059 
 
Ellipsoid parameters of individual crystal particles were also calculated 
(Figure 44). Comparison of the morphology before and after compaction reveals 
the detailed deformation behaviour of single particle. Oblate and prolate describe 
the magnitude of change in shape of objects from an ideal sphere. When the 
oblate and prolate value equal zero, the object is a standard sphere. Higher 
values of the prolate parameters indicate object shape like a “cigar”, while an 
increase of oblate value reflects a shape similar to a “disc”. The value of 
Oblate/Prolate-1 was also evaluated as shown in Figure 44 and Table 5. The oblate 
and prolate values of CLP I original crystal particles were both larger than that of 
CLP II, indicating the particles of CLP I had a longer axis and flatter shape in 
comparison with CLP II. After the compaction, the average value of oblate 
increased and of prolate decreased for both CLP I and CLP II. The deformation 
during compaction made crystal particles flatter and the cracks developed against 
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the longest axis. During the compaction, the oblate/prolate-1 value for both CLP 
I and CLP II changed consistently. Detailed calculated value of the original 
oblate/prolate-1 of CLP I was 0.354, which specified a flat shape, whilst the value 
of -0.030 for CLP II was very close to 0, indicating a cylinder-like shape. After 
compaction, both oblate/prolate-1 value of CLP I and CLP II increased 
dramatically. For the CLP I, the increased with the oblate/prolate-1 reaching an 
average value of 1.616. 
In combination with the result of volume change and height of tablet, the 
deformation processes of CLP I and CLP II can be illustrated. Under compression, 
the relative magnitude of three different deformation mechanisms which 
determines the consolidation of CLP I was Plastic ≥ Elastic > Brittle Fracture. 
Theoretically, plastic deformation facilitates the formation of permanent particle–
particle contact regions during compaction, the binding between particles has 
also been observed in Figure 43 and Figure 45.e. The superior mechanical 
properties compared with CLP II could be due to the higher density and stronger 
interaction between the molecules, resulting in the most favourable packing of 
molecules in the crystal[90]. In contrast, the sequence of CLP II was Brittle 
Fracture > Plastic > Elastic. This rank order explains the good compressibility and 
higher densification of CLP II, for the crystal particles are readily fractured and 
this contribute to the reduction in volume as a result of an applied pressure. 
Owing to the plastic deformation and binding between particles under 
compression, CLP I shows great tabletability and compactibility, which can be 
observed in Figure 43 [90]. 
The sphericity, volume and position of particles in a tablet affect particle 
behaviour on compaction (Figure 45). This feature is clearly different between CLP 
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I and CLP II. After tableting, the particles of CLP II exhibited a smaller volume 
and a lower sphericity than particles of CLP I in the same regions, because the 
CLP II particle fragmented more readily than those of CLP I. Nevertheless, the 
importance of particles position and sphericity of CLP II was consistent with CLP 
I behaviour. The sphericity reduced, and the volume was decreased, particularly 
in section C of the tablets. 
 
Figure 45 Heterogeneous pressure distribution within the tablets. 
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 Particle position (a, b. distance from the centre of the tablet) and the sphericity coloured with 
volume (Section A: intermediate pressure, Section B: low pressure, Section C: high pressure. The 
chromatic stripes on the right side of the axis represent the volume, a. CLP I, b. CLP II); c, d. 
Sphericity distributions of CLP I and CLP II in different parts of a tablet. (c. CLP I, d. CLP II, ■
Section A (intermediate pressure), ◆Section B (low pressure), ▲Section C (high pressure)). e. 
The pressure distribution in a tablet was indicated by the distribution and agglomeration of crystal 
particles and divided into three sections (Section A: intermediate pressure, Section B: low 
pressure, Section C: high pressure. The enlarged part indicated the ultra-high pressure within the 
tablet with a dense cluster of crystals of CLP I). 
In regions close to section C of the CLP I tablets, some small particles were 
observed due to the localized high pressure during compaction. The changes in 
sphericity were different in section A, section B and section C (Figure 45 and Table 
6). The sphericity of CLP I and CLP II were the highest in section B, and the 
sphericity was the smallest in section C. The distribution range for the sphericity 
in section C was wider than that for the two other areas. 
The relationship between the changes in sphericity, volume and particle 
position inside the tablets showed that the greater the pressure the particles were 
subject to greater change in sphericity and volume. Therefore, section C 
experienced high pressure, especially at the edges of the tablet, section A 
experienced the intermediate pressure, and section B experienced low pressure. 
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Table 6 Sphericity of CLP I and CLP II in section A (intermediate pressure), section B (low 
pressure) and section C (high pressure) regions. 
Sphericity CLP I CLP II 
Section A (intermediate pressure) 0.841 ± 0.099 0.754 ± 0.094 
Section B (low pressure) 0.858 ± 0.067 0.767 ± 0.110 
Section C (high pressure) 0.803 ± 0.096 0.735 ± 0.110 
 
In this study, a new method combining synchrotron radiation X-ray 
microtomography and 3D reconstructions was developed to visualize and 
quantify the deformation behaviour of clopidogrel bisulfate polymorphs CLP I and 
CLP II. At the same compression ratio, CLP II deformed easily with higher 
compressibility and hence higher densification as compared with CLP I. Both CLP 
I and CLP II particles exhibited different deformation behaviour in the different 
pressure distribution regions within the tablets. At the surface of the tablets, the 
degree of deformation behaviour of particles was larger than other areas. The 
degree of deformation behaviour was linked to the changes of volume, sphericity 
and ellipsoid parameters. The different morphology of CLP I and CLP II particles 
showed different deformation behaviours after compaction. Plastic and elastic 
mechanisms dominated deformation behaviour for CLP I. With the disc shaped 
crystal particles flatterening under the pressure loading. The deformation of CLP 
II was dominated by the brittle fracture mechanism as the lower bonding strength 
did not prevent fracturing of the crystal particles. The direct observation and 
quantitative characterization of the deformation behaviour are in excellent 
agreement with the published results of mechanical test and molecular modelling 
of CLP I and II [90]. SR-μCT is shown as a powerful tool to provide in situ 3D 
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parameters of each particle in the tablets, enabling an improved understanding 
of particle behaviour during compression and tableting. 
4.3 Structure of laser drilled delivery orifices in osmotic 
pump tablets 
The controlled release of drugs has gained increasing attention in the 
pharmaceutical sector and drug delivery systems (DDSs) remain extremely 
important for optimizing pharmacological and therapeutic efficacy for many drugs 
[94]. Osmotic pump drug delivery systems (OP-DDSs) are regarded as one of the 
most reliable techniques for controlled delivery of therapeutic drugs, such as anti-
hypertension, antidiabetic, and anti-angina compounds, as well as hormones and 
other agents [95, 96]. Compared with other approaches used in controlled release 
formulations, drug release from OP-DDS is independent of the external pH and 
hydrodynamics, which attributes minimal patient-to-patient variability and allows 
accurate prediction of in vivo performance from in vitro dissolution in many cases 
[97]. With such highly predictable drug release rates, OP-DDS generate various 
attractive biomedical advantages, e.g., reduced dosage and constant release 
rate leading to fewerside effects [98]. In terms of the clinical benefits and good in 
vivo-in vitro correlations (IVIVC), OP-DDS provide a promising technology for 
extending product life-cycles and optimization of therapeutic effects [95]. In 
addition, OP-DDS can be designed to deliver either highly soluble drugs or 
sparingly soluble drugs [95] in zero-order release profiles or other release 
behaviours, e.g., sigmoidal shape release [99] and pulsatile release [97].  
The OP-DDS generally consist of a core tablet containing drug(s) mixed with 
osmotic agents and other excipients, and a semipermeable membrane with an 
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orifice(s) for the release of dissolved drug substance [54]. Release of the drug(s) 
is driven by the osmotic pressure gradient across the membrane from the inner-
side to the outer-side as well as the solubility of the drug, the penetrability of the 
coating membrane to external aqueous liquids, and the size and the number of 
the delivery orifices [100]. A typical OP-DDS has at least one delivery orifice, for 
which the structure is critical for uniform drug release [55]. The size and number 
of the delivery orifices must be optimized in order to achieve the desired drug 
release rate. A tablet with an undersized delivery orifice may lead to the burst of 
the membrane and dysfunction of the OP-DDSs caused by internal high 
hydrostatic pressure. On the other hand, the delivery orifices with too large a size 
could result in solute diffusion dominated drug release through the orifices [54]. 
However, the effects of the shapes, depths and other structural parameters of 
delivery orifices on OP-DDSs have not been reported. 
Methods used to create delivery orifices in the coating membranes of OP-
DDSs include: mechanical drilling, passageways formed in situ, and laser drilling 
[55]. Mechanical drilling generally involves the use of a micro drill to create 
orifices on the surface of the tablets after coating [101-103] or modifying the upper 
punch of the tableting machine with a needle to produce an indentation at the 
centre of the surface of the tablet cores [104-106]. The orifices formed in situ are 
formed by adding a pore-forming agent to the semipermeable membrane 
composition [100, 107, 108] or by preparing the asymmetric membrane systems 
by controlled phase separation [109, 110]. However, the OP-DDSs prepared by 
inclusion of a pore forming agent and asymmetric membrane methods are usually 
limited by the solubility of active ingredients. Laser drilling is the most widely used 
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industrialized technique to create delivery orifices in the membrane of the OP-
DDSs with high efficiency, accuracy and reliability.  
The architecture of micro-structures formed after laser drilling contains not 
only the delivery orifices in the membranes, but also any melting and solidification 
in the tablet cores adjacent to the drilled orifices need to be examined. The effects 
of laser drilling parameters on the quality of delivery orifices and some structural 
parameters of the orifices have been reported in other fields, such as alumina 
ceramics and metals, using optical microscopic [111], and scanning electron 
microscopic methods [112]. However, for OP-DDS the evaluation of delivery 
orifices have been mainly limited to cross section two-dimensional (2D) 
observations to determine the cross section diameter of the delivery orifice by 
microscopes using a pre-calibrated ocular micrometer [113]. An alternative 
approach was to measure the delivery orifice microscopically using empty shells 
obtained after complete dissolution of the contents of OP-DDS [102], a 
techniques which is likely to introduce some errors or structural movement. In 
contrast, non-invasive imaging techniques are efficient tools which can reveal 
directly the internal structure and dynamic characteristics of OP-DDSs at different 
stages of the drug release process.  
Although a critical structural feature of OP-DDSs, the structures of delivery 
orifices of OP-DDSs have been almost ignored in OP-DDSs development with an 
absence of published literature on this topic. The architectural detail extracted via 
SR-μCT can provide the real structures of laser drilled orifices with 3D 
visualization and enable quantitative assessment of the effects of laser drilling. 
Such structural detail will provide a deeper understanding in guiding the design 
of OP-DDSs to optimize their performance in controlled drug delivery to patients.  
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In this study captopril tablets and commercial felopidine tablets were studied 
using SR-uCT.  Laser drilling was carried out on prepared captopril tablets, with 
cores composed of 42% captopril, 26% copovidone, 26% lactose, 5% sodium 
chloride and 1% magnesium stearate. Detailed information on the preparation of 
captopril tablets and the laser drilling of orifices is given in S 5 
4.3.1 Visualization and 3D structure determination of drilled 
orifices 
     For OP-DDS, the ideal delivery orifice would be a controlled size of the circular 
opening in the semi-permeable membrane without any disturbance of the tablet 
core beneath the opening. In this study, an osmotic pump tablet containing 
captopril was selected to demonstrate the potential of SR-μCT 3D visualization 
and extraction procedures for examining laser drilled orifices (Figure 46). The 
slices of the reconstructed structure (Figure 46 a,b) show that the orifice has a 
border with readily distinguishable differences from the surrounding material. 
Additionally, the membrane, high density materials in the tablet core (e.g., the 
brightest particles are sodium chloride), are distinguished from each other.  
Based on the recognized morphology and structure of the membrane and 
tablet core, the initial study was to determine whether the laser drilled orifice 
penetrated the membrane completely. The red coloured regions (Figure 46 e) 
showed the structure and form of the laser drilled orifices in the osmotic pump 
tablets. The rough surfaces of the architectures of drilled orifices, with some 
irregular protuberances attached, are attributed to the re-solidification of melted 
materials in the tablet cores after laser drilling (with melting points of cellulose 
acetate, polyethylene glycol, copovidone and captopril all less than 200oC).  
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The overall shape of the drilled orifice was conical, with the cone angle 
inserted into the tablet core (Figure 46 c, the grey region). The unexpected conical 
shape, rather than an expected cylindrical structure, is thought to be due to one 
or more of a number of factors - i) any melted material as liquid re-solidify into a 
conical well; ii) the laser energy at the edge of the laser spot is weaker than that 
in the centre. However, it is regarded that the first factor is the primary cause for 
the conical shape of the orifice. Compared to the thickness of the membrane 
(approximately 50 μm), the depth of the drilled orifice was 575.61 μm, which 
indicated that the drilling penetrated through the membrane and into the tablet 
core. It is also shown that the membrane around the edge of the orifice protruded 
from the surface of the osmotic pump tablet. This feature was able to be identified 
due to the low reflection and good absorption of the coating and tablet core 
materials to the scanning laser, as well as the generation of thermal energy during 
their contact with the laser beam. It is hypothesized that the membranes in 
regions adjacent to the laser beam melted and re-solidified into curled circle 
edges after drilling.  
The shape of the orifice opening resulting from the laser drilling was irregular 
and elliptical, although the original set shape for laser drilling was a regular circle. 
In addition to the potential melting event mentioned above which would have a 
major influence in the shaping of the orifice geometry [114], another explanation 
for the elliptical shape is that variation of directional control during the high speed 
movement of the laser beam led to the formation of an elliptical shape. It is also 
interesting to note that many very small micro-porous structures were observed 
around the edge of the drilled orifices, which might be due to thermally induced 
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vaporization of tablet core and membrane components during the drilling 
operation with subsequent re-solidification.  
 
Figure 46 Visualization and 3D structure determination of laser drilled orifices. 
 Slice of the orifice (a and b, from different perspectives), 3D visualization of the orifice (c and d, 
d is the magnification of c), and extraction of architectures (e) of the laser drilled orifices from the 
osmotic pump tablet. 
 
4.3.2 Drilling parameters and the structure of orifices 
Reproducibility verification for 3D structural determination of drilled orifices 
In order to assess the accuracy and reproducibility of the methodology, 
osmotic pump tablets subjected to the same laser drilling parameters were 
examined in triplicate. Architectures of the laser drilling orifices and the 
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corresponding cross section 2D and structural 3D parameters were extracted and 
analysed (Figure 47 a-c). In practice, it is challenging to produce uniform delivery 
orifices with laser drilling, which makes it difficult to achieve fabricating orifices 
with the desired orifice-geometry with industrial tolerances. It was reported that 
orifices with the same laser parameters generate different orifice geometries 
[114]. However, the results in our study revealed that the architectures of the 
orifices drilled by the same laser parameters had relatively good consistency in 
term of the cross section 2D structural parameters, with the area of 1.56 E6±0.01 
E6 (±8.19%) μm2, and aspect ratio of 1.30±0.06 (±4.71%). In contrast, there were 
much greater differences for the 3D structural parameters with average volume 
of 1.05 E7±0.04 E7 (±34.2%) μm3, surface area of 4.33 E5±0.81 E5 (±18.7%) 
μm2, depth of 214.29±26.04 (±12.2%) μm, and cone angle of 90.11±35.25 
(±39.1%)o (Table 7). The relatively high variance of 3D parameters compared to 
the 2D parameter indicates that a 3D sensitive measurement uncovers more 
structural information of laser drilled orifices. 
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Figure 47 Architectures of the laser drilled orifices. 
 Generated by the same laser drilling parameters for the repeatability verification (a-c), and by 
one laser drilling (d), two laser drillings (e), and five laser drillings (f). 
Intriguingly, in one example there was a large pore in the architecture (Figure 
47 b), which was associated with the removal of a particle with a much higher 
melting point in the wall of the orifices. It was confirmed that the particle was 
sodium chloride (the osmotic pressure modulating agent, with the melting point 
of 804oC, Figure 46 b), as indicated by the brightness of X-ray image of the particle 
in the cross section. As a result, it can be argued that the presence of particles 
with a relatively large size and hardness close to the region of laser drilling will 
dramatically affect the architecture of the resulting orifices, especially the depth 
of the drilled orifices.  
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Table 7 Quantitative structural parameters of the laser drilled orifices generated by the same 
laser drilling parameters for the repeatability verification. 
Orifice ID 
Structural parameter 
Cross 
section 
area (E6, 
μm2) 
Cross 
section 
aspect 
ratio 
Depth 
(μm) 
Cone 
angle 
(o) 
Volume 
(E7, μm3) 
Surface 
area (E5, 
μm2) 
a 1.48 1.23 184.6 125.9 0.64 3.45 
b 1.68 1.30 233.2 55.4 1.24 4.50 
c 1.73 1.35 225.0 89.1 1.27 5.04 
 
Effects of repeated laser drilling on orifices 
The 3D structural changes of orifices occurring after repeated laser drilling 
were also observed. Under the identical laser operating parameters, three tablets 
were drilled for different number of times, namely, one, two and five drillings, 
respectively (Figure 47 d-f). It was found that whilst the 2D structural parameters 
remained almost unchanged, the 3D parameters were markedly different. For 
example, the 2D cross section areas of the architectures of orifices laser drilled 
one, two and five times were similar at 1.74 E5, 2.01 E5 and 1.75 E5 μm2, 
respectively. In contrast, the depths of the orifices laser drilled for one, two and 
five times were in proportion to the number of drillings at 208.99, 428.01 and 
675.27 μm, respectively.   
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Figure 48 Effects of laser powers on the architectures of the drilled orifice. 
 3D visualization of architectures extracted from the osmotic pump tablets formed by different 
laser powers (a-e, a. 2 W, b. 6 W, c. 10 W, d.14 W, and e. 20 W), and the relationship between 
laser powers and structural parameters (f-k, f. cross section area, g. cross section aspect ratio, 
h. depth, i. cone angle, j. volume, and k. surface area). 
Effects of scanning speeds of laser beam on orifices 
If uniform orifice diameters can be formed with faster speeds, a shorter 
working time for laser drilling will occur. The orifice architectures resulting from 
speeds ranging from 600 mm/s to 2,000 mm/s, penetrated the membranes with 
minimum disturbance to the tablet core, with depths from 286.76 μm to 148.80 
μm (Figure 48 c-f, i). The scatter diagrams and the exponential function fitting for 
the extracted structural parameters are shown in Figure 48 g-l. Architectures of the 
drilled orifices from faster speeds had smaller areas, volumes, surface areas and 
depths than for orifices formed at slower speeds. It was also clear that the 
reduction of speed values over the range of 200-1000 mm/s increased the cone 
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angle. Moreover, the relative standard deviations of the six drilled orifices for 3D 
parameters were larger than those determined from the 2D parameters. For 
example, the average 2D aspect ratio was 1.40±0.10 (±9.52%), ranging from 1.23 
to 1.59 and the average area was 1.94 E5±0.58 E5 (±29.71%) μm2, ranging from 
1.32 E5 to 2.87 E5 μm2. However, the average 3D determined depth, volume, 
surface area, and angle were 305.75±160.92 (±52.63%) μm, 1.88 E7±1.59 E7 
(±84.50%) μm3, 5.79 E5±2.89 E5 (±49.85%) μm2, and 66.6±0.4 (±36.91%)o, 
respectively. 
Effects of laser powers on the orifices 
In general, the same orifice diameter formed under lower laser power 
involves a lower working energy or laser drilling. With the depth of 84.92 μm 
(Figure 49 h), the architecture of the orifice resulting from laser power of 2 W (Figure 
49 a) was smaller and shallower than others (Figure 49 b-e), although, a low laser 
power often induces some instability into the drilling operation. The scatter 
diagrams and the exponential function fitting for the cross section 2D and 3D 
structural parameters are shown in Figure 49 f-k. The data show that the 
architectures formed by the higher laser power had larger cross section areas, 
depths, volumes and surface areas. However, the effects of laser power on the 
structural architecture of the orifices were more variable compared with those of 
the speed, especially for the 3D parameters of depth, cone angle, volume and 
surface area. The average aspect ratio was 1.40±0.11 (±7.54%). Apart from the 
lowest power (2 W), the cone angle widened with an increase in laser power. The 
steric morphologies of the architectures also changed when the laser power 
increased from 2 W to 6 W, but at a reduced rate over the power range 6-20 W. 
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Figure 49 Effects of scanning speeds of laser beam on the architectures of drilled orifices.  
3D visualization of architectures extracted from the osmotic pump tablets formed by different 
speeds (a-f, a. 200 mm/s, b. 400 mm/s, c. 600 mm/s, d. 800 mm/s, e. 1,000 mm/s, and f. 2,000 
mm/s), and the relationship between speeds and structural parameters (g-l, g. cross section area, 
h. cross section aspect ratio, i. depth, j. cone angle, k. volume, and l. surface area). 
Stability of chemical change around the orifices after laser drilling 
The materials used as components of membranes and tablet cores of OP-
DDSs may be sensitive to heat, and the laser drilling process is a high energy 
operation which can cause localized heating. Therefore, the materials within the 
membranes and close to the orifices may undergo some chemical change as a 
result of any melting and re-solidification of the membranes. Any such chemical 
changes and the chemical distribution can be identified by Fourier transformed 
infrared microspectroscopy (FTIR). Therefore, the regions close to the orifice in 
the membrane were mapped in situ by synchrotron radiation-based FTIR (SR-
FTIR) (Figure 50 a). The region around the edge of the orifice was not transmittable 
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to the SR-FTIR if it was raised up to form a relatively high rim (approximately >100 
μm). From the line mapping extraction SR-FTIR image (Figure 50 b), there was no 
dramatic difference among the microspectroscopy of the membranes from the 
edge of the orifice to the normal membrane region. However, the magnitude of 
absorbance of the regions adjacent to the normal membrane increased, due to 
the increased thickness of the membrane. 
 
Figure 50 SR-FTIR imaging of membranes around the laser drilled orifice.  
Morphologies of the membrane with an orifice (a). SR-FTIR spectra extracted from the line 
mapping image demonstrated there was no dramatic change from the edge of the orifice to the 
normal membrane (b). 
4.3.3 Evaluation of the orifices on marketed OP-DDSs 
The laser drilled orifices of felodipine OP-DDS (Linuo®, a marketed osmotic 
pump product in China) were evaluated using the above methodologies. However, 
the presence of a water-soluble crimson coloured coating outside of the cellulose 
acetate semipermeable membrane eliminated the opportunity to study any 
chemical feature of the membrane of felodipine OP-DDSs, since SR-FTIR 
imaging could not be carried out. The extra coating constituent did not, however, 
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interfere with the X-ray analyses for the SR-μCT measurement, and three 
felodipine sustained release tablets, providing six orifices, were measured (Figure 
51). The architectures of the laser drilled orifices had similar 2D parameters, with 
an average cross section area of 2.48 E5±0.25 E5 (±10.03%) μm2 and aspect 
ratio of 1.08±0.04 (±3.75%). As mentioned above, consistent and regular cross 
section areas and aspect ratios of laser drilled orifices would play an important 
role in achieving uniform and reproducible drug release profiles. In comparison, 
there were major differences in 3D parameters average volume of 3.27 E7±0.95 
E7 (±29.05%) μm3, the surface area of 7.85 E5±1.82 E5 (±23.25%) μm2, depth 
of 394.18±257.57 (±65.34%) μm, and a cone angle of 68.10±28.38 (±41.67%)o. 
All the depths of the orifices were larger than the average thickness 
(approximately 60 μm) of the membranes, penetrating into the tablet core. 
Although the effects of the orifice differences in 3D parameters on the drug 
release need to be further identified, it is considered that minimization of 
differences of the delivery orifices in 3D parameters could improve the 
consistency of drug release and the quality of the products in the future.  
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Figure 51 Evaluation of the laser drilled orifices from the market product. 
 Architectures of orifices (a-f) extracted from felodipine OP-DDS. 
In this section, 2D and 3D visual and structural quantitative methods were 
established based on the SR-μCT to investigate the architectures of laser drilling 
orifices in the osmotic pump tablets. Results and findings using the new 
methodology have demonstrated the effects of laser drilling on the reproducibility 
and fine architecture of orifices, which are the key functional structure for the 
osmotic pump controlled drug release systems. The in situ SR-FTIR spectra and 
mapping have shown that there was no chemical change close to the delivery 
orifices when compared to the normal membrane. In conclusion, quantitative 
visualization by SR-μCT and structural reconstruction of the architectures on the 
semipermeable membranes and orifices generated by laser drilling provides 
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valuable information for improving the design and performance of osmotic pump 
drug delivery systems for controlled release. 
General comments 
In conclusion, studies reported in this chapter focused on the intermediate 
microstructures in pharmaceutical manufacturing processes. The blend of 
microcrystalline cellulose and starch granules was studied and the derived mixing 
index used to evaluate the mixture homogeneity of the particle system. Particle 
mixing and segregation as visualised in 3D images and found to be Influenced 
by the time of rotations and the time of vibration. Tableting of crystal particles was 
tested in situ non-invasively. With the advantages of SR-μCT to obtain the 
individual particle characteristics of CLP I and II polymorphs, the deformation 
behaviours of the two crystal forms was measured without destroying the integrity 
of the tablets and correlated closely to the published result of their mechanical 
properties. The quantified degrees of deformation illustrated the heterogeneous 
pressure distribution in various regions of the compacted tablet.  
Examination of the laser drilled orifices in OP-DDS was  also carried out. 
Rather than the conventional microscopic evaluations being limited to 
measurement of two-dimensional cross-section diameters, a novel method to 
measure quantitatively the three-dimensional architectures of orifices was 
established. Quantitative analysis of architectures of orifices drilled with different 
laser power and scanning speed revealed variation in cross section area, volume, 
surface area and depth of the orifices.  
In the next chapter, chapter 5, various microstructures affected by swelling, 
dissolution, erosion and hydration to deliver drug release will be investigated 
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using in part DDS systems previously examined . In this way a correlation of the 
microstructure with drug release profile can be probed to provide insight into, and 
reveal details of, drug release mechanisms.  
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Chapter 5 
Innovation of Novel Architecture Driven 
Drug Release Mechanism 
-Dynamic Structures during Release 
  
 137 
 
5.1 Internal architectures correlated to release kinetics 
of particulate systems 
Conventional dissolution testing is routinely performed using methods 
described in Pharmacopoeias. The solid dosing unit is placed in a suitable buffer, 
agitated under controlled conditions, and the results represent the amount of 
active pharmaceutical ingredient (API) that is released over time. The key 
components for optimizing the formulation and manufacturing processes, as well 
as the release mechanism, are the dose level of drug and the target release 
profile of the drug over time. However, this approach toward establishing a 
release profile does not provide the contributions of individual pellet, in case of 
multi-pellet products, due to the extremely tedious experiments required and the 
analytical constraints of quantifying very low levels of a substance. However, this 
strategy for multi-pellet product is insufficient because the release kinetics for 
ensembles is a composite profile of the individual units [115-117]. An ensemble 
of zero-order releasing units will exhibit first-order kinetics under certain 
conditions [118]. The results from single pellet experiments can also be used to 
simulate the release behaviour on the dose level [119-122]. 
The rate and mechanism of drug release from solid dosage forms depend 
strongly on their shape and microstructure. Lorck et al. found that rough pellets 
had a higher release rate than smooth pellets after approximately 2 h of release 
where spherical pellets were classified as smooth, and all other shapes were 
denoted as rough [123]. The internal micro-structure of pharmaceutical tablets 
can not only influence mechanical strength but also impact the rate at which APIs 
are released from some types of dosage forms [124]. For microcrystalline 
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cellulose (MCC)-carbopol pellets with a high proportion of carbopol, the size, 
shape, mechanical properties and release behaviour can be tuned by modulating 
the CaCl2/carbopol ratio and the drying conditions due to the influence of these 
variables on the pellet microstructure [125]. In another study, a good correlation 
was also reported between the total porosity, mean pore diameter and drug 
release rate, while the porosity parameter was important when evaluating the in 
vitro performance of the multi-unit erosion matrix during the controlled release of 
an insoluble drug [126].  
This section details SR-μCT investigations into the relationships between the 
microstructure parameters and single pellet drug release from a multi-pellet DDS 
(TSH sustained release pellets). The release behaviour of a single TSH pellet 
was analysed using a LC/MS/MS quantification analysis method, SR-μCT 
method to reveal the microstructure of TSH sustained release pellets: (i) visualise 
the surface morphology and internal 3D structure while investigating the drug 
release behaviour of the individual pellets; (ii) elucidate the release mechanism 
of individual pellets and probe relationships between the microstructure and 
release kinetics; (iii) correlate the release behaviour of single pellets and the 
pellet ensemble from a single-unit dose capsule. 
5.1.1 Identifiable pellets preparation 
To investigate the release behaviour of the individual pellets with the 
microstructures discussed above, samples containing identified pellets 
containing tamsulosin from a commercial multi-pellet controlled release DDS 
were prepared for a SR-μCT scan. PVP/VA was introduced and mixed with the 
pellets; five samples were examined. Therefore, three differently sized capsules 
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were filled with a specific number of tamsulosin hydrochloride (TSH) pellets (i.e., 
seven pellets for the largest size capsule and five pellets for the two smaller sizes); 
these capsules were closed to form a sample for CT scanning. Figure 52. a is a 2D 
synchrotron X-ray tomographic image showing how the two components of the 
capsule shells fitted together. Every capsule was identified using a specific code. 
The pellets in each capsule were easily distinguished by size and shape. The 
images of the pellets were acquired using a CCD camera (20× magnification) and 
analysed by software Image-Pro Plus (Version 7.0, Media Cybernetics, Inc., USA) 
to verify the differences for every pellet.  
Identifying and matching the pellets with the reconstructed 3D model 
Pellets separated from the PVP/VA were transferred to a black plastic board 
after the CT scan. Then, photos of each pellet were taken using the CCD camera 
(20× magnification times) and the digital images analysed using Image Pro 
Analyser 3D. The pellets on the image were sequenced according to their size 
and shape (Figure 52. b and c) and each pellet was identified with an ID by 
comparing the true pellet to the sequenced pellet image. Data from CT scan and 
3D reconstruction, the reconstructed model and the pellet image were linked and 
compared. In this way, every pellet was successfully matched with the 
corresponding 2D image and 3D model. 
 140 
 
 
Figure 52 Preparation and identifying of the pellets. 
 a Tomography of the prepared sample (TSH pellets (bright) and PVP/VA (grey)); b original image 
of the pellets from one typical capsule; c the sorted sequence with the corresponding label 
5.1.2 Dissolution testing and data analysis 
The dissolution testing included two parts - the original capsule at the unit 
dose level and single pellets. The dissolution testing with the original capsule was 
performed using a USP31-NF26 Apparatus II (paddle) at 100 rpm and 37 ℃ in 
500 mL of phosphate buffer (pH 6.8) (n=6). Five mL samples were withdrawn at 
established time intervals (15, 30, 45, 60, 90, 120, 180, 240 and 300 min), and 
the amount of drug released was determined using LC/MS/MS analysis (see 
details below). After sampling, 5.0 mL of the fresh release medium was added to 
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each dissolution vessel. For the single pellets, the dissolution test was performed 
using a constant temperature oscillator at 100 rpm and 37 ℃ in a 10.0 mL release 
medium and 0.5 mL samples were withdrawn for quantification, as well as the 
other parameters tested for the single unit dose capsule. Ultrasonic processing 
was performed for 30 min before the concentration was determined to obtain the 
total amount of drug in each single pellet (M∞ in Eq.(6)).  
The cumulative amount of drug released over time was calculated using Eq. 
(5): 
M୲ ൌ C୬ ∙ Vଶ ൅ ሺC୬ିଵ ൅ ⋯൅ Cଶ ൅ Cଵሻ ∙ Vଵ                                               Eq. (5) 
where Mt is the cumulative amount of the drug released at time t, C1 is the 
concentration of drug during the first sample collection, C2 is the concentration 
of the drug after the second sample was collected, Cn is the concentration of the 
drug at time t, V1 is the volume of sample withdrawn at different times, V2 is the 
volume of the dissolution medium. 
The cumulative percentage of drug released over time was calculated using 
Eq. (6): 
R୲ ൌ M୲ Mஶ⁄                                                                                          Eq. (6) 
where Rt is the cumulative percentage of the drug released at time t, and M∞ 
is the total amount of drug. 
LC/MS/MS analysis  
The chromatographic experiments were performed on an Agilent 1260 series 
HPLC system (Agilent Technologies Inc., China). The separation was carried out 
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at 30 ℃ on a Luna C18 column (150 mm × 4.6 mm, 5 μm, Phenomenex). The 
mobile phase consisted of methanol-acetonitrile (30:40, v/v) and ammonium 
formate (10 mmol/L) (58:42, v/v, pH 4.2-4.5) flowing at 0.4 mL/min. The total run 
time for each sample was 8.0 min.  
The mass spectrometric data were collected with a G6460 tandem mass 
spectrometer (Agilent Technologies Inc., China) equipped with an atmospheric 
pressure chemical ionisation (APCI) module. Nitrogen was used as the nebuliser 
gas at 20 psi and the drying gas at 6 L/min and 350 °C. The instrument was 
operated with a 3.5 kV capillary voltage. Multiple reactions monitoring (MRM) was 
employed during data acquisition. The optimised MRM fragmentation transitions 
for tamsulosin and the internal standard (IS, diphenhydramine) were m/z 
409.0→m/z 228.1 with a fragment voltage of 135 V and a collision energy (CE) 
of 20 V and m/z 256.1→167.1 with a fragment voltage of 75 V and a CE of 6 V, 
respectively. The dwell time for each transition was 200 ms. Quadrupoles Q1 and 
Q3 were set to unit resolution.  
The stock standard solution of TSH (0.2 mg/mL) was prepared by dissolving 
the drug in phosphate buffer (pH 6.8) before storage at 4 ℃ . A standard 
calibration curve (peak area ratio of TSH/IS vs. known drug concentration) was 
built using standard solutions (1.00, 2.50, 5.00, 10.00, 25.00 and 50.00 ng/mL) 
prepared by diluting the stock standard solution with phosphate buffer. The IS 
(5.16 ng/mL) was prepared by dilution in acetonitrile. For the analyses, 40 μL of 
each sample was combined with 60 μL of IS solution (diphenhydramine, 5.16 
ng/mL). After vortexing (2500 rpm, 1 min), a 2 μL aliquot of each sample was 
injected into the HPLC system.  
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The peak area ratios of the calibration standards were proportional to the 
concentration of Tamsulosin in each assay over the nominal concentration range 
(1.00-50.00 ng/mL). The calibration curves were linear and were well described 
by least-squares linear regression lines. Compared to the 1/x weighing factor, a 
weighting factor of 1/x2 achieved the homogeneity of variance and was used 
accordingly. The correlation coefficient was ≥ 0.9950. The validated linearity 
range justified the concentrations observed when analysing the real samples. 
The LLOQ (lower limit of quantification) of the method was 0.1 ng/mL at a signal-
to-noise ratio (S/N) ≥ 32. The accuracy and precision for tamsulosin were 93.1-
106.2% and 4.8%, respectively. The recovery for the analyte and the internal 
standard were obtained by comparing the peak areas at the low, medium and 
high quality control (LQC, MQC and HQC) concentration levels. The recovery of 
the analyte at the LQC, MQC and HQC samples was calculated: 99.1±7.0%, 
103.6±5.3% and 96.8±6.4%, respectively. 
5.1.3 Single pellet release kinetics 
The total amount of drug in each single pellet was determined as mentioned 
above and additional data analyses were performed (Figure 53. a and b) to 
understand the drug release behaviour. The drug loading of the individual pellets 
was distributed across a wide range and was weakly correlated  (R2 =0.7790) to 
the pellet volume, as shown in Figure 53. a. In Figure 53 b, the points on the scatter 
plot spread further as the diameter increases, indicating that the drug loading on 
the small pellets with high sphericity show a higher homogeneity. Furthermore, 
the drug concentration in the pellet matrix (content in a unit of volume) of most 
pellets was approximately 1 to 2 ng/μm³. This concentration is markedly lower 
than the saturated solubility of TSH; this feature is important for understanding 
 144 
 
the drug release mechanism. Several outliers are apparent in the plot showing 
the differences in the drug concentration in the pellet matrices because the 
manufacturing process is unable to provide a perfectly heterogeneous product. 
The drug concentration decreased slightly as the pellet diameter increased. 
 
Figure 53 Correlation between (a) volume and drug loading, (b) diameter and concentration of 
drug in the matrix. 
 The colour coding (bar on the right) has been chosen such that yellow to red illustrates an 
increasing and big value of sphericity whereas green to dark blue corresponds to a decreasing 
and small value of sphericity. Outliers were highlighted with elliptical. 
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A 3D map of the drug release profiles from 74 single pellets is shown in Figure 
54. The IDs of the pellets were rearranged as the drug loading increased to 
facilitate visualisation in the graphical displays. The blue domains correspond to 
lower amounts of drug release, and the red domains correspond to the higher 
amount of drug release. The drug loading of individual pellets ranged from less 
than 100 ng to 700 ng. The amount of drug released from each pellet at various 
test points changed as the colour changed in Figure 54.b. The regularity of drug 
loading and release behaviour as the colour changed gradually is linked to the 
fact that the individual pellet data were rearranged according to the drug loading. 
Figure 54 e and f show the threshold of drug release. The rate gradually decreased 
during the release process. The number of pellets with the total drug content 
released at specific points was (cumulative release percent ≥ 85%) was 1, 1, 10, 
37, 22, 3 at 60, 90, 120, 180, 240, 300 min, respectively. Therefore, after 240 min 
almost all of pellets had completed their release. The release distribution at each 
point appears similar. 
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Figure 54 Single pellet release profile for released amount (a–c) and released percent (d–f). 
 3D surface plot (a, d), top view (b, e) and front view (c, f). The colour legend (bar on the right) 
refers to the amount of drug released (ng) in a–c and the cumulative release percentages (%) in 
d–f 
 
5.1.4 Correlation between structural parameters and drug 
release 
The rate and mechanism of the drug released from the pellets depend on 
their microstructure. The correlation between these parameters and the drug 
release was investigated further.  
Correlation and release mechanism analysis 
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The nine subplots in Figure 55 show the correlations between the surface area 
of individual pellets and the cumulative amount of drug released at each sampling 
point. The 74 data points in each subplot correspond to the 74 individual pellets 
analysed. As shown in Figure 55, the cumulative amount released correlated well 
with pellet surface area, with particularly strong linear correlations observed from 
45 to 120 min. 
 
Figure 55 Correlation between the surface area and cumulative amount released at different times. 
 The colour legend (bar on the right) refers to the drug loading of the pellets (ng) 
The above analysis shows that the surface area of the pellet represents a key 
steric parameter that determines the drug release profile. The drug release 
kinetics may also be controlled by the diffusion of the drug from the pellet. The 
pellets tested in this study contain microcrystalline cellulose (MCC) as a bulking 
excipient. MCC is insoluble in water but does swell. The van der Waals interaction 
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will be the main inter particle interactions between the drug particles and MCC 
and the sustained release of the drug will also be affected by the insolubility of 
MCC in water [127]. Thus in this case, the drug release mechanism of the MCC-
based pellets can be classified as that occurring from an inert matrix [128]. In the 
inert matrix, the drug is released through both the initial, existing pores of the 
matrix and the pores formed when the drug has been dissolved [129]. MCC has 
a porous structure. From observations, it was noted that the drug-containing 
pellets maintained their original shape during the drug-release tests and no 
swelling or disintegration was observed.  
The drug release patterns of single pellets from MCC matrices can be 
expressed as the well-known relationship reported by T. Higuchi in 1963 and 
reduced to Eq.(7) [130]. 
ܳ ܣ⁄ ൌ ට஽௄ఛ ሺ2 െ ܭܥௌሻܥௌݐ                                                                        Eq. (7) 
where Q is the amount of drug released per unit of surface area for the matrix 
(mg/cm2), A is the concentration of that component in the matrix (mg/cm3), D is 
the diffusion coefficient (cm2/min), τ is the tortuosity factor, Cs is the concentration 
of a saturated solution of the drug or solubility (mg/cm3), t is time (h) and K is the 
specific volume of each soluble component (cm3/mg). 
The release rate is controlled by the drug concentration, the dissolution speed 
and how fast the dissolved drug diffuses throughout the matrix. The largest value 
of M∞/V is 3.5 μg/mm³, a value which is considerably lower than the solubility of 
TSH. Therefore, if TSH dissolves fast during the first and middle periods of the 
drug release period, the drug concentration in the pellet is constant and equal to 
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M∞/V. Because the matrix of the pellet formed by MCC remained throughout the 
release, the surface area of the pellets remained unchanged, allowing τ and the 
surface area to remain constant. For specific cases in this research where the D, 
K, Cs, and τ is constant, this equation can be reduced to form Eq. (8): 
ܳ ܣ⁄ ൌ √߱ݐ                                                                                             Eq. (8) 
where ω is the slope of the square root of the time relationships, and Q can 
be rewritten as dM/S; A can be rewritten as M/V, allowing Eq. (8) to be rewritten 
as Eq. (9): 
݀ܯ ൌ ெ௏ ∙ ܵ ∙ √߱ݐ                                                                                     Eq. (9) 
where M is the drug loading of the pellet, and V and S are the volume and 
surface area of the pellet, respectively. According to Eq. (9), the cumulative 
amount of drug released is a linear function of the square root of time. 
Therefore, the level of correlation between M*(S/V) and drug release kinetics 
was investigated in this study. The results are shown in Figure 56. a and confirm a 
high level of correlation.   
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Figure 56 Correlation between the newly defined parameters (M×(S/V)) 
 (a) and (M×(Sa/V)) (b) cumulative release amount. The colour legend (bar on the right) refers to 
the drug loading of the pellets (ng) 
At the beginning of the drug dissolution process, only the outer surface of the 
pellet is infiltrated with dissolution medium. When the pellet is well hydrated, the 
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voids are also filled with dissolution medium and the surface area of the internal 
void will affect the dissolution and speed up the diffusion process. Take these 
factors into account, the surface area, an important steric parameter for the 
release profile, has been adjusted to Sa (Sa =surface area of pellet + surface 
area of void). The adjusted parameter (M*(Sa/V)) produced an improved 
correlation with higher R² values, as shown in Table 8 and Figure 56. b, 
demonstrating that the voids play a profound role during drug release. 
Table 8 Correlation between the newly defined parameter and cumulative release 
amount at different release time points 
Time(min) 
M*(S/V) M*(Sa/V) 
Equation R2 Equation R2 
15 y=18.6646x+14.6874 0.7620 y=15.5782x+19.0202 0.7290 
30 y=31.2213x+19.7131 0.8414 y=26.6961x+24.9757 0.8448
45 y=42.3283x+21.2302 0.8944 y=36.2690x+28.1294 0.9019
60 y=53.5459x+14.2706 0.9172 y=45.8026x+23.2418 0.9216
90 y=63.6359x+7.2662 0.9306 y=59.7397x+18.3916 0.9406
120 y=79.7005x+6.6756 0.8964 y=68.8736x+17.8536 0.9193
180 y=101.7183x-9.8328 0.8912 y=88.1092x+3.7832 0.9183
240 y=120.8122x-35.6993 0.9184 y=103.9438x-17.3337 0.9337
300 y=131.6917x-57.3757 0.9204 y=113.7402x-38.7131 0.9429
 
 152 
 
Cluster analysis of release behaviour 
During an attempt to categorise differences in drug release behaviour, a 
cluster analysis of the pellet release data was carried out using the k-means 
method (39) to force a three-group solution. Compared to the release profile of 
the unit dose capsules, the pellets were identified as quick (n=12), slow (n=24) 
and similar (n=38). The centre of cluster-1 shows similarities with the 
compositional release curve of all 74 tested pellets and the entire capsule at the 
dose level, as shown in Figure 57 a.  
 
Figure 57 Dissolution profile after clustering, the compositional release curve of all individually 
tested 74 pellets and the unit dose capsule dissolution 
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Figure 58 Correlation between the diameter and M×(Sa/V) 
 (a), surface area and drug loading (b) (green, Similar; blue, Slow; red, Fast) 
The key structural parameters discussed above for the three groups are also 
clearly distinguished. In Figure 58 a, three colours (green, blue and red) represent 
clusters 1, 2 and 3, respectively. The three colours of the individual data points 
on the scatter plot (Figure 58 b) varied, demonstrating that the cluster result links 
strongly with the key structural parameters, such as diameter, surface area and 
drug loading. 
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These findings provide important knowledge regarding the investigation of 
drug delivery systems, specifically the visualization and quantification of the 
apparent morphology and internal void structure of the individual pharmaceutical 
pellets using SR-μCT imaging technology. This strategy also provides the 
opportunity to predict the effect of the pellet design parameters (e.g., shape, size 
and composition of pellets) on the resulting manufacturing process and drug 
release rate, thus facilitating the development of new pharmaceutical products. 
The proposed LC/MS/MS method yielded high quality single-pellet drug release 
data, even though the drug content of some pellets was as low as 100 ng. 
Experimental evidence has confirmed that the structure parameters that 
determine drug release are surface area, volume, and internal porosity. Further 
investigations using these methodologies can provide additional insight into the 
impact of other material and physicochemical properties on drug dissolution from 
solid dosing forms. Consequently, these analyses will provide knowledge and 
understanding of release mechanisms, thereby enabling the rational design, 
formulation and manufacture of solid dosing medicines with specific and 
controlled drug release profiles.  
5.2 Fractal structure dependent release kinetics of 
osmotic pump tablets 
The conventional in vitro dissolution tests for ODDS tablets with HPLC or 
LC/MS analysis can quantify the extent and rate of the drug release kinetics. The 
release profiles measured by conventional methods do not, however, provide the 
insight of the internal structure information of the ODDS tablet cores. Even though 
tight dissolution specifications are introduced to monitor the quality of the final 
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products, a number of batches of dosage forms often fail to meet in-house 
specifications, or even regulatory approval, and consequently have to be recalled 
from the market [21]. Thus, it is of interest to develop a new methodology to 
visualize the internal characteristics of the ODDS. When an internal structure 
method is established, the conventional in vitro release method can be calibrated. 
Modern in-vitro tomography techniques can directly reveal the internal structure 
and dynamic characteristics of ODDS tablet cores at different stages of the drug 
release process. 
This section details studies of the internal 3D structure of commercially 
available monolith osmotic pump controlled release tablet containing the API of 
felopidine using SR-μCT, as used in chapter 4. The tablets tested in this study, 
Linuo®, are swelling monolithic osmotic tablets of felodipine with a viscous 
suspending agent(s) [131, 132].  The primary objectives are  (i) to visualize the 
surface morphology, the internal 3D structure and their changing characteristics 
of the ODDS tablet core at different stages of the drug release process using a 
synchrotron radiation X-ray microtomography technique; (ii) to correlate the 3D 
steric data with the remaining percentages of the in the tablet core quantitatively 
and (iii) to elucidate the drug release mechanism of the monolith pump controlled 
release systems with the internal 3D steric data. Additional detailed experimental 
information is given S 6 Pre-treatment of felodipine osmotic pump tablets. 
5.2.1 In vitro dissolution testing 
In vitro drug release of the felodipine sustained tablet was measured using 
the basket method according to the Chinese Pharmacopoeia. The dissolution test 
was conducted with the rotation speed of 100 rpm, medium volume of 500 mL 
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and temperature of 37℃. 10 mL aliquot samples were withdrawn at 0.5, 1, 2, 3, 
5, 6, 8, 10, 12h and equivalent volumes of fresh medium were added to maintain 
the sink condition. The samples were then filtered and analysed with the UV 
method at 361 nm (λmax for felodipine).  
In vitro release kinetics of felodipine from the ODDS 
The dissolution profile of felodipine sustained release tablets showed a typical 
osmotic pump release profile (Figure 59). It was found that the zero-order model 
provides a good correlation coefficient for the test formulations (R = 0.9911), 
suggesting that the release rate of felodipine remains approximately constant. 
 
 Figure 59 The in vitro dissolution profiles of felodipine sustained release tablets (n = 6). 
Felodipine is a widely used antihypertensive drug with poor aqueous 
solubility, less than 10 μg/mL at ambient temperature [26]. For drugs with 
moderate or poor aqueous solubility, the osmotic delivery system delivers a 
portion of the drug as a suspension [27].  
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The drug release mechanism of MOTS is different from that of an elementary 
osmotic pump tablet (EOP) or a push-pull osmotic pump tablet (PPOP) [133]. In 
the dissolution medium, water is firstly imbibed from the environment through the 
difference of the osmotic pressure between the inside and outside of the semi-
permeable membrane with the aid of the osmotic agent. Then, a viscous drug 
suspension is consequently formed in situ within the coated tablet, which is 
enabled by the presence of the suspending agent and the imbibed water. The 
suspension is subsequently pumped out through the orifices as a result of the 
swelling of the suspending agent. The drug release is co-controlled by both the 
osmotic mechanism and suspension mechanism, which can be expressed by the 
Poiseuille's law of laminar flow (Eq. 10)  
h
PPRC
dt
dM 21
4
8
 
                                                                              Eq. (10) 
Where dM/dt is the drug release rate, C is the concentration of drug in 
suspension, R is the radius of the orifice, η is the viscosity of the suspension, 
(P1−P2) is the pressure difference between two sides of the semi-permeable 
membrane and h is the thickness of the semi-permeable membrane. As shown 
in Eq. 10, the drug release rate is directly proportional to C, R4 and (P1−P2), and 
inversely proportional to η and h. Values of (P1−P2) and η are dependent on the 
suspending agent. In summary, the dynamic process of the drug release from 
MOTS can be linked to the osmotic, suspending and expanding properties of the 
tablet. 
5.2.2 Correlation between the 3D steric parameters and the 
remaining percents of felodipine in the tablet cores 
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The volume and surface area of the remaining tablets core are calculated 
from the reconstructed 3D images (Figure 60). The remaining percents of 
felodipine MOTS in the tablet cores at 0.5, 1.0, 3.0, 6.0 and 8.0 h are calculated 
by 100% minus the in vitro release percent of felodipine (Figure 60). As a result, 
the 3D volume values correlate well with the remaining percent of felodipine in 
the MOTS (R = 0.9988), suggesting that the 3D parameter accurately reflects the 
release characteristic of the felodipine MOTS. 
 
Figure 60 Released percent and remaining percent of felodipine. 
Measured by in vitro dissolution testing plotted with 3D volume of the tablet core calculated from 
the reconstructed images ((*): the released percent; (○): the remaining percent; (△): 3D volume 
of the tablet core). 
For MOTS, the release of felodipine is co-controlled by the osmotic pressure 
and suspension. Firstly, the pump is controlled by the osmotic mechanism, which 
is similar to the EOP systems. The water is imbibed and the suspension is created. 
Then, the core within the pump is covered by suspension liquid. The solid content 
of the tablet core (containing solid drug) is then eroded. Figure 61 illustrates the 
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two dimensional images of the cross-sections of felodipine MOTS acquired at 3.0 
and 6.0 h, and the images are consistent with the occurrence of erosion of the 
solid content from the tablet core to the suspension. As a result of the osmotic 
pressure and suspension co-mechanism, the suspension is pumped out through 
the orifice, which is also similar to the EOP systems.  
 
Figure 61  Two dimensional images of the cross-sections of felodipine MOTS acquired at 3.0 and 
6.0 h. 
Demonstrating the erosion of the solid content from the tablet core to the suspension, red 
represents the solid moiety of the tablet core, yellow represents the semi-solid moiety of the tablet 
core, air appears blue, and green represents the hydration layer. 
Among these processes, the detachment of the solid content from the tablet 
core is complex. According to Eq. 9, for MOTS with zero-order drug release 
kinetics, values of R, η, (P1−P2) and h are nearly constant. However, the apparent 
value of C is dependent on the extent of solid content detached from the tablet 
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core to generate the suspension. It is the erosion controlled process and can be 
expressed as Eq. 11 [134].  
l
CDA
dt
dM s                                                                                          Eq. (11) 
Where D, A, Cs, and l are the diffusion coefficient, the surface area of diffusion or 
erosion, drug solubility, and the thickness of boundary layer, respectively. For a 
given drug and tablet, values of D, l and Cs in Eq. 10 are invariable parameters. 
The surface area of diffusion or erosion, namely, the surface area of the 
remaining tablet core.  
Common sense might expect the surface area as well as the volume of the 
tablet core to decrease with the disappearance of the solid content during the 
drug release process. However, it is observed in our study that the surface area 
of the tablet core during the drug release process remains virtually unchanged 
whilst the shape of the internal solid content is changing markedly from ellipse to 
irregular shape with voids, which results in the 3D surface area values being 
almost constant.  
In summary, values of C, R, η, (P1−P2) and h in Eq. 9 are all constant during 
the drug release process, which demonstrates the intrinsic mechanism of the 
drug release kinetics of the MOTS. Thus, the 3D surface area might be a key 
steric parameter for the quality control of the felodipine MOTS products 
It has been shown that formulations with similar dissolution profiles can 
generate variable in vivo biological activities [135, 136]. This may be due to the 
dissolution profile lacking specificity and spatial resolution, which leads to an 
insufficient understanding of the intrinsic quality of drug delivery systems [21]. 
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Tomographic imaging techniques, such as X-ray computed 
microtomography [22, 137], magnetic resonance imaging [138, 139] and 
terahertz imaging [140], offer a means to generate improved understanding of the 
structural characteristics of solid dosage forms. Further understanding of the 
hydration kinetics have been obtained through the imaging techniques, including 
the visualization of the surface morphology and internal structure (i.e. front 
position or layer thickness), the rate of water penetration into the polymer matrix, 
the polymer concentration across the formed hydrogel and the location of the 
drug substance in the hydrogel during swelling [141, 142]. In addition, 
mathematical models describing drug release mechanisms and critical 
parameters for successful formulation design have also been proposed [143]. 
Through 3D reconstruction in these studies, the calculated volume of the 
tablet core correlated well with in vitro drug release kinetics. The 3D surface area 
exhibited only minor changes during the dissolution process, which demonstrated 
the intrinsic mechanism of the controlled drug release. However, most of these 
studies provide only qualitative information on the surface morphology and 
internal structure of the tablets during drug dissolution, which are irregular, 
complex and continuously changing. A quantitative method or an indicator to 
define the complexity of the surface morphology and internal structure of tablets 
during drug dissolution is required. 
5.2.3 Qualitative 3D fractal analysis of the tablet during drug 
release  
Fractal analysis is a quantitative analytical method to characterize morpho-
metric variability and complexity of an object in nature [144, 145]. Fractal analysis 
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has been applied in medical signal processing and pharmacokinetic modelling 
extensively. Using this concept, the irregular degree of the subject can be highly 
abstracted into a non-integer fractal dimensional value (Df) [146]. For solid 
pharmaceutical dosage forms, Df derived from surface imaging techniques have 
been employed to characterize the surface morphology of particles, mainly 
focusing on 2D static measurements, such SEM and AFM [147-150]. Information 
on surface roughness and shape for particles and tablets has been gained from 
the fractal dimension values. However, three dimensional fractal analysis and its 
relationship with controlled drug release has not been explored. 
In this section, the concept of a three-dimensional fractal analysis based on 
box-counting method is explored with the aim of simultaneously quantifing the 
entire shape, interior porous channels and surface structure of felodipine osmotic 
pump tablets during the drug release process. 
For fractal dimension calculation, the box-counting algorithm has been 
widely used in medical image processing due to the ease of implementation. 
Additionally, there is a strong correlation between this algorithm and classical 
geometry [151]. These factors indicate that using the box-counting algorithm can 
be a sound approach to generate fractal descriptors for the characterization of 
the internal complex structure of tablets during a release profile. Thus, the box-
counting algorithm was employed to calculate the volumetric and surface fractal 
dimension using the reconstructions images acquired from SR-μCT.  
3D objects were extracted from rendered data of solid tablet cores with 
Image-Pro 3D to obtain the mask of volume. From this volume, the sobel operator 
was performed to enhance the principle edges to obtain the mask of 3D surface 
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object. Then the bitmap information was extracted from the mask of 3D surface 
and volume to construct the point cloud matrix and the box-counting method was 
performed. Three dimensional fractal values of volume (Df,volume) and surface 
(Df,surface) of the solid core were calculated. The fractal dimension computing 
procedures are shown in Figure 62. 
 
Figure 62 Computing procedures for the fractal dimension values of the felodipine osmotic pump 
tablet core. 
 The computing sequence includes four steps: (1) 3D objects are extracted from rendered data 
of solid tablet cores with 3D reconstruction model in Image-Pro analyser software to obtain the 
mask of volume; (2) the sobel operator is performed to enhance the principle edges to obtain the 
mask of 3D surface object; (3) the bitmap information is extracted from the mask of 3D surface 
and volume to construct the point cloud matrix; (4) the box-counting method is performed and 3D 
fractal values of volume and surface of the solid core are calculated. 
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Due to the absence of solid fraction left after 10.0 h dissolution testing, the 
fractal analysis was carried out with the data between 0 and 8.0 h. Df,volume and 
Df,surface values of the osmotic pump tablet core during felodipine release are 
shown in Figure 63.  
During felodipine release from the osmotic pump tablets, the values of 
Df,volume and Df,surface are both within the range of 2-3, indicating that the 3D 
structural complexity of the reconstructed tablet core was different from 2D fractal 
analysis derived form scanning imaging methods (Df ≤ 2). Values of Df,volume are 
maintained at 2.73 for the first three hours of drug dissolution, and then decrease,  
reaching a value of 2.3 after 8.0 h. However, for Df,surface, values increase within 
the first three hours (from 2.28 (0.5 h) to 2.36 (3.0 h)) and then decrease to value 
of 2.25 at 8.0 h. 
 
Figure 63 The calculated Df,volume and Df,surface values of the reconstructed osmotic pump 
tablet core during felodipine release at sampling times of 0.5, 1.0, 3.0, 6.0 and 8.0 h. 
 165 
 
 ◆, Df,volume; ■, Df,surface. Error bars in these plots represent a range of standard deviations 
for triplicate samples, except for the time points of 1.0 h (n = 2) and 8.0 h (n = 1), due to the 
erosion of the tablet core and the variance of the drug release characteristics for the three tablets. 
As can be seen from Figure 63, values of Df,volume and Df,surface change from 
3.0 h, a time which corresponds to  the extensive changes  observed in the  
microstructure of the tablet core. This can be visualized from the 3D 
reconstructed images (Figure 64). The shape of the tablet is elliptic and some 
cracks can be seen at 0.5 and 1.0 h. As a result of the hydration of the tablet core, 
the shape of the core becomes more irregular with several voids present after 3.0 
h. At 8.0 h, the solid content of the tablet core is approaching complete 
dissoluttion. 
 
Figure 64 The determined in-vitro dissolution profiles for felodipine osmotic pump tablets at 
sampling times of 0.5, 1.0, 3.0, 6.0 and 8.0 h (n = 6). 
 The reconstructed 3D images for one of the three tablets in the imaging acquisition are shown 
(black represents the solid moiety of the tablet core, void appears grey). 
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5.2.4 Correlation between fractal dimension values and drug 
release  
Correlations between Df,volume and the volume of the tablet core, Df,surface and 
the surface area of the tablet core have also been considered. As shown in Figure 
65, the curve for Df,volume mirrors that of the volume of the tablet core, with a 
correlation coefficient (R) of 0.97 between Df,volume and the volume of the tablet 
core. However, the curve of Df,surface is different from that of the surface area of 
the tablet core, with the latter showing an initial upward profile followed by a 
decrease. In addition, no correlation is observed between Df,surface and the surface 
area of the tablet core. From these findings, it is proposed that the values of 
volume and surface area do not comprehensively represent the changes to the 
microstructure of the tablet core, which is especially complex during drug release. 
The value of fractal dimension reflects not only the size of object’s volume 
(surface) but also the degree of spatial complexity of the object in 3D and 
provides an appropriate parameter to characterize the complexity of the 
dimensional changes of the tablet core during drug release. 
 
Figure 65 The correlation between volume, surface and the corresponding Df. 
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The  calculated volume and Df,volume values (a, ◆, the volume of the reconstructed tablet core; 
■, Df,volume) and the calculated surface area and Df,surface values (b, ◆, the surface area of 
the reconstructed tablet core; ■, Df,surface) for the reconstructed osmotic pump tablet core during 
felodipine release at sampling times of 0.5, 1.0, 3.0, 6.0 and 8.0 h. Error bars in these plots 
represent a range of standard deviations for triplicate samples, except for the time point of 1.0 h 
(n = 2) and the time point of 8.0 h (n = 1), due to the erosion of the tablet core and the variance 
of the drug release characteristics for the three tablets. 
As discussed in the previous section, the release of felodipine from a 
monolith osmotic pump tablet is co-controlled by the osmotic pressure and drug 
suspension. Also, the zero-order drug release kinetics is dependent on the extent 
of solid content detached from the tablet core to the suspension, which can be 
expressed as Eq. 11. The felodipine release from the tablet is determined by the 
surface area of the tablet core.  
The correlations between values of the fractal dimension and drug release 
kinetics are shown in Table 9. A strong correlation exists between Df,volume and the 
remaining percent of felodipine (R = 0.94), Df,surface and the felodipine release rate 
(dM/dt, R = 0.99). No correlation is found when the Df,volume and Df,surface were 
interchanged.   
Table 9 Correlation between fractal dimension values and drug release kinetics 
Time (h) Released percent (%) Remaining percent (%) Df,volume dM/dt Df,surface
0.5 3.3 96.7 2.73  8.57  2.28  
1 7.5 92.5 2.73  8.88  2.31  
3 26.3 73.7 2.65  9.65  2.36  
6 55.2 44.8 2.56  9.38  2.34  
8 73 27 2.29  8.26  2.25  
Correlation Coefficient   0.94a 0.99b 
aCorrelation between the percentage of drug remaining in the tablet core and Df,volume. 
bCorrelation between the drug release rate and Df,surface. 
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    The correlation between Df,surface and drug release rate can be expressed by 
Eq. 12.  
54207812 .D.
dt
dM
surfacef,                                                                     Eq. (12) 
Therefore, Df,surface is an efficient fractal parameter that can be used to 
characterize the complex changes to the tablet core during drug release and can 
be regarded as a key indicator for assessing the quality control of felodipine 
osmotic pump tablets. 
The 3D volume and surface area related fractal dimensional values were 
then calculated and correlated with drug release kinetics. Finally, the mechanism 
of drug release for felodipine controlled release system was elucidated through 
3D fractal data. 
In summary, a new method combining 3D fractal analysis and SR-μCT was 
developed to research the drug release kinetics of felodipine monolithic osmotic 
tablets. The values of Df,volume and Df,surface are both within the range of 2-3 and 
Df,surface correlated well with the felodipine release rate, which indicates that the 
3D fractal analysis is not only able to characterize the microstructural changes to 
the tablet core during drug release process but also provide information on the 
final drug release performance of the product. 
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5.3 Quantification of swelling and erosion in hydrogel 
matrix tablets 
5.3.1 Erosion studies testing 
Detailed experimental information related to this section can be found in S 7 
Pre-treatment of felodipine HPMC gel matrix tablet. 
Felodipine extended release tablets (Plendil®, eachtablet containing 5 mg of 
felodipine) produced by AstraZeneca PLC has been investigated. In addition to 
the active ingredient felodipine, the tablets contained the following inactive 
ingredients: cellulose, red and yellow oxide, lactose, polyethylene glycol, sodium 
stearyl fumarate, titanium dioxide, and other ingredients. The rate of uptake of 
the dissolution medium by the tablets and the rate of polymer erosion were 
determined by gravimetric analysis methods. Dry matrix tablets were accurately 
weighed using a Mettler-Toledo ML-203 electronic balance (Mettler-Toledo, Inc.). 
In separate experiments, tablets were removed from the dissolution medium at 
0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0 and 10.0 h following exposure to the 
dissolution medium and lightly blotted with filter paper to remove excess water. 
The swollen tablets were weighed to determine the extent of water uptake and 
then dried in a convection oven at 40 °C. After 12 h the tablets were cooled to 
ambient temperature and then weighed This measurement was termed the dried 
weight. All studies were conducted in triplicate. The percent increase in tablet 
weight that can be attributed to the uptake or absorption of water was calculated 
at each time point using Eq. 13. The percent matrix erosion was estimated at 
each time point using Eq. 14. 
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WWpercenterosionMatrix                                      Eq. (14) 
where Ws is the weight of swollen samples at sampling times, Wi is the initial 
weight of tablet and Wt is the weight of dried matrices at sampling times. 
In vitro release kinetics of felodipine from the HPMC matrix tablets 
Much attention has previously been paid to the mechanism governing drug 
release from hydrophilic matrices, where it has been suggested that the diffusion 
front at the interface between the undissolved drug and the dissolved drug in the 
hydration layer influences the rate of drug release from cellulose ether based 
systems. In addition, water penetration and/or diffusion are postulated to be the 
rate limiting steps for the release of highly water-soluble drugs. For poorly water-
soluble drugs, matrix erosion is considered to provide a major contribution to the 
mechanism of the drug release [152]. Compared with studies on water soluble 
drugs, few quantitative analyses have been reported on the detailed contribution 
of swelling and erosion to the release mechanism of poorly soluble drugs.  
In vitro dissolution profiles of felodipine tablets are shown in Figure 66 B. In 
order to describe the drug release mechanism, n values are obtained from the 
following well known equation proposed by Ritger and Peppas [153], as shown 
in Eq. 15. 
nt kt
M
M 

                                                                                             Eq. (15) 
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where Mt is the moiety of the drug released at time t, M∞ is the moiety of drug 
released over a very long time that corresponds in principle to the initial loading, 
k is the kinetic constant and n is an exponent dependent on the release 
mechanism.  
Since drug release occurs through the hydrophilic gel barrier created around 
the tablets, the rate of drug release from the matrix is dependent on the formation 
and viscosity of the hydration layer and its swelling or erosion rate. For a 
cylindrical matrix, values of n ≤ 0.45 indicate Fickian release, values 0.45 < n < 
0.89 indicate anomalous release kinetics (coupled diffusion/relaxation) and n ≥ 
0.89 indicate a zero order release also known as purely relaxation controlled 
(erosion controlled) drug release. Studies of drug release from cylindrical 
matrices containing HPMC obtained values of the exponent n approximately 0.6 
[154]. When a soluble polymer is used, linear drug release is obtained and the 
value of the exponent n is close to 1.0, implying an erosion controlled mechanism. 
In our study, the n value for the felodipine tablet is 1.09, indicating that erosion of 
the hydration layer is the dominant factor determining the extended release of 
felodipine. Our results are also in full agreement with the reported findings that 
erosion is the controlling factor for poorly water-soluble drugs in hydrophilic 
HPMC matrices [73, 74].  
Hydration and erosion studies by gravimetric analysis 
The gravimetrical analysis is a conventional procedure to study the hydration 
and erosion of tablets, although data obtained always exhibit relatively large 
errors. As a consequence, this methodology generally only provides qualitative 
information with regard to swelling and erosion. Thus in this study, the 
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gravimetrical analysis is used primarily as a qualitatively supplementary method 
to verify that erosion is a critical factor in the controlled release of felodipine from 
the tested tablets. 
Figure 29 C (section 3.3.2) shows the results of weight gain and mass loss of 
felodipine tablets. The swelling rapidly increases to a plateau, and then 
decreases over the course of the dissolution test. The curves of swelling and 
erosion intersect at the time point between 5.0 and 6.0 h, after which the tablets 
do not demonstrate any further swelling. However, mass loss occurs throughout 
the entire time course of the dissolution process. Furthermore, erosion kinetics 
appears to follow a similar pattern to those of drug release, suggesting that 
erosion is a critical factor influencing the controlled release of felodipine from the 
tablets tested.  
5.3.2 Correlation of the 3D hydration parameters with drug 
release kinetics 
X-ray absorption of the glassy core is stronger than that of the hydration layer 
for the matric tablet. The density of the hydration layer is lower than that of the 
glassy core as the hydrated matrix is much more porous after the uptake of the 
dissolution medium. From these observations, it is possible to distinguish the 
hydration layer from the glassy core based on the X-ray intensity. Thus, the 
hydration layer has been extracted from the 3D models and quantitative steric 
parameters have been calculated accordingly.  
23 three dimensional steric parameters have been calculated based on the 
extracted Iso-Surface models in this study. The names, descriptions and the units 
of these parameters are listed in Table 10.  
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Table 10 The names, descriptions and the units of the 3D parameters 
3D Parameters Description Units 
Volume of tablet Volume of the whole tablet μm3 
Volume of core Volume of the unhydrated core μm3 
Volume of hydration layer Volume of the hydrated gel layer  μm3 
Surface of tablet Surface area of whole tablet μm2 
Surface of core Surface area of unhydrated core μm2 
surface of hydration layer Surface area of the hydrated gel layer μm2 
Specific surface of tablet Surface area of tablet / Volume of tablet μm-1 
Specific surface of core Surface area of core / Volume of core μm-1 
Specific surface of hydration 
layer 
Surface area of tablet / Volume of tablet μm-1 
Porosity of hydration layer 
The volume of voids over the total 
volume 
% 
Length of whole tablet Size of bounding box in Y direction μm 
Width of whole tablet Size of bounding box in X direction μm 
Height of whole tablet Size of bounding box in Z direction μm 
Box ratio of whole tablet 
Ratio between the maximum and the 
minimum size of the bounding box 
dimensionless
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Box ratio of core 
Ratio between the maximum and the 
minimum size of the bounding box 
dimensionless
Sphericity of whole tablet A measure of how spherical an object is dimensionless
Sphericity of core A measure of how spherical an object is dimensionless
Surface deviation of tablet Deviation of normal vectors on surface dimensionless
Surface deviation of core Deviation of normal vectors on surface dimensionless
Volume fraction of tablet 
Ration of object’s volume to the box 
volume 
Dimensionless
Volume fraction of core 
Ration of object’s volume to the box 
volume 
Dimensionless
Diameter of tablet Equivalent diameter of whole tablet μm 
Diameter of core Equivalent diameter of unhydrated core μm 
With regard to correlations between single parameters and drug release 
kinetics, it is reported that the volume and surface area related parameters of the 
tablet are key variables in controlling drug release from HPMC matrix tablets [155]. 
Therefore, correlation between volume and cumulative release percent has been 
investigated, as shown in Figure 66 A, B and C. All the volume parameters, 
including volume of the whole tablet, volume of the glassy core and volume of the 
hydration layer, correlate well with percentages of drug release (R2 = 0.90, 0.94, 
and 0.81 respectively). Generally, the correlation of the volume parameter to the 
cumulative release percentages are higher than that for those of single surface 
area parameters.  
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Figure 66  Correlation between steric parameters and drug release kinetics. 
In contrast to the routine quality control indicators of the cumulative release 
percentages, drug release rate (dM/dt) values provide the key characteristics of 
drug delivery systems. Thus, the correlations between surface area parameters 
and drug release rate are shown in Figure 66 D, E and F. The R2 values for these 
correlations are 0.45 for the surface area of the tablet and 0.80 for the surface 
area of the hydration layer, whilst the R2 value between the surface area of the 
glassy core and the release rate is 0.87, indicating that the surface area of the 
glassy core is one of the key factors determining constant drug release rate. 
Namely, the matrix swelling has an important and controlling effect on the drug 
release kinetics.  
In addition, a statistical model was constructed using SPSS PASW statistics 
(version 18.0) for multivariate analysis, using drug release rate as the dependent 
variable (n = 9). The sample of 0 h was excluded as the value of specific surface 
area of hydration layer at 0 h is not available. Independent variable reduction was 
carried out with the consideration of the value of R2, the equation significance, 
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the parameter coefficient significance and physical meaning of the variables. 
Three parameters with marked influence on the drug release from felodipine 
matrix tablets were identified from 23 three dimensional structural parameters by 
independent variable reduction. There three parameters are surface area of 
hydration layer, surface area of glassy core and specific surface area of hydration 
layer. 
Based on these three selected parameters, a multiple-linear regression 
model was established, as given in Eq. 16. 
423SSA.9142SA128.4SA4204dt
dM
layerhydration coreglassy layerhydration ..        Eq. (16) 
The SAhydration layer is the surface area of the hydration layer, which includes 
the areas of pores and channels inside the hydration layer. The SAglassy core is the 
surface area of the non-hydrated glassy core, which is the interface where the 
glassy core swells into gel and hydration occurs. The SSAhydration layer is the 
specific surface area of the hydration layer (as shown in Table 9 and Figure 67), 
which reflects the magnitude of the hydration layer. All the relevant parameters 
in Eq. 16 have been normalized to ensure that all parameters have equal 
determinant strength to drug release rate. The statistical model exhibits relatively 
good predictability, with R2 = 0.96 and significant p values (< 0.001). 
5.3.3 Relative importance of swelling and erosion in controlled 
release of felodipine 
Few researches have discussed the relative importance of swelling and 
erosion to the controlled release of poorly water-soluble drugs. Bettini et al. have 
studied the release mechanisms of drugs with different solubilities (buflomedil 
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pyridoxalphosphate with water solubility of 65% (w/v), sodium diclofenac with 
water solubility of 3.1% (w/v), nitrofurantoin with water solubility of 0.02% (w/v)) 
from HPMC matrices [156]. The role played by polymer swelling in drug transport 
was demonstrated with two different swelling/release experiments. The results 
showed that the tendency of the matrix to erode increased as drug solubility 
decreased. In swellable matrixes loaded with sparingly or slightly soluble drugs, 
solid drug particles can be transported within the hydration layer by polymer 
swelling. The presence of solid particles in the gel reduced the swelling and the 
entanglement of polymer chains and affected the resistance of gel towards 
erosion. As a consequence, the matrix became more erodible. The rate and 
amount of drug released from swellable matrices were dependent not only on the 
drug dissolution and diffusion but also on solid drug translocation in the gel due 
to polymer swelling. 
 
Figure 67 Schematic of the layers of felodipine HPMC tablet during drug dissolution 
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It can be observed from Eq. 16 that the rank order of the independent 
variables is SAhydration layer > SSAhydration layer > SAglassy core. These three parameters 
represent the interface where the erosion and swelling of the hydrophilic matrix 
occur. The first two parameters represent the contribution of matrix erosion to 
controlled drug release, while the third represents the contribution of matrix 
swelling. Based on the quantitative relationship between 3D hydration 
parameters and drug release kinetics, drug release rate is determined primarily 
by matrix erosion. This finding is in accordance with the reported evidence that 
the matrix erosion governs the transport of poorly soluble drugs from the 
hydrophilic controlled drug release systems. Importantly, this model provides 
details of the quantitative contribution of matrix erosion and swelling to drug 
release rate for poorly water-soluble drugs with 3D hydration parameters that 
cannot be measured by conventional methods. Thus, the release mechanism is 
identified as a combination of erosion and swelling.  
In this study, the relative importance of swelling and erosion in the controlled 
release of felodipine is quantified through the application of a statistical model 
and SR-μCT. The solubility of felodipine in the dissolution medium is 970 μg/mL 
(0.097%, w/v), which is relatively closer to the low level solubility of API (0.02%, 
w/v) in Bettini et al.’s study [156]. Although different techniques are used in these 
two studies, consistent results are obtained, the release of poorly water-soluble 
drugs from HPMC matrix being dominated by erosion and swelling. Furthermore, 
three dimensional structures of the hydration layer revealed in our study by SR-
μCT with high resolution (9-micron) provides additional insight into the internal 
architecture of the swellable matrices as well as additional quantification of events 
controlling drug release. The 3D reconstruction and structural parameter 
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calculation methods detailed above are effective tools to visualize and quantify 
the translocation of drug particles in HPMC matrix hydration layers from a 
structural point of view. 
Among 23 structural parameters, three key parameters were selected with a 
variable reduction to establish and optimize the statistical regression model, 
which covers nine data points over the release profile. For the constant release 
of felopidine during the sampling time period and limited SR-uCT beam time 
available, samples were obtained at nine time points to obtain as much data as 
possible from the imaging acquisition. Thus only a small sample model has been 
established. A large scale model or a real-time structure reconstruction, although 
challenging, would provide further in-depth information and knowledge. 
Nevertheless, the correlation coefficient (R2) and the significance value (p) for the 
regression model are statistically significant. 
Several imaging approaches have been employed to explore the hydration 
layer change during drug release. Among them, SR-μCT provides high spatial 
resolution. However, as the X-ray attenuation coefficient of water is similar to that 
of polymer material in the tablet, the image contrast would be affected when tablet 
is placed in aqueous dissolution media. To overcome this drawback in our study, 
the tablets were dried with the method caused minimal change to the structure of 
the tablet core. In addition, it is desirable to employ complementary methods to 
clarify chemical composition for the structural information obtained by SR-μCT, 
such as using MRI to identify the water content change or using matrix-assisted 
laser desorption/ionization (MALDI) to identify the drug position in the tablet core 
and the gel layer. 
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5.4 Dynamic Computed Tomography Reveals a Novel 
Release Mechanism Driven by Droplets 
Novel controlled drug delivery systems are being explored to overcome the 
limitations of conventional formulations, which include sustained/controlled drug 
delivery system. The challenges involved are substantial but not insurmountable 
[157]. The osmotic system tablet that delivers constant release rates and is 
presented as a solid dosage unit with a laser-drilled hole in the surface of a 
polymer coating has been an attractive option [158]. 30 years of development 
and clinical use prove that these systems offer a promising technology for product 
life-cycle strategies [56].  
Osmotic pump drug delivery systems with their versatility and highly 
predictable drug release rates offer various advantages and hold a prominent 
place in human medicines, such as reducing the risk of adverse reactions, 
independence from  the environment pH of absorption site, and exhibiting a high 
degree of in vitro/in vivo correlation. As one of the most important formulations of 
controlled release preparation in the pharmaceutical field, various structures have 
been developed since the concept, “osmotic pump”, was first invented by Rose 
and Nelson in 1955 [53]. From the Rose-Nelson elementary osmotic pump, 
design in structures has advanced markedly such as osmotic drug delivery using 
swellable-core technology, micro-osmotic pumps, asymmetric membrane 
capsule osmotic pump (ACM) and other new approaches. However it is not 
always desirable that a controlled release formulation provides zero-order drug 
release, and alternative release profiles are preferred, such as pulsatile drug 
delivery.  
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Despite the extensive research carried out on osmotic pump drug delivery 
system with various structures, tuning the internal structures and understanding 
the release mechanisms remain a challenge, especially for understanding the 
role of fine micro-structures. With most research focusing on the macro scale, it 
is thought that innovation in the design of new osmotic pump drug delivery 
systems will result from examination of internal micro-structures. As 
demonstrated above it has been established that a drug release profile is closely 
related to dynamic changes in microstructure, and fractal structure determines 
the controlled release kinetics of monolithic osmotic pump tablets. The values of 
Df,surface correlated well with the drug release rate and Df,surface was found to be an 
efficient fractal parameter that could be used to characterize the complex 
changes in the tablet core that take place during drug release [159]. 
Tools which directly reveal the internal structure and dynamic characteristics 
of the osmotic pump tablets at different stages of the drug release process, such 
as benchtop-magnetic resonance imaging (BT-MRI) [160], terahertz pulsed 
imaging (TPI) [161], magnetic resonance imaging (MRI) [162] and X-μCT [163] 
are some of the popular techniques can be applied to reveal deeper 
understanding of dosage form static structures. SR-μCT imaging technique, is 
able to provide quantitative details of the internal three dimensional (3D) 
structures of various objects as demonstrated above.  
During studies for this thesis with 3D reconstructions of an osmotic tablet 
containing PVP/VA, numerous micro-droplets were observed. After contact with 
solution media, the structure of micro-droplet presented a certain evolution 
regularity. Whilst not all osmotic pump tablets will possess this kind of structure, 
a hypothesis is proposed that there will be a relationship between the micro-
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droplets structure and the drug release behaviour. The following study details 
which research into how the micro-droplets are formed and how to adjust the 
evolution of the micro-droplets to achieve zero-order controlled release of drugs 
using the dynamic CT.  
Detailed methodology of these studies is provided in S 8 Preparation and 
structural analysis of droplet generated tablet) 
5.4.1 Discovery of droplet like structures in osmotic pump 
tablets 
 Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID) regarded as a 
nonselective cyclooxygenase (COX) inhibitor and described as practically 
insoluble in water (<1 g in 100,000 ml) [164, 165]. The design of a ketoprofen 
osmotic pump tablets aimed to deliver well-controlled drug release over 12 hours. 
The tablet composition was 50.0 mg of ketoprofen, 58.1 mg of copovidone 
(PVP/VA S630), 10.7 mg of sodium phosphate (Na3PO4) and 1.2 mg of 
magnesium stearate. of The powders for the osmotic pump cores were passed 
through 100# sieve and mixed in geometric proportion to form a uniform blend of 
powder, prior to direct compression on a rotary tablet machine (ZP-5, Shanghai 
Tianjiu Machinery Factory) using 6.0-mm-diameter punches. CA in acetone 
containing plasticizer (PEG 4000) was used as a coating solution. The coating 
was carried out in a pan coater (BY 300A, Shanghai Huanghai Drug Instrument 
Co., Ltd., China). The temperature of the coating pan was 40℃, rotating at 25rpm. 
The coated tablets were dried to remove the residual solvent acetone at 40℃ for 
24 h, and laser machines drilled (CRS-C20D, Ceres Wuhan Photoelectric 
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Technology Co., Ltd., China) a single 0.8-mm-diameter orifice on the membrane 
surface on one of the faces of the tablet. 
During the drug released process, the dynamic structure of tablets was 
investigated with 2D X-Ray Imaging for tablets removed at different times during 
the drug release process. Droplet-like structure were observed (Figure 68) as well 
as internal structure of stationary ketoprofen osmotic pump tablets in water with 
the drug release orifice upward using SR-μCT. As water was taken up by the 
tablet through the semipermeable membrane, numerous micro-droplets were 
generated in situ continuously in the osmotic pump tablet with the core, also 
containing fluid, suspension and/or gel. All the micro-droplets migrated to the drug 
release orifice close to the semipermeable membrane and those generated 
opposite the orifice chose the shorter way to reach the orifice (Figure 68). 
Ultimately, the micro-droplets which exited from the orifice gradually diffused and 
mixed in the bulk aqueous dissolution medium outside of the semipermeable 
membrane and the majority of the micro-droplets appeared to have uniform size 
and shape. 
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Figure 68 Numerous micro-droplets generated in the ketoprofen osmotic pump tablets and moved 
to the drug release orifice through the shorted way when set in water.   
After the first observations of the droplet-like structure in the laboratory made 
ketoprofen osmotic pump tablets, different formulation compositions were 
prepared in an attempt to identify the key factors that cause the formation of 
micro-droplets. Four kinds of osmotic pump tablet were prepared according to the 
formulations shown in Table 11. All tablets were coated with the same 
semipermeable membrane and the same size of laser drilled orifice. 
Table 11  Composition of the core of osmotic pump tablets 
Core (tablet) Per tablet (mg) 
A B C D 
Na3PO4 10.7 0.0 0.0 10.7 
PVP/VA 58.1 58.1 58.1 58.1 
ketoprofen 0.0 50.0 0.0 50.0 
MS 1.2 1.2 1.2 1.2 
(* Note: Formulation D is the tablet core formulation described and discussed above) 
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Figure 69 2D and 3D internal structure of three kinds of osmotic pump tablets at 1.0 h and 
2.0 h. 
(Blue represents the micro-droplets, green represents the remaining matrix, red 
represents NaCl). (A) Osmotic pump tablets containing copovidone and sodium 
phosphate (B) ketoprofen and copovidone and (C) copovidone. 
Formulations A, B and C osmotic pump tablets were tested with SR-μCT 
after immersion in water for 1.0 h and 2.0 h. The plane slices (Figure 69) indicated 
difference in the degree of droplet generation for these three osmotic pump 
tablets formulations. Droplets in osmotic pump tablets containing PVP/VA and 
sodium phosphate are irregular. Droplets in tablets containing ketprofen and 
PVP/VA appear slowly and the sizes of droplets are small. Tablets containing 
PVP/VA contain many and multi-sized spherical droplets. From one plane slice 
of osmotic pump tablet only containing PVP/VA at 2.0 h in Figure 69, 1950 fine 
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spherical micro-droplets formed in the tablet with the min and max diameters of 
4 μm and 2054 μm. These structral information indicates the PVP/VA might be 
the material base of the generation of droplet. 
Cumulated dissolution release profile and release rate of ketprofen osmotic 
pump tablets of formulation D are demonstrated in Figure 70. The zero-order 
kinetic model provides a strong correlation coefficient for the test formulations (R2 
= 0.9796) over the period 0 - 10 hours and the cumulative release after 12 hours 
was over 93%.  
 
Figure 70 Drug release profiles of ketoprofen osmotic pump tablets of formulation D with a nearly 
zero-order controlled release behaviour, n = 6.  
5.4.2 Quantitative evolution regularity of droplet-like structure 
To understand the evolution regularity of droplets in the osmotic pump tablets, 
ketoprofen osmotic pump tablets of formulation D were examined after different 
periods of time immersed in water at 37℃ by SR-μCT. To describe and quantify 
the internal structure accurately, all the tablets were dried naturally to avoid the 
influence of water on the measurement. Numerous micro-droplets were detected 
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at 0.5 h, and with increasing time, the micro-droplets gradually move toward the 
table core and merged into a few larger droplets. From one slice at 0.5 h, 537 
micro-droplets with 33 μm mean diameter were detected. As the core hydrated 
further at 1.0 h, the mean diameter and number of micro-droplets increased 
slightly with one plane slice at 1.0 h, 544 micro-droplets with a mean diameter of 
37 μm.  A smaller number of bigger micro-droplets with the max diameter of 132 
μm, also emerged in the zone of the fully hydrated core and several micro-
droplets were observed in the centre of the core. Whilst the number of micro-
droplets decreased at 1.5 h due to coalescence, a single droplet with the diameter 
of 1592 μm was present. At 2.0 h, the mean diameter of micro-droplets and the 
largest droplet further increased to 58 μm and 2730 μm, respectively. Droplets 
could be seen concentrated at the core centre at 3.0 h with the largest micro-
droplets occupying approximately 30% volume of the tablet. At 4.0 h, one large 
droplet with a diameter of 4531 μm with surrounding microdroplets surrounding 
was identified and at 6.0 h and 8.0 h, all the micro-droplets had coalesced into a 
single droplet occupying the whole region of the dissolved core. This sequence 
is illustrated in Figure 71. As displayed with Figure 71. D, the co-localization 
demonstrate micro-droplets and Na3PO4 are associated in deposits. This 
phenomenon indicate the recrystallization of dissolved Na3PO4 in micro-droplet 
might take place during the drying of tablet. 
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Figure 71 Internal structure of ketoprofen osmotic pump tablets at different time  
(blue represents the micro-droplets, red represents the Na3PO4, green represents the remaining 
matrix). Time interval observations of (A) generation and evolution of micro-droplets, (B) 
distribution of Na3PO4, (C) morphology of the matrix, (D) relationship of micro-droplets and 
Na3PO4,(E) distribution of Na3PO4, (F) distribution of micro-droplets with Na3PO4 and(G) plane 
slices of ketoprofen osmotic pump tablets, the scale bar is 2000 μm. 
The quantitative tracking of the micro-droplets at a different time reveals was 
obtained from collected data (Figure 71. From these tracks, droplets are identified 
and seen to move to the core centre in diminishing number as time increase 
(Figure 72). Although the position of micro-droplets is not the same in the different 
tablets examined, the evolution tendency is consistent. 
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Figure 72 Distribution of micro-droplets in the ketoprofen osmotic pump tablet at different time 
(labelled with the total number of micro-droplets) 
The correlation of micro-droplets volume and drug release 
In probing correlations between drug release and 3D structure parameter, 
the area and volume of micro-droplets, Na3PO4, matrix and Na3PO4-matrix were 
choosen for analysis (Figure 73). Using surface area as the 3D structure parameter, 
the area of Na3PO4 showed a relatively good correlation with the cumulative drug 
release (R2 = 0.9006). The correlation index (R2) between the drug release and 
the micro-droplets volume, matrix and Na3PO4-matrix were all weaker (R2 < 0.90). 
When using volume as the 3D structure parameter, the correlations with the drug 
release improved, (R2 > 0.95) with a correlation index of R2 = 0.3184. Over all, 
the total volume of micro-droplets with drug release showed the best index (R2 = 
0.9803).  
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Figure 73 Correlation between drug release and total area/volume of micro-droplets, Na3PO4 and 
matrix of ketoprofen osmotic pump tablets.  
5.4.3 Release mechanism revealed by dynamic computed 
tomography  
The internal structure is a critical factor in the design of drug delivery systems. 
In osmotic pump formulations. Microporous, sandwiches, mixed pass, 
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asymmetric membrane osmotic pumps, and other osmotic pump varieties have 
appeared in recent years. These forms expressed unique dosage form structural 
complexity and diversity and provided different drug release characteristics and 
beneficial clinical outcomes. These innovative structures have promoted the 
development of other sustained and controlled release dosage forms. For any 
new structured dosage form designs based on internal fine dynamic droplet-
containing structures, an important requirement is a theoretical demonstration 
and application value to investigate of any new drug release mechanism and 
potential application benefit in therapeutics. 
 
Figure 74 Reconstructed slice after phase retrieval and the position correction by alignment 
After the phase retrieval and position correction, quantification of the 
dynamic evolution of the 3D structure of osmotic pump tablets, based on the 
optimized reconstruction algorithm was performed (Figure 74) on data obtained 
from formulation D. Droplets present at different dissolution times were quantified 
according to the following list of parameters:  
a) Area. The sum of the triangle surfaces. 
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b) Centre Position X Y Z 
c) Ellipsoid Axis 
In mathematics, an ellipsoid is a type of quadric that is a higher dimensional 
analogue of an ellipse.  
The equation of a standard ellipsoid in an x-y-z Cartesian coordinate system is: 
௫మ
௔మ ൅
௬మ
௕మ ൅
௭య
௖మ ൌ 1                                                                                          Eq. (18) 
where a, b and c (the lengths of the three semi-axes) are fixed positive real 
numbers determining the shape of the ellipsoid.  
  
Surfaces - Ellipsoid (oblate) 
Surfaces - Ellipsoid (prolate) 
If we assume a ൑ b ൑ c, then when: 
• a = 0 it is an Ellipse 
• a = b = c it is a Sphere (three equal sides) 
 • a≠b≠c it is a scalene Ellipsoid (three unequal sides) 
If two of these sides are equal, the Ellipsoid is a Spheroid: 
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 • a = b < c it is a prolate Spheroid (cigar-shaped) 
• a < b = c it is an oblate Spheroid (disk-shaped) 
 ݁௣௥௢௟௔௧௘ ൌ ଶୟ
మ
௔మା௕మ ∗ ቀ1 െ
௔మା௕మ
ଶ௖మ ቁ                                                                   Eq. (19) 
eprolate = prolate Ellipsoid 
 ݁௣௥௢௟௔௧௘ ൌ ଶୠ
మ
௖మା௕మ ∗ ቀ1 െ
ଶ௔మ
௖మା௕మቁ                                                                     Eq. (20) 
eoblate = oblate Ellipsoid 
d) Speed, is the instantaneous speed of the object. 
 ܵሺݐሻ ൌ ඥ஽೉ሺ௧,௧ିଵሻమା஽ೊሺ௧,௧ିଵሻమା஽ೋሺ௧,௧ିଵሻమ்ሺ௧ሻି்ሺ௧ିଵሻ                                                           Eq. (21) 
S(t) = TrackSpeed 
 ܦ௑ሺݐଵ, ݐଶሻ ൌ ௑ܲሺݐଵሻ െ ௑ܲሺݐଶሻ                                                                        Eq. (22) 
PX(t) = x-position of object at time index t 
T(t) = time in seconds at time point t 
e) Track Sphericity, is a measurement parameter that tells how spherical an 
object is. Defined by Wadell in 1932, the sphericity, , of a particle is the ratio 
of the surface area of a sphere (with the same volume as the given particle) 
to the surface area of the particle: 
ߖ ൌ గ
భ
యሺ଺௏೛ሻ
మ
య
஺೛                                                                                                 Eq. (23) 
Vp = volume of the particle  
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Ap = surface area of the particle 
f) Time Index, number indicates the current time point in the series for the 
selected object.  
g) Track Duration, is the duration between the first and last time point within the 
Track. 
Duration ൌ ܶሺݐ௅ሻ െ ܶሺݐிሻ 
Duration = TrackDuration 
T(t) = time in seconds at time point t 
tL = last time index of track 
tF = first time index of track 
h) Track Length, is the total length of displacements within the Track. 
ܮ ൌ෍ ඥܦ௑ሺݐ, ݐ െ 1ሻଶ ൅ ܦ௒ሺݐ, ݐ െ 1ሻଶ൅ܦ௓ሺݐ, ݐ െ 1ሻଶ
௧ಽ
௧ୀ௧ಷାଵ
                            Eq. (24) 
L = TrackLength 
tL = last time index of track 
tF = first time index of track 
 ܦ௑ሺݐଵ, ݐଶሻ ൌ ௑ܲሺݐଵሻ െ ௑ܲሺݐଶሻ                                                                        Eq. (25) 
PX(t) = x-position of object at time index t 
i) Track Straightness 
ܵݐݎ݄ܽ݅݃ݐ݊݁ݏݏ ൌ ୈ୧ୱ୮୪ୟୡୣ୫ୣ୬୲୐ୣ୬୥୲୦                                                                          Eq. (26) 
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j) Volume, is a quantification of how much space an object occupies. 
 
Figure 75 The dynamic computed tomography  tracking the numerous droplet-like structure 
quantitatively 
The structure and drug delivery system characteristics of an osmotic pump 
film coated tablet with laser drilled orifice that is determined by in situ generated 
micro-droplets is now considered. By tracing the position, size and distribution of 
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every micro-droplet at different stages of the drug dissolution from the tablet, this 
analysis is now possible. Result indicate that the structure of micro-droplets was 
predominant in determining the drug release behaviour. The total volume and 
area of micro-droplets correlated well with the drug release percentage and drug 
release rate, respectively.  
 
Figure 76 The quantitative tracking of single droplet 
As highlighted above, a key factor of droplets formation in the tablet was the 
presence of PVP/VA in the tablet core. Via segmentation of the formulation 
components, without the semipermeable membrane coating, a number of 
droplets on the surface of the tablets were found. However, these droplets 
appeared static due to the lack of pressure caused by the film. It is concluded 
that the droplet-like structures form due to the unique property of matrix of 
PVP/VA with appropriate viscosity, Morphological changes of the micro-droplets 
are observed especially near the drug release orifice (Figure 75, Figure 76). Around 
the orifice, the shape of droplets changes from spherical to elliptical shape due 
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to the different local pressures. Results also show that the droplets deform 
markedly after moving to the orifice and recover a spherical shape after migrating 
from the orifice. According to the strong correlation between the volume of 
droplets and the release of drug and also the associated presences of 
recrystallized Na3PO4 with the droplets, the droplet is composed of drug in 
solution or suspension embodied in the swelling PVP/VA. 
General comments 
In this chapter, the diffusion controlled drug release mechanism of pellets 
was revealed with SR-μCT and a sensitive LC/MS/MS method at single pellet 
level. The microstructures and drug release behaviours of 76 single pellets were 
investigated individually. Correlations indicated that the dissolution rate of the 
individual pellets depended on the combined effects of the drug loading, volume 
and surface area of the pellets. Most important is that the inner void 
microstructures were critical to the drug release profiles whereas the 
microstructure characteristics of the hydration layer and the glassy determined 
the release profile. Thus, the investigation of the hydration dynamics of felodipine 
HPMC matrix tablet verified that the release of felodipine was dominated by a 
combination of erosion and swelling. The structural investigation of monolith 
osmotic drug delivery system also indicated that the hydration, swelling and 
changing surface morphology of internal structure played a key role in the 
sustained-release. Finally, the droplet related structure research revealed a 
unique type of drug delivery system. With further studies, it is proposed that 
specific drug release patterns can be designed and optimized by regulating the 
evaluation rate of micro-droplets to achieve targeted pharmacokinetics and 
therapeutic performance. This new evidence of micro-droplets in osmotic pump 
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controlled release systems provides wide opportunities perspectives in 
pharmaceutical sciences.  
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Chapter 6 
General Discussion 
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Definition of Four Levels of Drug Delivery System Architectures 
Diverse range of dosage forms and drug delivery systems have been 
developed for the care and welfare of patients. The development of dosage forms 
draws on the discipline of pharmaceutics, which integrates an understanding of 
numerous topics including solid state properties, material science, formulations, 
drug dissolution, stability, and processing technologies. The resulting 
architectures of the dosage form determine the drug release characteristics and 
thereby the clinical efficacy and safety of the drug. The design of optimised 
dosage forms and the optimization of formulations require a comprehensive 
understanding of the structure and microstructure of the dose units. To date, the 
role and characterisation of dosage form microstructure is unusual, primarily due 
to a lack of suitable non-invasive tools.  The research and findings of this thesis 
point to the benefits offered by SR-uCT in providing the required details of 
microstructures of DDS.  
Apart from pure solutions for injection or oral delivery, drugs are usually given 
in structured dosage forms of solid dosage forms as the vast majority of marketed 
medicines. The architecture of solid dosage forms can be categorised into four 
levels according the spatial scale and the lifespan (Figure 7): 
Primary level, the static structure of the whole dosage form 
Size ranges from microns to centimetres 
The final structure after formulation 
a) Oral solids dosage forms (tablets, capsules, powders, granules, premixes, 
and medicated blocks) or semi-solids (creams, ointments, and pastes). 
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b) Parenteral dosage forms and drug delivery systems include injectable 
powders, intravaginal delivery systems, and implants.  
c) Transdermal delivery systems that elicit clinical responses by carrying 
medications across the skin barrier to the bloodstream. 
Secondary level, formation of DDS  using intermediate structures during 
pharmaceutical processing 
Size distribution is from nanometres to millimetres 
The materials exposed to processes such as mixing, grinding, granulation, 
tableting, packing, coating and etc. 
a) Powders: a mixture in which a drug particle is mixed with other powdered 
excipients for processing. Particle size distribution and particle shape, along 
with selected chemical and solid-state material properties, usually constitute 
the critical variables of a pharmaceutical manufacturing process. 
b) Granules or pellets: a solid particle consisting of powder particles that have 
been aggregated to form a larger mass, usually 1–4 mm in diameter. 
c) Crystal or crystalline: a solid material whose constituent atoms, molecules, or 
ions are arranged in an ordered pattern extending in all three spatial 
dimensions. 
Tertiary level, the dynamic structure during drug release after 
administration 
Size distributed from nanometres to millimetres 
The changing structure during drug release due to dissolution, swelling, 
erosion, diffusion 
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a) Dissolution: the soluble contents of DDS form a solution in a solvent. The 
solute has its crystalline structure disintegrated as separate ions, atoms, and 
molecules form. Dissolution is a kinetic process, and is quantified by its rate. 
b) Swelling: when a polymer is in contact with the solvent, it starts swelling and 
dissolution simultaneously due to the penetration of the solvent. There are two 
distinct regions. One is the liquid solution wherein the dissolved polymer 
molecules are carried away by diffusion; the other one is the gel layer of the 
polymer in which the solvent diffuses. The gel/liquid interface separates the 
diffusion of the dissolved polymer in the liquid solution from that of the solvent 
in the polymer. 
c) Erosion: the process by which the solid contents are removed from the DDS’s 
surface by exogenetic processes such as liquid flow, and then transported 
and deposited into the solvent. 
d) Diffusion: the transport phenomenon that occurs in a release. A distinguishing 
feature of diffusion is that it results in mixing or mass transport, without 
requiring bulk motion. The transport mechanism is that contents move from 
one position to another. 
Quaternary level, the meso or micro scale architectures of active and non-
active molecules within a DDS 
Size distribute from Å to nanometres 
The molecular structure of drug and excipients 
The drug molecule is the basic element of DDS, the smallest structural unit 
during absorption, metabolism and pharmacodynamics performance.
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Figure 7 Framework of thesis and the four levels of drug delivery system architectures 
 204 
 
As shown in Figure 7, the major knowledge gap between input and output 
target product is the microstructure of intermediate and dosage form structures 
across the size range from of nanometres to millimetres. As defined above for the 
four levels of drug delivery system architectures, much attention has been given 
to computer simulation at the molecular level.  For the other three levels of 
architecture, highly sophisticated and advanced techniques provide full chemical, 
2 dimensional and mechanical profiles. However, the internal architecture and 
microstructure are not well understood. This is true across the various scales of 
scrutiny relevant for solid dosage forms - from nanometres to millimetres. The 
poor investigation and characterization of internal microstructure is due to the 
lack of suitable in situ imaging techniques and methodologies to quantify the 
features of three dimensional structures. 
In Chapter 2, SR-μCT imaging methodology was designed for quantitative 
characterization of microstructures. Principles of the synchrotron radiation 
imaging include the preparation of samples, optimization of imaging parameters 
and the evaluation of image quality. Protocols and workflows of data analysis 
especially image processing and 3D reconstruction, were devised tested and 
established. The developed methodologies were then applied to generate 
quantitative evaluation of the irregular micro-structures of DDS as well as 
particles from intermediate processing, demonstrating the potential of the new 
methods for presentation the full details of the surface morphology and the 
internal 3D structure of solid pharmaceutical structures. 
In Chapter 3, the SR-μCT imaging method was employed for the visualization 
of typical pharmaceutical structures includes particulates, polymorph crystals, 
and tablets. 1) Granules of spherical microcrystalline cellulose and irregular 
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starch were characterized quantitatively and individually. Particle distribution was 
investigated by calculating the frequency distribution of steric parameters. 
Microstructures of pellets of multi-unit DDS were investigated. The volume, 
surface area and the internal void structure of every single pellet were 
characterized individually.  2) Polymorphic crystal particles of clopidogrel 
bisulphate were analysed by a range of calculated structural parameters. With 
the irregular surface patterns of CLP II and CLP I, crystals and agglomerated 
crystal forms, an accurate and sensitive detection method was devised to identify 
the polymorphs based on the quantitative morphological property of particles. 
The term of volume bias percent (VBP) was devised, defined and successfully 
used for the identification of single polymorphic particle, with a total matching rate 
of 99.91% for 4544 particles and a lowest detectable limit of 1%.  3) Based on 
the SR-μCT technique, the surface morphology, the internal 3D structure of the 
osmotic pump tablet core and their changing characteristics were clearly 
visualized from the 2D monochrome X-ray CT images and the reconstructed 3D 
tomographic images. These researches provide strong evidence  that SR-μCT is 
a powerful non-invasive and quantitative technique with great potential for 
quantitative investigation of solid pharmaceutical structures. Based on the 
quantitative parameters, the methodology should be considered for the routine 
testing of pharmaceutical materials, the evaluation of formulations and act as a 
conventional test for the quality control of pharmaceutical products. 
In Chapter 4, pharmaceutical processes include mixing, tableting and laser 
drilling of orifices for osmotic pump tablets were evaluated by the investigation of 
intermediate structures during processing. The various outcomes of these 
research studies were 1) Deep understanding of the dynamics of granular 
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materials hehavious during mixing. The blend homogeneity of binary granular 
mixtures of microcrystalline cellulose and starch was monitored non-invasively. 
Influences of the time of rotations and the time of vibration on the mixture 
homogeneity were investigated with statistical evaluation. A mixing index was 
also adopted to evaluate the mixture homogeneity of the particle system. The 
results showed that mixture homogeneity was improved with increasing the time 
of rotations. Furthermore, segregation increased with longer time of vibration. 2) 
The in situ 3D deformation of two polymorphs (I and II) of clopidogrel bisulphate 
particles under pressure was determined to illustrate pressure distribution profiles 
within the tablet by the deformation of the crystalline particles for the first time. 
SR-μCT was utilized to visualize and quantify the morphology of thousands 
crystalline particles of CLP I and CLP II before and after compression. As a result, 
the deformation was examined for quantitative comparison to CLP I and CLP II. 
The different degrees of deformation under the same compression conditions of 
CLP I and CLP II were observed and characterized quantitatively. The map of 
degree of deformation within the tablet illustrated the heterogeneous pressure 
distribution in various regions of the compacted tablet. 3) A novel method to 
measure quantitatively the three-dimensional architectures of orifices drilled in 
the membrane based on SR-μCT has been established. Quantitative analysis of 
architectures drilled by a range of operating parameters indicated that laser 
power correlated with the cross section area, volume, surface area and depth of 
the orifices, while scanning speed of laser beam showed inverse relationships 
with the above structure characteristics. The first three-dimensional structural 
insight of orifices in osmotic pump tablets by SR-μCT and structural 
reconstruction for the architectures has provided deeper insight into improving 
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the design of advanced osmotic pumps for controlled drug release. As 
demonstrated, the 3D structural insight of intermediate microstructures in 
processing provides valuable information for the optimization of manufacturing 
processes and design of drug delivery systems. 
In Chapter 5, the dynamic structures during release were characterized and 
correlated quantitatively with the release behaviours to reveal the mechanisms 
controlling drugrelease. Single pellets, osmotic pump tablets and hydrogel matrix 
tablets have been investigated. Important finding were 1) The release profiles of 
single tamsulosin hydrochloride pellets correlated well with the combined effects 
of the drug loading, volume and surface area of the pellets and the void 
microstructures within the pellet were critical during drug release. 2) At different 
stages of the drug release process, the surface morphology, the hydration, the 
swelling, and the structure changing of the felodipine osmotic tablets were 
visualized. The volumes of the remaining tablet core correlated well with the 
release profile with the surface area of the core remaining almost unchanged 
during the drug release process. The 3D fractal values of volume (Df,volume) and 
surface (Df,surface) of the tablet core calculated based on the box counting method 
and the values of Df,surface correlated well with the drug release rate which 
reflecting the drug release performance and could be regarded as a key indicator 
for the quality control of oral controlled drug delivery systems. 3) Investigations 
provide quantitative detail on the relative importance of swelling and erosion in 
the release of poorly soluble drugs, and 3D structures of the hydration layer, 
which plays a key role in the controlled drug release of gel-forming matrix tablets. 
A statistical model of the hydration layer was conceived and developed based on 
the reconstructed 3D rendering of tablets. The surface area hydration layer 
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(SAhydration layer and SSAhydration layer) and of the glassy core (SAglassy core), were 
identified to establish the statistical model. The order of  significance of 
independent variables was SAhydration layer > SSAhydration layer > SAglassy core, which 
indicated that the release of felodipine was dominated by a combination of 
erosion and swelling. 4) Dynamic computed tomography methods have been 
developed for  in-situ testing in the dissolution medium during release. With the 
discovery of a new micro-droplet architecture driven release mechanism, a novel 
osmotic pump tablet was designed.  
In this thesis, new methods for SR-μCT imaging of the pharmaceutical 
dosage forms have been created, developed and employed, including the image 
processing method, 3D reconstruction method and construction of 3D models. 
Methods for the quantitative evaluation of the irregular micro-structures of DDS 
as well as the intermediate particles has been established. The powerful 3D 
research tool has been applied to explore the world of pharmaceutical structures. 
High resolved 3D images present full details of the surface morphology, the 
internal 3D structure and the dynamic behaviours in architecture oriented release 
kinetics. All of the above provide a basis for the concept of structure 
pharmaceutics, which enables fundamental understanding of formulations, 
manufacturing processes and drug release mechanisms, broadens the vision of 
pharmaceutical scientists and ultimately promotes the design of novel drug 
delivery systems with innovative structures. 
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Appendix 
S 1 Granule sample preparation and reconstruction 
SR-μCT Morphology for Granule Characterization  
Granular samples of microcrystalline cellulose and starch were imaged 
individually using SR-μCT. To avoid overfilling perturbation, the two individual 
particle systems were filled to a volume of 1 mL separately into the cylindrical 
container with a filling level F = 66%. If Oz represents the axis of the cylindrical 
vessel (vertical), segmented regions of Z-axial images were used to obtain 
characteristics of particles because the sample size of the container was 
excessively large for the image acquisition process. Using this experimental 
design, samples at the upper and lower levels of the container were scanned in 
upright position. In consideration of the maximum height of X-ray beam line, the 
heights of the acquisition window for the samples were set as 3315 μm.  
SR-μCT scans and 3D reconstruction 
Samples were scanned with synchrotron radiation X-ray at 13.0 keV. After 
penetration through the sample, images were recorded with an X-ray digital 
camera with direct coupled (micro) fiber-optic (photonics Science Ltd, 
Robertsbridge, UK). The pixel size was 13.0 µm, the exposure time was 1.0 s 
and the sample-to-detector distance was 25.0 cm. For each acquisition, 630 
projection images over 180°were taken. Light field images (i.e. X-ray illumination 
on the beam-path without the sample) and dark-field images (i.e. X-ray 
illumination off) were also collected during each acquisition procedure to correct 
for the electronic noise and variations in the X-ray source brightness. 
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The total projected images were reconstructed using the software developed 
by SSRF to perform a direct filtered back-projection algorithm (Shen et al., 2012). 
In order to enhance the quality of reconstructed slices, the X-TRACT SSRF CWS 
x64 (Commonwealth Scientific and Industrial Research Organization, Australia, 
http://www.ts-imaging.net/Default.aspx ) was used for phase contrast extraction. 
The 3D rendered data were analysed with commercially available software 
VGStudio Max (Version 2.1, Volume Graphics GmbH, Germany) and Image Pro 
Analyser 3D (Version 7.0, Media Cybernetics, Inc., USA) to obtain qualitative and 
quantitative data respectively. The reconstruction and phase contrast extraction 
process are shown in Figure 77. 
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Figure 77 The reconstruction and phase contrast extraction process for the two-component 
system.  
(a) tomography after background correction, (b) reconstructed slice, (c) reconstructed 
slice with phase contrast extraction. 
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S 2 Imaging and quantitative characterization of single 
pellet 
Sample preparation  
When using μCT to characterise a material, the sample size is roughly 
proportional to the image resolution; in addition, the sample must be entirely 
contained within the field of view. Due to the limitation on sample maximum height, 
10 mg of TSH pellets were used to fill a capsule with 10 mg of PVP/VA. PVP/VA 
is widely used as an excipient in solid dosing forms and was introduced as a 
diluent to enable the extraction of data for each pellet for individual 
characterisation from a sample including many pellets. Due to the stability, small 
size, good flow ability and X-ray absorption contrast of this diluent, the extraction 
of data for the individual pellets during image processing was facilitated. Before 
analysis, the filled capsule was manually rotated horizontally at 30 rotations per 
minute (rpm) for 30 s to ensure that the pellets and PVP/VA were well mixed. The 
height of the acquisition window used to cover the pellets in the capsule was 
adjusted, and the CT scan was carried out. 
SR-μCT scans  
The samples were scanned with synchrotron radiation X-rays at 16.0 keV. 
After penetrating the sample, the projections were magnified using diffraction-
limited microscope optics (2× magnification) and digitised using a high-resolution 
2048 pixel× 2048 pixel CCD camera (pco.2000, PCO AG, Kelheim, Germany). 
The pixel size was 3.7 μm, the exposure time was 2.0 s and the sample-to-
detector distance was 12 cm. For each acquisition, 720 projections over 180° 
were collected. Light field images (i.e., X-ray illumination on the beam-path 
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without the sample) and dark-field images (i.e., X-ray illumination off) were also 
collected during each acquisition to account for the electronic noise and variations 
in the brightness of the X-ray source. 
3D reconstruction 
The CT scan was a 3D map of the X-ray phase contrast. Further analysis of 
the data was needed for a quantitative description of the microstructure. The total 
projected images were reconstructed using software developed by SSRF to 
perform a direct filtered back-projection algorithm. To enhance the quality of 
reconstructed slices, X-TRACT SSRF CWS x64 (Version 6.5, Commonwealth 
Scientific and Industrial Research Organisation, Australia, http://www.ts-
imaging.net/Default. aspx) was used to extract the phase contrast. The 3D 
rendered data were analysed with the commercially available VG Studio Max 
(Version 2.1, Volume Graphics GmbH, Germany) and Image Pro Analyser 3D 
software (Version 7.0, Media Cybernetics, Inc., USA) to obtain the qualitative and 
quantitative data, respectively.  
After the 3D reconstruction, the resolved images had a high quality phase 
contrast. It was found that  nearly one third of pellets were hollow. Based on the 
2D slices, all of the pellets in the scanned sample were individually examined. 
Then a 3D model of each pellet was selected from rendered objects, and the 
ROIs (region of interest) were re-sliced to determine the surface morphology. The 
void in the pellet was extracted using grey value based segmentation with a self-
programed algorithm; the extracted slices of the inner void and the pellet were 
merged when characterising the entire pellet; 3D models of both the pellet and 
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the inner void were rendered to calculate the quantitative parameters. The 
modelling procedures are shown in Figure 78. 
 
Figure 78 Structural characterisation procedures for the TSH sustained release pellet.  
The procedure includes four steps: (1) the segmented slice is extracted from the reconstructed 
slice; (2) the void extraction is performed to derive the slice of the void; (3) the 3D model is 
acquired by reconstructing a series of slices from the void; (4) the slice and without void are 
merged together 
S 3 Crystallographic analysis and reconstruction of 
CLP polymorphs particles 
CLP polymorphs characterization. The PXRD was performed to verify the 
crystal form of the two polymorphs following pulverization (<5 μm) and 
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homogenization. PXRD scans were acquired using a Bruker D8 Advance 
(Siemens) powder diffractometer equipped with a 2.2 kW sealed Cu X-ray source, 
a graphite monochromator to filter out the Cu K β radiation, and a NaI (Tl) 
scintillation detector. The scans were performed between 3° and 40° 2θ with a 
0.01° step size and a counting time of 0.1s per step.  
The morphological information of CLP particles was also acquired using 
optical microscopy and SEM. The optical microscopy images were acquired with 
magnification at 200(1280960 pixels and pixel size was 0.450 µm), and for 
the SEM test all polymorph samples were scanned at 300(800900 pixels and 
pixel size was 0.450 µm) and 3000(800900 pixels and pixel size was 0.045 
µm) respectively to capture the full surface morphological detail of particles.  
Sample preparation. In order to simulate the real capsule dosage form, and to 
extract and characterize every particle individually from a mixture sample with 
hundreds of particles, PVP/VA was introduced as typical and widely used 
excipient. The stable, smaller size, good flowability, and X-ray absorption contrast 
of this diluent facilitates the CLP particle extraction during image processing. 
5 mg of CLP I and CLP II (-60 mesh~ +80 mesh, sieve sizes between 180-
280 µm) were weighed and filled into the capsule with 10 mg of PVP/VA 
respectively.  In order to ensure the CLP crystals and excipients were blended 
thoroughly, the capsule was rotated manually and horizontally at a speed of 30 
rotations per minute (rpm) for 30 seconds. The capsule was then fixed at the 
centre of the stage positioned in the synchrotron beam line, then the heights of 
the experimental acquisition window were adjusted to cover the whole sample in 
the capsule and then the CT scan was carried out. 
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SR-μCT scans and 3D reconstruction. SR-μCT tomographic images were 
acquired with beam line BL13W1 at SSRF. Samples were scanned with 
synchrotron radiation X-ray at 16.0 KeV. After penetration through the sample, 
the projections were magnified by diffraction-limited microscope optics (2 × 
magnification). Then X-rays were converted into visible light by a Lu2SiO5: Ce 
scintillator (10 μm thickness) and digitized by a high-resolution 2048 pixel × 2048 
pixel CCD camera (pco.2000, PCO AG, Kelheim, Germany). The pixel size was 
3.7μm, the exposure time was 2.0 s and the sample-to-detector distance was 12 
cm. For each acquisition, 720 projection images over 180°were taken. Light field 
images (i.e. X-ray illumination on the beam-path without the sample) and dark-
field images (i.e. X-ray illumination off) were also collected during each 
acquisition, for the correction of electronic noise and variations in the X-ray 
source brightness. 
The projected images were reconstructed using the software developed by 
SSRF to perform a direct filtered back-projection algorithm[76]. In order to 
enhance the quality of reconstructed slices, the X-TRACT SSRF CWS x64 
(Version 6.5, Commonwealth Scientific and Industrial Research Organization, 
Australia, http://www.ts-imaging.net/Default.aspx) was used for phase contrast 
extraction. The 3D rendered data were analysed with commercially available 
software VGStudio Max (Version 2.1, Volume Graphics GmbH, Germany) and 
Image Pro Analyser 3D (Version 7.0, Media Cybernetics, Inc., USA) to obtain 
qualitative and quantitative data respectively.  
Quantitative characterization and classification of the polymorphs. After 
segmentation, image slices were all converted into black and white images by 
removal of the background and noise. Then 3D ISO-Surface models were 
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constructed with segmented slices. The surface level, surface range and the 
simplification parameters were adjusted to optimize the models. Then all of the 
CLP particles in the samples were extracted and characterized quantitatively. 
Finally, in order to classify CLP I and II quantitatively, several steric parameters 
were calculated and the overall surface patterns of the two polymorphs were 
presented by the new designed quantitative parameter, Volume Bias Percentage 
based on Surface Smooth (VBP). 
Validation of the quantitative polymorph classification methods based on 
VBP. For the previously mentioned samples in the section of Sample Preparation, 
the sample of CLP II particles and excipient was transferred into the capsule with 
CLP I after the CT scans, and the capsule were mixed and the capsule positioned 
in the beam line as detailed above. Then, another CT scan was performed. In 
total 27 samples have been examined, and details are shown in Table 12.  
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Table 12 Detail information of CLP samples. 
Sample ID CLP I (mg) CLP II (mg) Excipients (mg) Description 
CLP-1 2.50 0.00 10.0 Pure CLP I
CLP-2 0.00 2.50 10.0 Pure CLP II 
CLP-3 2.50 2.50 20.0 CLP-1+CLP-2 
CLP-4 1.00 0.00 10.0 Pure CLP I 
CLP-5 0.00 4.00 10.0 Pure CLP II 
CLP-6 1.00 4.00 20.0 CLP-4+ CLP-5 
CLP-7 4.00 0.00 10.0 Pure CLP I 
CLP-8 0.00 1.00 10.0 Pure CLP II 
CLP-9 4.00 1.00 20.0 CLP-7+ CLP-8 
CLP-10 0.50 0.00 10.0 Pure CLP I 
CLP-11 0.00 4.50 10.0 Pure CLP II 
CLP-12 0.50 4.50 20.0 CLP-10+ CLP-
CLP-13 4.50 0.00 10.0 Pure CLP I 
CLP-14 0.00 0.50 10.0 Pure CLP II 
CLP-15 4.50 0.50 20.0 CLP-13+ CLP-
CLP-16 0.25 0.00 10.0 Pure CLP I 
CLP-17 0.00 4.75 10.0 Pure CLP II 
CLP-18 0.25 4.75 20.0 CLP-16+ CLP-
CLP-19 4.75 0.00 10.0 Pure CLP I 
CLP-20 0.00 0.25 10.0 Pure CLP II 
CLP-21 4.75 0.25 20.0 CLP-19+ CLP-
CLP-22 0.05 0.00 10.0 Pure CLP I 
CLP-23 0.00 4.95 10.0 Pure CLP II 
CLP-24 0.05 4.95 20.0 CLP-22+ CLP-
CLP-25 4.95 0.00 10.0 Pure CLP I 
CLP-26 0.00 0.05 10.0 Pure CLP II 
CLP-27 4.95 0.05 20.0 CLP-25+ CLP-
 
After 3D reconstruction the samples were divided into 3 groups: group A 
(CLP-1, 4, 7, 10, 13, 16, 19, 22, and 25) with pure CLP I, group B (CLP-2, 5, 8, 
11, 14, 17, 20, 23 and 26) with CLP II and group C (CLP-3, 6, 9, 12, 15, 18, 21, 
24 and 27) with mixtures of polymorphs. For every sample, all particles were 
extracted and the Volume Bias Percentage based on Surface Smooth calculated 
individually. Then the distribution of VBP values for group A and group B was 
compared, and threshold values for the classification of crystal forms were 
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calculated. The number of misclassified particles was also considered to 
provide an estimate of the accuracy of  the method. 
For samples in group C, particles in the polymorphs mixture were extracted 
one by one. After the classification of the crystal form with the VBP value, every 
particle was matched with the corresponding pure crystal form sample based on 
the surface morphological information and quantitative parameters such as 
volume, surface area and sphericity. By counting the number of mismatched 
particles, a method was developed to determine the lowest detectable limit of the 
experimental procedure. 
Grey value analysis 
After the reconstruction based on the filtered back-projection algorithm and 
phase contrast extraction with X-TRACT, the reconstructed slice stack was 
converted into 8 bit greyscale format and re-sliced vertically. Then the vertical 
slices of samples were analysed to determine the threshold grey values to 
distinguish the excipients, clopidogrel particles and capsule shell (Figure 79).  
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Figure 79 Line profile of vertical slice of sample in the capsule for the distinguish of crystal 
particle 
 (after background correction and noise reduction the grey value of background 
is near 0, the     line at 25 shows the grey value of excipients (in this sample 
PVP/VA), the     line at the value of 100 is the grey value of the capsule film, the     
line indicates that the average grey value of clopidogrel crystal is 185). 
As shown in Figure 79, clopidogrel can be distinguished from the excipients 
and most of the clopidogrel crystal particles were separated by diluents. Owing 
to the successful noise reduction and phase retrieval procedures, the grey value 
of background is close to 0, the excipients have a grey value of 50, the grey value 
between 80 and 120 is the shell of the capsule, and the clopidogrel particles have 
the grey value above 150. 
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Definition of important quantitative parameters 
In order to characterize the morphological information of particles, more than 
thirty parameters were calculated, most important ones as follow: 
Size: could be derived from volume, surface area. 
Equivalent diameter: is defined as the diameter of a ball of equivalent volume. 
Volume fraction: Ratio of object's volume to the bounding box volume (R = Vobj 
/ Vbox). 
Sphericity: 6 volumes of object divided by equivalent diameter and surface 
area of object. For a spherical object this parameter equals 1, for all other 
shapes it is less than 1. 
Surface deviation: The deviation of endpoints of triangle normal vectors. 
Uniform surface will have deviation of 0. The maximum deviation of 1.336 will 
have a sphere. 
Radius Min: Minimum distance between an object's centroid and surface. 
Radius Max: Maximum distance between an object's centroid and surface. 
Radius Ratio: Ratio between Radius (max) and Radius (min). 
Feret Min: Minimum distance between two parallel planes enclosing an object. 
Feret Max: Maximum distance between two parallel planes enclosing an object. 
Feret Ratio: Ratio between Feret (max) and Feret (min). 
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Box ratio: Ratio between maximum and minimum size of the bounding box (R 
= Max / Min).  
Note. 3 Validation of the quantitative polymorph identification methods 
based on VBP 
As all the microcrystalline particles have been scanned twice in pure and mixed 
samples, and a quantitative method has been devised and introduced to 
recognize particles in polymorph mixture, it is possible to track each individual 
particle in different scanned samples. For the sample containing the mixed 
particles of CLP I and CLP II, after the CT scan, reconstruction and 3D model 
construction, particles in the sample have been extracted and quantitative 
parameters calculated. Subsequently, particles were analysed one by one to 
classify the crystal form with the VBP value. Then for each particle with classified 
crystal form, a matching process has been performed on particles in 
corresponding individual sample of CLP I or CLP II with the lower proportion in 
the mixture to find the matched particle based on size related and morphological 
parameters such as volume, surface area, diameter, sphericity and radius min 
(Figure 80). 
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Figure 80 One by one CLP crystal particle identification and matching. 
For the validation, 4544 particles have been analysed and the volume, 
surface area and sphericity selected as key parameters for matching (Figure 81). 
The results are shown in Table 13. In total 4540 particles were matched. The 
matching rate was 99.91%.  
 
Figure 81 VBP value based in situ crystal form identification for polymorphic mixture (n = 
4544).  
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Table 13 Accuracy and lowest detectable limit. 
Sample 
ID 
Content (mg) Identified Matched 
Accuracy %
CLP I CLP II CLP I CLP II CLP I CLP II 
CLP-3 2.50 2.50 297 202 297 202 100.00 
CLP-6 1.00 4.00 99 313 99 313 100.00 
CLP-9 4.00 1.00 498 68 497 69 99.64 
CLP-12 0.50 4.50 48 380 49 379 99.53 
CLP-15 4.50 0.50 518 47 518 47 100.00 
CLP-18 0.25 4.75 30 413 31 412 99.54 
CLP-21 4.75 0.25 576 17 575 18 99.71 
CLP-24 0.05 4.95 9 390 9 390 100.00 
CLP-27 4.95 0.05 635 4 635 4 100.00 
 
S 4 Reconstruction of compaction behaviours of CLP 
polymorphs 
 
Tablets of CLP I and II each containing 25 mg of sieved (180-250 μm) CLP I 
and II particles respectively and 75 mg PVP/VA particles were prepared. The 
PVP/VA powder was sieved to obtain samples with an average size of 150 μm. 
Although CLP particles were sieved by the same mesh sieve, CLP particles may 
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have different size due to their different morphology. A rotary tablet presser (ZP-
5; Tianjiu Machinery factory, Shanghai, China) was equipped with 5 mm D-tooling 
with concave-faced punch tips and a feed frame was used to fill the die uniformly. 
The position of the bottom punch was adjusted, and the distance between the 
two punches at peak loading was set at 3 mm. During the compaction process, 
the rotation speed was set at 8 rpm. Tablets were compacted under the same 
conditions to ensure that the compression ratio was the same, and the 
deformation behaviour of different CLP particles was dominated by the 
morphology of different CLP particles. The weight for each tablet was adjusted 
before tableting and was set at 100 ± 5 mg. The height of the acquisition window 
during SR-μCT scanning was 4.5 mm, covering the whole side of the tablet while 
performing the CT scan. 
PVP/VA S630 was proven to be a good diluent for CLP particles in the tablets. 
By experimental verifications, when excipients like lactose, cornstarch, and 
microcrystalline were used, the CLP particles were easy to be compacted into 
large particles, which made it unable to detect CLP particles easily by SR-μCT. 
Details about Powder X-ray diffraction, Scanning electron microscopy as 
given in S 3.  
SR-μCT.  The SR-μCT tomographic images of prepared samples were acquired 
using the BL13W1 beam line at the Shanghai Synchrotron Radiation Facility 
(SSRF). X-rays were derived from an electron storage ring with an accelerated 
energy of 3.5 GeV, and an average beam current of 180 mA. The samples were 
scanned with a photon energy of 16.0 keV. The size of the beam was 
approximately 45 mm (horizontal) × 5 mm (vertical) and a double-crystal 
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monochromator with Si (111) and Si (311) crystals was used to monochromatize 
the X-rays. The monochromatized has a flux density about 5.8×1010ph/s/mm2 
and the energy resolution was ΔE/E = 5×10−3. After penetrating the sample, the 
X-rays were converted into visible light by a YAG:Ce scintillator (200 μm 
thickness). The projections were magnified by diffraction-limited microscope 
optics (2 × magnification) and digitized using a high-resolution 2,048 pixel × 2,048 
pixel CCD camera with a physical pixel size of 7.4 μm (pco.2000, PCO AG, 
Kelheim, Germany). The effective pixel size was 3.7 μm, the exposure time was 
2.0 s, and the sample-to-detector distance was 12 cm. For each acquisition, 720 
projection images were captured with an angular step size of 0.15° for 180°. Flat-
field and dark-field images were also collected during each acquisition procedure, 
in order to correct the electronic noise and variations in the X-ray source 
brightness. 
The projected images were reconstructed using direct filtered back projection 
algorithm. To enhance the quality of reconstructed slices, the X-TRACT SSRF 
CWSx64 (Commonwealth Scientific and Industrial Research Organization, 
Australia, http://www.ts-imaging.net/Default.aspx) was used for phase contrast 
extraction. The 3D rendered data were analysed with commercially available 
software (VGStudio Max (Version 2.1, Volume Graphics GmbH, Germany) and 
Image Pro Analyser 3D (Version 7.0, Media Cybernetics, Inc., USA) to obtain the 
qualitative and quantitative data, respectively. 
S 5 Laser drilling and the reconstruction of orifices 
Captopril and excipients were passed through a 100 mesh sieve (mesh size 
of 150 μm), weighed accurately, and mixed in geometric proportions to form a 
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uniform blend of powders prior to direct compression. The mixed powders were 
compressed on a rotary tablet press (ZP-5, Shanghai Tianjiu Machinery Factory) 
using 6.0-mm-diameter shallow concave punches. An acetone solution 
containing cellulose acetate and polyethylene glycol (3:1), at 2% w/w 
concentration was used in the coating process to form a semipermeable 
membrane on the surface of core tablet. The coating was carried out by spraying 
the coating solution in a high efficiency coating machine (BGB-5F, Zhejiang 
Xiaolun Pharmaceutical Machinery Co., Ltd., China) equipped with a hot air 
blower. The stainless steel and peristaltic pump were both set a rotating speed 
of 12 rpm. The temperatures of air intake and outlet were 40oC and 30oC, 
respectively. The rotate speed of air intake and outlet were set at 500 rpm and 
1,450 rpm, respectively, with coating continuing until a 4% weight increase in 
tablet weight was reached. The coated tablets were then dried to remove any 
residual solvent at 40oC for 16 h. An orifice was then drilled through the coating 
membrane with laser drilling machine (CRS-C20D, Ceres Wuhan Photoelectric 
Technology Co., Ltd., China).  
Since laser drilling involves selecting a set of operating conditions, including 
laser power, pulse width, pulse frequency, focus plane position, and number of 
pulses[112], laser drilling parameters that markedly affected the quality of orifices 
were investigated using the above mentioned laser drilling machine and the 
software Mark Studio (0x0001.1946) setting, developed by Shenzhen Earain 
(China). Power for laser drilling (2, 6, 10, 14 and 20 W) and movement speeds of 
laser spot (namely, scanning speeds of the laser beam, 200, 400, 600, 800, 1,000 
and 2,000 mm/s) that can be set in the software by user were investigated. The 
CRS-C20D laser drilling machine was assembled with the ultra-pulsed laser (max 
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power of 20 W, Access, USA), optical offset mirror (Ceres, China), optical 
focusing mirror (Wavelength, USA), and control card (Ceres, China). The 
frequency of laser was 5 KHz. For the drilling, the coated tablets (diameter of 6 
mm and thickness of 2 mm) were positioned in wells of a board and then placed 
in the operational stage 12.5 cm away from the laser light source.  
The slight shake of samples during the data acquisition process can result in 
the poor image quality, so it is necessary to apply an appropriate method to fix 
the samples. In the present study, two osmotic pump tablets were positioned 
separately orifice to orifice in a plastic pipe with a diameter of 6 mm. The pipe 
was then firmly attached to the sample stage in the beam line. For the marked 
Felodipine OP-DDSs with diameters of 7 mm, the tablets were cut along with the 
edges carefully to avoid disturbance to the orifices and reduce the diameters to 
about 6 mm and then fixed in the plastic pipes.  
The SR-μCT measurements were carried out at beamline BM13W1 of 
Shanghai Synchrotron Radiation Facility (SSRF, China). X-rays were derived 
from an electron storage ring with an accelerated energy of 3.5 GeV, and an 
average beam current of 180 mA. The size of the beam was approximately 45 
mm (horizontal) × 5 mm (vertical) and a double-crystal monochromator with Si 
(111) and Si (311) crystals was used to monochromatize the X-rays. The energy 
resolution was ΔE/E < 5×10−3. The photon energy of 18.0 keV was selected for 
the CT scan. After penetration through the sample, the X-rays were first 
converted to visible light by a Lu2SiO5: Ce scintillator (10 μm thickness) cleaved 
single crystal scintillator. Data were acquired with the sample placed 34 m 
downstream of the synchrotron source. Projections were magnified by diffraction-
limited microscope optics (magnification of 2) and digitized by a high-resolution 
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2,048 pixel × 2,048 with a physical pixel size of 6.5 μm (ORCA Flash 4.0 Scientific 
CMOS, Hamamatsu K.K, Shizuoka Pref., Japan). The effective pixel size was 
3.25 μm and the exposure time was 1 s. The distance from the detector to sample 
was set at 10 cm. For each acquisition, 720 projection images were captured with 
an angular step size of 0.25o for 180o. Flat-field and dark-field images were also 
collected during each acquisition procedure, in order to correct for the electronic 
noise each other and variations in the X-ray source brightness.  
The projected images for the samples were reconstructed using the X-TRACT 
SSRF CWSx64 (CSIRO, Commonwealth Scientific and Industrial Research 
Organization, Australia, http://www.ts-imaging.net) to perform a direct filtered 
back projection algorithm. To enhance the quality of reconstructed slices, 
propagation-based phase contrast extraction was carried out. As described in the 
paper [166], the larger sample-to-detector distances increased the contrast 
primarily due to the contribution from differences in the refractive properties 
across the sample in addition to the differential absorption. In combination with 
homogeneous Transport of Intensity equation (TIE-Hom) phase retrieval can 
achieve high quality reconstructed 3D images. During phase extraction, the 
parameter of δ/β was adjusted at 400 for the best contrast between different 
materials. After phase retrieval and reconstruction, the calculated images were 
truncated and rescaled to a grey value of 0 to 255 (8 bit grey level). The 3D 
rendered data were analysed with commercially available software Amira 
(version 6.01, FEI, USA) and Image Pro Analyser 3D (Version 7.0, Media 
Cybernetics, Inc., USA) to obtain qualitative and quantitative data, respectively. 
Images were processed to reduce noise and enhance the contrast. All 
radiograph images were normalized based on the intensity within the selected 
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rectangular reference region which was never occluded by the sample in any of 
the images for the correction of varied illumination, and a simple median 
smoothing filter was performed for the noise reduction. During the TIE-Hom 
phase retrieval, zingers filter has been applied to remove isolated pixels or small 
clusters of pixels in which the signal was much higher than that in the surrounding 
part of the input frame files or dark and flat field files for the correction of artefacts. 
Brightness, contrast and gamma settings were also adjusted for the contrast 
enhancement of reconstructed slices. After the optimization, the crystal particles, 
membranes and delivery orifices could be distinguished due to the noise 
reduction and phase retrieval. The grey value of the background was about 0 to 
50, while the grey value of excipients were between 70 and 150, and the crystal 
particles gave a grey value above 150.  
From the analysis of grey values, X-ray CT data from all of the delivery orifices 
in the OP-DDSs were examined. Highly resolved tomographic images with high 
quality phase contrast were then derived after 3D reconstructions. Based on the 
difference of grey value, the matrix of OP-DDSs and orifices had been segmented 
and the constructed 3D models were used for the calculation of quantitative 
parameters. 
Recently, synchrotron radiation-based Fourier transformed infrared 
microspectroscopy (SR-FTIR) has been developed as a rapid, direct and non-
destructive chemical microprobe with high flux and brightness, high coherence, 
high signal-to-noise ratio at high-spatial resolutions and allow for smaller regions 
within a specimen to be analysed [167]. In this study, SR-FTIR 
microspectroscopy was performed in the BL01B beamline at SSRF (Shanghai 
Synchrotron Radiation Facility). Spectra of the membrane samples were 
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recorded on a Nicolet Continμm XL microscope (Thermo Fisher Scientific, Inc.) 
equipped with a 250 × 250 μm2 liquid nitrogen cooled MCT/A detector, a 
32X/NA0.65 Schwarzschild objective, a motorized knife-edge aperture, and a 
Prior XYZ motorized stage and coupled with Nicolet 6700 spectrometer (Thermo 
Fisher Scientific, Inc.) equipped with a Michelson interferometer. After peeled 
from the OP-DDS, the membranes with the orifice attached was mapped in 
transmission mode between 600 cm-1 and 5,000 cm-1, with 64 scans at 4 cm-1 
resolution, 10 μm ×10 μm aperture dimension, 10 μm × 10 μm step size, and 26 
× 6 points (coving the part of orifices) on the BaF2 substrate. With the OMINIC 
software 9.2.86 (Thermo Fisher Scientific, Inc.), chemical distribution maps were 
created and analysed after smoothing and baseline correction. 
S 6 Pre-treatment of felodipine osmotic pump tablet 
Samples pretreatment 
Follow the instruction about sample preparation in Section 2.2. For the SR-
μCT test, 18 tablets were divided into six groups and three tablets in each group. 
The dissolution medium was a phosphate buffer (pH 6.5) with 1% sodium lauryl 
sulfate and was prepared as follows: transfer 206 mL of 1 mol/L monobasic 
sodium phosphate monohydrate, 196 mL of 0.5 mol/L dibasic sodium phosphate 
anhydrous and 20g of cetyltrimethylammonium bromide to a 5000 mL volumetric 
flask, diluted with water to volume, and mix well, adjust the pH to 6.5. A standard 
dissolution test was carried out. At 0.5, 1.0, 3.0, 6.0, 8.0 and 10 h, three tablets 
were taken out from the dissolution medium gently and put on a piece of flat, dry 
filter paper. In order to keep the intrinsic structure of the tablet, the liquid on the 
surface and inside the tablet was absorbed as completed as possible by the filter 
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paper. Then, the tablet was kept at room temperature for 24 hours to remove the 
residual liquid. The tablet was not reused for the dissolution test, nor put back 
into the dissolution medium again. 
SR-μCT tomography 
SR-μCT tomographic images were acquired with beam line BL13W1 at 
Shanghai Synchrotron Radiation Facility (SSRF). Samples were scanned with 
synchrotron radiation at 13.0 keV. After the penetration through the sample, the 
X-rays were converted into visible light by a YAG:Ce scintillator (200 µm 
thickness). Projections were magnified by diffraction-limited microscope optics 
(1.25 × magnification) and digitized by a high-resolution 2048 × 2048 pixel CCD 
camera (pco.2000, PCO AG, Kelheim, Germany). The pixel size was 5.92µm, the 
exposure time was 4s and the sample-to-detector distance was 25 cm. For each 
acquisition, 900 projection images were taken. Light field images (i.e. X-ray 
illumination on and the specimen out of the beam-path) and dark-field images (i.e. 
X-ray illumination off) were also collected during each acquisition procedure, in 
order to correct the electronic noise and variations in the X-ray source brightness.  
The projected images at each time point of dissolution (0.5, 1.0, 3.0, 6.0, 8.0 and 
10.0 h), were reconstructed using the software developed by SSRF to perform a 
direct filtered back-projection algorithm. The 3D rendered data were analysed 
with VGStudioMax and Image-Pro 3D to obtain the qualitative and quantitative 
data, respectively. 
S 7 Pre-treatment of felodipine HPMC gel matrix tablet 
In Vitro Release test 
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In vitro drug release of the felodipine extended release tablets was measured 
using the paddle method according to the Chinese Pharmacopoeia. The 
dissolution test was conducted at a rotation speed of 100 rpm, medium volume 
of 500 mL at 37 ℃. The dissolution medium was a phosphate buffer (pH 6.5), 
which was prepared as follows: 206 mL of 1 mol/L monobasic sodium phosphate 
monohydrate, 196 mL of 0.5 mol/L dibasic sodium phosphate anhydrous and 20g 
of cetyltrimethylammonium bromide were transferred to a 5000 mL volumetric 
flask, diluted with distilled water to volume, and mixed well (pH = 6.5). Following 
addition of the tablet to the dissolution vessel, aliquot samples 10 mL were 
withdrawn from the dissolution vessel at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 7.0, 8.0, 
10.0 h and then replaced with equivalent volumes of fresh medium in order to 
maintain sink conditions since the solubility of felodipine in phosphate buffer (pH 
= 6.5) containing 0.4% cetyltrimethylammonium bromide was 970 μg/mL [168]. 
The samples were then filtered with 0.45 μm microporous membrane and 
analysed using a validated HPLC method to calculate the percent of felodipine 
released at different stages of the dissolution test. The HPLC analysis was 
performed on a Diamonsil C18 column (150×4.6 mm, 5 μm) (Dikma Technologies, 
China) using methanol-water (80:20) as mobile phase, with a flow rate of 1.0 
mL/min and injection volume of 20 µL. The detection wavelength was 238 nm. 
Calibration curves were prepared over the concentration range of 0.1, 1.0, 2.0, 
5.0, 10.0 and 20.0 μg/mL. The linearity regression coefficient exceeded 0.995, 
showing a good linearity over this concentration range. Precision results revealed 
that the intra- and inter-assay RSD were below 1.0 %, and the sample was stable 
over 24 h, with RSD below 1.0 %. 
Pre-treatment of Samples 
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In order to evaluate temporal changes in the microstructure of the matrix 
tablets during drug release by SR-μCT test, 18 tablets were taken and divided 
into nine groups, each containing two tablets and a standard dissolution test was 
carried out. At 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0 and 8.0 h, two tablets were 
removed from the dissolution medium and prepared for further testing.  
As discussed in Section 2.2, samples have been prepared and pre-treated. 
In order to maintain the original shape of the tablets, swollen tablets were 
carefully removed using small spoons together with about 2 mL of the medium 
and placed individually in 24-well plates with 2 mL of the corresponding 
dissolution medium added to maintain the original shape of the tables. The 24-
well plates containing the tablets in various states of hydration and erosion were 
then immediately placed into the ultra-low temperature refrigerator at -80 ℃ for 
12 hour. After this process, the tablets were freeze-dried over a period of 24 hours 
at -50℃ and 10 mTorr using a freeze dryer (FD5-3, China-GOLD SIM (Beijing) 
International Co. Ltd., China). These tablets were then kept in the dry cabinet 
under ambient temperature (relative humidity of 20%) for further SR-μCT tests 
and were not reused in dissolution tests. 
Tomography 
SR-μCT tomographic images of prepared samples were acquired using 
beam line BL13W1 at the Shanghai Synchrotron Radiation Facility (SSRF). 
Samples were scanned with synchrotron radiation at 13.0 keV. Images were 
recorded with an X-ray digital camera with direct coupled (micro) fiber-optic 
(Photonics Science Ltd, Robertsbridge, UK). The pixel size was 9 µm, the 
exposure time was 4s and the sample-to-detector distance was 10 cm. For each 
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acquisition, 720 projection images over 180º were taken. Flat field images and 
dark-field images were also collected during each acquisition procedure, in order 
to correct the electronic noise and variations in the X-ray source brightness.  
The projection sets of tablet for each time point of dissolution (0.5, 1.0, 2.0, 
3.0, 4.0, 5.0, 6.0, 7.0 and 8.0 h) were reconstructed using developed software 
based on a filtered back-projection algorithm [76]. The 3D rendered data were 
analysed with VGStudio Max and Image-Pro 3D to obtain qualitative and 
quantitative data, respectively. Statistical models were constructed with PASW 
Statistics version 18.0 (Polar Engineering and Consulting). 
Three dimensional parameter calculations 
After segmentation, slices were all converted into black and white images by 
removal of the background and noise. Then, three dimensional Iso-Surface 
models were constructed with segmented slices. The surface level, surface range 
and the simplification parameters were adjusted to optimize the models and to 
extract objects for further calculation of quantitative steric parameters. 
 
S 8 Preparation and structural analysis of droplet 
generated tablet 
Tablet Preparation. All powder components of the osmotic pump cores were 
passed through the 100 mesh sieve (150 μm), weighted accurately, and mixed in 
geometric proportion to form a uniform blend of powder ready for direct 
compression. The uniform blend of powder was direct compression on a rotary 
tablet machine (ZP-5, Shanghai Tianjiu Machinery Factory) using 6.0-mm-
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diameter punches. Cellulose acetate (CA) in acetone containing plasticizer (PEG 
4000) was used as coating solution. The coating was carried out in a pan coater 
(BY 300A, Shanghai Huanghai Drug Instrument Co., Ltd., China). The 
temperature of coating pan was 40 oC, pan-rotating rate was 25 rpm. The coated 
tablets were dried to remove the residual solvent acetone at 40 oC for 24 h, and 
laser machines drilled (CRS-C20D, Ceres Wuhan Photoelectric Technology Co., 
Ltd., China) a 0.8-mm-diameter orifice on the membrane surface.  
In Vitro Release Test. In vitro drug release test was conducted in a dissolution 
apparatus (ZRS-8G, Haiyida Co., Ltd, China) using the paddle method. The 
release medium was 900 mL distilled water. The temperature of the release 
medium was maintained at 37 ± 0.5 oC and the rotation speed of the paddle was 
adjusted to 75 rpm. Samples of 5.0 mL were withdrawn at 0.5, 1.0, 2.0, 4.0, 6.0, 
8.0, 10.0 and 12.0 h and replaced 5.0 mL fresh release media to each vessel. 
The solution was filtered through a 0.45 µm membrane filter, suitably diluted and 
determined by Ultraviolet Spectrometer (UV-4802，Shanghai Unico Instruments 
Co., Ltd., China). 
Sample Preparation for SR-μCT Test. Prior to the SR-μCT scanning, the 
sample positioned in a dissolution apparatus using the paddle method. The 
temperature of the release medium, 900 mL deionized water, was maintained at 
37 oC. The rotation speed of the paddle was adjusted to 75 rpm. The tablets were 
taken out at a set time, and carefully placed on a piece of flat, dry filter paper. 
The liquid on the surface and inside the tablet was absorbed as much as possible 
by the filter paper. Then the tablets were kept in an amber-coloured drying 
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container holding the drug releasing orifices upward at room for 24 h to remove 
the remaining residue liquid as possible. Experiment were carried out in triplicate. 
SR-μCT Tomography. SR-μCT analysis were performed using BM13W beam 
line at Shanghai institute of applied physics, Chinese academy of science (SSRF) 
with a resolution of 3.7 microns per pixel. The rotation step was fixed at 0.25 μ, 
the range of angel was -5 ° to 175 ° and exposure time was 2 s. For each sample, 
totally a stack of 720 2D tomographic sections was obtained. The X-TRACT 
software was used for 3D reconstruction. X-TRACT is a powerful software 
package for reconstruction and analysis of X-ray tomographic data, which has 
been parallelised to run on GPU clusters enabling great gains in speed and the 
ability to process larger image files. One of the unique features of X-TRACT is its 
ability to process phase-contrast images to improve the quality of the 
reconstructed data. 
3D Reconstruction and Quantitative Analysis. The Image Pro Analyser 3D 7.0 
was used for the building, rendering, visualization and measurements. 3D models 
were constructed from the stacks of 2D images after threshold of the objects of 
interest from the relevant objects and background noise. After selecting volume 
of interest (VOI), multiple iso-surface has been rendered based on segmentation 
of selected intensities and colours. For each tablet, the areas of the Na3PO4 and 
the matrix were first segmented respectively based on the difference in the grey 
value. As after drying, the bubbles in the tablets are all full with air and cannot be 
distinguished with the air out of the tablets by intensities. Algorithm base on the 
software platform of Image Pro Analyzer 3D  was designed which can pick out 
micro-droplets in an image intelligently and segment them with specific colour. 
After the segmentation, images were divided into three regions and coloured. The 
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Na3PO4 area was dyed red, the matrix area was green and the micro-droplets 
were blue. These three regions of different colour were regarded as three 
channels and reconstructed into three models in the Image Pro Analyser 3D 
software. Then the quantitative measurements will be carried out based on these 
3D models and computed parameters will also be correlated with the drug release 
kinetics.  
Sample Preparation for In Situ Test. The film coated tablet was fixed inside the 
self-controlled device, which was made by plastic pipe. After deionized water was 
added in the device, the in situ test started.  
To gain insight into the most authentic internal fine-structure dynamic change 
in the course of drug release and understand the release mechanism, it is 
necessary to monitor the real-time drug release behaviour of the tablets in situ. 
However, in vitro dissolution testing of tablets is usually carried out in large 
volumes of dissolution medium and acquisition of the internal refined information 
about structure requires high resolution. It is a major challenge for the 
conventional testing  methods to record the real-time data. In the present study, 
the internal refined static structure change of the tablets in the previous release 
phase was successfully real-time monitored using the advanced SR-μCT.  
Drug release mechanism of the film coated tablets driven by in situ 
generated numerous micro-droplets 
The strong correlation between the volume of micro-droplets and drug release 
could be explained by the following mechanism: When the osmotic pump drug 
delivery system come in contact with the aqueous environment, water imbibitions 
by the active agents take place dissolving the core and the micro-droplets 
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generate. The total volume of micro-droplets increase from 0 to Vb. However, the 
outline volume (Vm) formed by the semipermeable membrane may be increased 
slightly but maintain constant in whole the release process. So, 
                                                                                             Eq. (27) 
At one bar pressure, that is in the osmotic pump tablet which is not totally 
hydrated, and if the solid content contacts the medium, this situation is equivalent 
to the “concentration” of the semi solid content extruded from the release orifice. 
If the volume is Vd. then： 
                                                                                                    Eq. (28) 
Clealy, at t, the percentage of the solid content discharged to the tablet is 
equivalent to the release R. That is: 
                                                                                                 Eq. (29) 
Where, a and Vd are both constants. Thus, the drug release of this kind of 
osmotic pump has a positive correlation to the volume of the micro-droplets 
structure. That can be simplified as the drug release R has a positive correlation 
to the total volume of the bubble structure formed in the tablet: 
                                                                                                  Eq. (30) 
 When ketoprofen was included in the osmotic pump tablets only containing 
copovidone without sodium phosphate (formulation C), spherical micro-droplets 
remained. But, only 2% of ketoprofen was released at 1.0 h. Absence of sodium 
mbtt
VV  maxlim
m
d
V
Va 
b
d
V
V
aR 
bkVR 
 249 
 
phosphate could therefore play a vital role in increasing the drug release. When 
sodium phosphate was added based on the osmotic pump tablets only containing 
copovidone without drug (formulation C), the original spherical micro-droplets 
changed markedly. Due to the presence of sodium phosphate, the ‘salting-out’ 
reduced the solubility of copovidone, thus the hydration was delayed and the 
number of micro-droplets decreased and the size of the micro-droplets was 
smaller compared with the formation that only containing copovidone (formulation 
C). Simultaneously, the presence of sodium phosphate increased the osmotic 
pressure and surface tension of the solutions, resulting in the non-uniform and 
low sphericity of micro-droplets. Also, water entering into the core under the 
osmotic pressure led to the radial distribution of dissolved sodium phosphate. 
After the cores were in contact with water, copovidone absorbed water resulted 
in a saturated solution of  sodium phosphate. Under the effect of the osmotic 
pressure, water accumulated in the centre area. Thus, the droplet formed by 
dissolved Na3PO4 pointed to the centre of the core. Fully dissolved sodium 
phosphate accelerated the dissolution of copovidone. Salt ions enhanced the 
polarity of the solution, thereby increasing the solubility of water-soluble polymer. 
Containing of sodium phosphate in the core made a large number of spherical 
aqueous micro-droplet not formed when contacting water. It could be explained 
that the existence of sodium phosphate solution leaded the increase of surface 
tension and solubility of polymer materials, resulting in the spherical micro-droplet 
could not be formed and exist stably. 
 
Size, shape and evaluation rate control of micro-droplets 
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Table 14 Size and shape of micro-droplets in the film tablets at different drug release time 
   Stats          Area        Aspect Diameter (mean)
0.5 h
     Min 137 1 13
     Max 19714 6 166
   Range 19577 5 153
    Mean 1165 1 33
 Std.Dev 1692 0 19
     Sum 625606 795 17679
 Samples 537 537 537
1.0 h
     Min 137 1 13
     Max 14333 9.7488108 133
   Range 14197 8.7488108 120
    Mean 1487 1.330917 38
 Std.Dev 1435 0.58254772 18
     Sum 809147 724.0188 20501
 Samples 544 544 544
1.5 h
     Min 137 1 13
     Max 2019111 6 1592
   Range 2018974 5 1579
    Mean 9538 1 53
 Std.Dev 111589 0 94
     Sum 4463556 678 24971
 Samples 468 468 468
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2.0 h
     Min 137 1 13
     Max 5924128 5 2731
   Range 5923992 4 2717
    Mean 21949 1 58
 Std.Dev 308299 0 155
     Sum 9130792 599 24227
 Samples 416 416 416
3.0 h
     Min 137 1 13
     Max 11640771 6. 3845
   Range 11640634 5 3832
    Mean 50797 2 64
 Std.Dev 712172 1 245
     Sum 13715149 453 17317
 Samples 270 270 270
 4.0 h    
     Min 137 1 13
     Max 16183538 10 4532
   Range 16183401 9 4519
    Mean 319168 2 129
 Std.Dev 2243562 1 623
     Sum 16277561 79 6558
 Samples 51 51 51
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Tablet Preparation. All compositions of the osmotic pump cores were passed 
through the 100 mesh sieve, weighted accurately, and mixed in geometric 
proportion to form a uniform blend of powder ready for direct compression. The 
uniform blend of powder was direct compression on a rotary tablet machine (ZP-
5, Shanghai Tianjiu Machinery Factory) using 6.0-mm-diameter punches. 
Cellulose acetate (CA) in acetone containing plasticizer (PEG 4000) was used as 
coating solution. The coating was carried out in a pan coater (BY 300A, Shanghai 
Huanghai Drug Instrument Co., Ltd., China). The temperature of coating pan was 
40 ℃, pan-rotating rate was 25 rpm. The coated tablets were dried to remove the 
residual solvent acetone at 40 ℃ for 24 h, and laser machines drilled (CRS-C20D, 
Ceres Wuhan Photoelectric Technology Co., Ltd., China) a 0.8-mm-diameter 
orifice on the membrane surface.  
In Vitro Release Test. In vitro drug release test was conducted in a dissolution 
apparatus (ZRS-8G, Haiyida Co., Ltd, China) using the paddle method. The 
release medium was 900 mL distilled water. The temperature of the release 
medium was maintained at 37 ± 0.5 ℃ and the rotation speed of the paddle was 
adjusted to 75 rpm. Samples of 5.0 mL were withdrawn at 0.5, 1.0, 2.0, 4.0, 6.0, 
8.0, 10.0 and 12.0 h and replaced 5.0 mL fresh release media to each vessel. 
The solution was filtered through a 0.45 µm membrane filter, suitably diluted and 
determined by Ultraviolet Spectrometer (UV-4802，Shanghai Unico Instruments 
Co., Ltd., China). 
Sample Preparation for SR-μCT Test. For the SR-μCT test, the sample 
preparation was conducted in a dissolution apparatus using the paddle method. 
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The temperature of the release medium, 900 mL distilled water, was maintained 
at 37 ℃. The rotation speed of the paddle was adjusted to 75 rpm. The tablets 
were taken out at a set time, three times in parallel experiments, and carefully 
placed on a piece of flat, dry filter paper. The liquid on the surface and inside the 
tablet was absorbed as much as possible by the filter paper. Then the tablets 
were kept in an amber-coloured drying container holding the drug releasing 
orifices upward at room for 24 h to remove the remaining residue liquid as 
possible. 
SR-μCT Tomography. SR-μCT analysis were performed using BM13W beam 
line at Shanghai institute of applied physics, Chinese academy of science (SSRF) 
with a resolution of 3.7 microns per pixel. The rotation step was fixed at 0.25 u, 
the range of angel was -5 ° to 175 ° and exposure time was 2 s. For each sample, 
totally a stack of 720 2D tomographic sections was obtained. The X-TRACT 
software was used for 3D reconstruction. X-TRACT is a powerful software 
package for reconstruction and analysis of X-ray tomographic data, which has 
been parallelised to run on GPU clusters enabling great gains in speed and the 
ability to process larger image files. One of the unique features of X-TRACT is its 
ability to process phase-contrast images to improve the quality of the 
reconstructed data. 
3D Reconstruction and Quantitative Analysis. The Image Pro Analyser 3D 7.0 
was used for the building, rendering, visualization and measurements. 3D models 
were constructed from the stacks of 2D images after a threshold of the objects of 
interest from the relevant objects and background noise. After selecting volume 
of interest (VOI), multiple iso-surface has been rendered based on segmentation 
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of selected intensities and colours. For each tablet, the areas of the salt and the 
matrix were first segmented respectively based on the difference in the grey value. 
As after drying, the bubbles in the tablets are all full with air and cannot be 
distinguished with the air out of the tablets by intensities. Another software was 
programmed which can pick out micro-droplets in an image intelligently and 
segment them with a specific colour. After the segmentation, images were divided 
into three regions and coloured. The salt area was dyed red, the matrix area was 
green and the micro-droplets were blue. These three regions of different colour 
were regarded as three channels and reconstructed into three models in the 
Image Pro Analyser 3D software. Then the quantitative measurements will be 
carried out based on these 3D models and computed parameters will also be 
correlated with the drug release kinetics.  
 
